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Abstract 
Infections are a major cause of morbidity and mortality in infants and children 
world-wide.  However, the severity of response of neonates to rotavirus (RV) infection or 
their ability to generate sufficient antibodies following influenza vaccination can vary 
due to immune immaturity and dietary differences.  Manipulating the composition of 
infant formula, by adding different ingredients, such as β-(1,3)-glucans (βG), nucleotides 
(NT), and human milk oligosaccharides (HMO) could stimulate the development of the 
neonatal immune and gastrointestinal systems.  Dietary βG are able to boost the natural 
defense mechanism by stimulating both innate (Descroix et al., 2006) and adaptive 
immune responses (Akramiene et al., 2007).  NT are conditionally essential for infants, 
particularly under stressful conditions, such as during disease and rapid growth.  Clinical 
studies demonstrate that supplemental NT improve immune function, modify the 
intestinal microbiota and reduce diarrhea in formula fed infants.  HMO contribute to the 
immunomodulatory and immunoprotective actions of human milk. Thus, the objective of 
this dissertation research was to investigate how early nutrition influences immune and 
gastrointestinal development.   
 βG have been shown to potentiate immune system responses, and it was 
hypothesized that orally administered βG would boost the neonatal immune system.  
Therefore we evaluated the influence of purified yeast (1,3/1,6)-β-D-glucan [WGP®] on 
the development of the intestinal and systemic immune systems in neonatal piglets.  
Piglets were fed formula containing 0 (control), 1.8, 18 or 90 mg WGP/kg body weight 
and vaccinated with human influenza vaccine (Fluzone ).  Piglets were euthanized at 7 
or 21 days of age.  Piglet weight and formula intake were similar for piglets in each 
dietary treatment group.  Small intestinal length and weight were unaffected by dietary 
WGP.  In addition, WGP did not affect ileal crypt depth, ileal villus height or ascending 
colon cuff depth.  Immune parameters analyzed included T cell phenotypes, cytokine 
gene expression, and cell proliferation.  These were not affected by WGP® 
supplementation.  Overall, the doses of 1.8, 18, and 90 mg (per kg body weight) of 
dietary WGP had no effect on intestinal development or intestinal and systemic immune 
development in neonatal piglets.  Additionally, dietary WGP did not improve the 
antibody response to Fluzone  vaccination.  We concluded that dietary supplementation 
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with WGP is not beneficial for intestinal or immune development in colostrum-fed, full-
term neonates. 
NT and HMO have been shown to impact epithelial cell growth, however their 
combined effects had not previously been examined.  Herein, a fetal epithelial cell line 
(FHs-74 Int) was used to determine the impact of NT and HMO on intestinal cell 
proliferation, apoptosis, necrosis and cell cycle.  Cells were incubated with media 
containing 2.5% FBS and no epidermal growth factor (EGF) (Control); Fucosyl-lactose 
(FL) mix [85% 2'FL/15% 3'FL], Sialyl-lactose (SL) mix [40% 6'SL/10% 3'SL/50% sialic 
acid (SA)] or LNnT at 125, 250, 500 or 1000 μg/mL with and without 250 μg/mL NT 
(43% CMP, 18.5% UMP, 16.4% AMP, and 22.0% GMP) for 24 or 72h.  NT alone 
significantly increased proliferation, but did not affect cell cycle or apoptosis/necrosis.  
All HMO treatments at 1000 μg/mL significantly decreased proliferation and some were 
also inhibitory at 250 or 500 μg/mL.  Inhibition of proliferation increased with longer 
HMO exposure (72h vs. 24h).  When NT and HMO were simultaneously added, NT 
reduced the anti-proliferative effect of HMO.  FL mix treatments significantly increased 
cells S phase and SL mix and LNnT treatments significantly increased cells in G2/M and 
S phases which concomitantly decreased cells in G0/G1 phase.  HMO with NT decreased 
the amount of cells in the G2/M phase compared to HMO treatments alone.  Higher 
HMO doses significantly increased the percentage of apoptotic and necrotic cells 
compared to control.  The percentage of necrotic and apoptotic cells were higher after 
24h vs. 72h exposure to HMO.  In conclusion, HMO reduced cell proliferation in vitro 
and this effect is partially ameliorated by the presence of NT.  It appears that HMO 
initially induced apoptosis/necrosis, which is later evidenced by cell cycle arrest and 
decreased proliferation.  Further studies are needed to determine whether HMO influence 
intestinal cell growth in vivo. 
Thus, we evaluated the interaction between chronic NT feeding and acute HMO 
treatment within the ileal lumen of both healthy and acutely rotavirus (RV)-infected 
piglets.  Piglets (n=9 group) were fed formula containing 64 mg NT/L (FF) or 314 mg 
NT/L (FF+NT) from d2 to d21 of age.  At d21, a midline laparotomy was performed and 
six 10-cm loops of ileum were isolated in situ.  The following treatments were injected 
into the loops: media, 2 mg/mL neutral HMO (LNnT), 2 mg/mL acidic HMO mixture 
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(aHMO: sialic acid (SA), 6'sialyllactose (SL), 3'SL, SA) or each treatment + SA-
dependent OSU strain RV (1 x 10
7
 FFU).  After 6h, samples were collected.  Body 
weight, formula intake, jejunum villus length/crypt depth, ileal proliferation, ileal 
macrophages and T cell phenotypes were unaffected by dietary NT.  Loops treated with 
either HMO treatments + RV had lower RV replication, as assessed by NSP4 mRNA 
expression, than RV-treated loop alone. Ileal loops not treated with RV showed no NSP4 
expression.  There was no difference in the mRNA expression of NF-κβ, TNF-α, CCL2 
or IL-1  in ileal mucosa as analyzed by loop or dietary treatment.  However, NT fed 
piglets had significantly greater IL-8 ileal mucosa mRNA expression than formula piglets 
and aHMO treatment had significantly greater IL-8 mRNA expression than control loops.  
Thus, chronic dietary NT only had minor effects on the parameters measured, but HMO 
decreased NSP4 replication during acute RV infection. 
The dissertation comes to a close with a discussion of overall conclusions and 
future directions for this work.  Future studies are warranted to determine the effect of 
these ingredients on the development of the neonatal immune and gastrointestinal 
systems. 
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Chapter 1 
 
Literature Review 
 
 Human breast milk is considered the gold standard nutrition for infants during the 
first six months of life, since it contains a diverse complement of factors that can promote 
maturation in the neonate (Walker, 2010). However there is a need to provide safe and 
effective alternative forms of nutrition to infants who do not receive breast milk.  
Breastfeeding has many protective mechanisms and has many positive effects on the 
infant that are not replicated by components in infant formula, such as disease prevention 
and increased vaccination response (Dorea, 2009).  Young infants need adequate levels of 
nutrition to support the development of their gastrointestinal and immune systems.  
Manipulating the composition of formula, by adding functional ingredients could 
improve the development of the immune and gastrointestinal systems in formula fed 
neonates. 
 
I.  Neonatal Immune System 
Immunity is comprised of two ‘arms’, the innate and the adaptive immune 
systems.  The innate immune response serves as the first line of defense, whereas the 
adaptive immune response is initiated after antigen uptake by antigen presenting cells 
(APC).  In the neonate, the adaptive arm of the immune system is not fully developed, so 
the innate immune system is largely responsible for the clearance of foreign antigens.  
Although the cells involved with triggering the innate immune system are functional in 
neonates, they are present at lower levels than adults (Kelly & Coutts, 2000).  Very little 
antigen exposure occurs in utero, so the immune system of the neonate is naïve 
immunologically at birth.  The development of the immune system is based on 
experience, and the exposure to different antigens primes and develops the immune 
response.   
 
A.  Innate Immunity 
The innate immune system is an ancient, evolutionarily-conserved response that 
protects the host during initial exposure to pathogens.  Innate immune responses are 
2 
 
induced by the recognition of bacteria, fungi, or viral replication by granulocytes, 
monocytes, macrophages, dendritic cells, and natural killer cells (Marodi, 2006).  
Repetitive structures on these microorganisms are called molecular-associated molecular 
patterns (MAMP) and the receptors that recognize MAMPs are pattern recognition 
receptors (PRR). 
Mammals have toll-like receptors (TLR), which are a set of PRR that recognize 
MAMP.  Some TLR act as cell-surface receptors, whereas others act intracellularly and 
are located in the membranes of endosomes, where they sense pathogens taken into the 
cell.  Genes corresponding to the 10 TLR genes identified in humans have also been fully 
cloned in pigs (Uenishi & Shinkai, 2009).  TLR and nucleotide-binding oligomerization 
(NOD) domains play important roles in the recognition of pathogen-derived molecules by 
the immune system in the immediate-early phase, as well as in the following immune 
responses, by causing cytokine production.  The early activation of NF-κβ, which is a 
transcription factor expressed in many cell types after activation by stimuli such as 
cytokines, growth factors, and viruses further increases immune responses. 
Cytokines are small proteins that are released by different cells in the body, due to 
increase of NF-κβ transcription.  Cytokines can act via autocrine, paracrine or endocrine 
manners.  The different classes of cytokines include the hematopoietin family, which 
includes growth hormones and many interleukins (IL), and the tumor necrosis factor 
(TNF) family, including TNF-α (Murphy et al., 2008).   
 
B.  Neonatal Innate Immune System 
The innate immune system does not require immunologic experience to function; 
it is functionally immature at birth compared to healthy older children or adults (Levy et 
al., 2004).  Neonates rely heavily on cytokines and other components of the innate 
immune system, due to the immaturity of the adaptive immune system.  The fetal 
immune system is heavily T helper cell 2 (Th2)-biased to avoid pro-inflammatory T 
helper cell 1 (Th1)-type alloimmune responses to maternal tissues that could trigger 
spontaneous abortion or preterm birth.  After birth, the neonate is exposed to bacteria 
which causes the first colonization of the skin and gastrointestinal tract, as well as foreign 
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antigens from foods.  High levels of Th2-type cytokines and low levels of Th1-type 
cytokines are initially used to counter this foreign antigen (Murphy et al., 2008). 
Neonates not only have lower levels of neutrophils, monocytes, and APC, but 
their cells also have decreased function compared to adult cells (Levy, 2007).  For 
example, cord blood monocytes of full-term human newborns express normal amounts of 
TLR, but upon stimulation of TLR 1-7, cells produced 1- to 3-log lower TNF-α 
concentrations compared to adult peripheral blood monocytes (PBMC) (Levy et al., 
2004).  Other studies have demonstrated neonatal monocytes and macrophages to have 
depressed TLR4-mediated, NF-κβ-dependent transcription activation (Hasegawa et al., 
2003).  A proposed mechanism accounting for this impairment is that the stress 
accompanying the birth process increases plasma concentrations of adenosine, an 
endogenous immunosuppressive purine metabolite.  Adenosine can act through adenosine 
receptors on neonatal mononuclear cells to induce cyclic adenosine monophosphate 
(c’AMP) production, which inhibits TLR-mediated production of Th1 cytokines (Levy, 
2007; Levy et al., 2006; Philbin & Levy, 2009).  In contrast, cord blood monocytes from 
full-term human newborns produce a robust TLR8 immune response, because TLR8-
mediated molecular pathway in the inflammatory response is uniquely preserved in 
human neonatal APCs (Levy et al., 2006).  Other proteins sharing features of their ligand-
binding domains with the TLR, are present in the cytosol of the cell.  These proteins are 
called nucleotide-binding oligomerization (NOD) domains.  Little is known about NOD 
protein expression or function in the neonate (Levy et al., 2006).   
 
C.  Adaptive Immunity 
The adaptive immune response commences either when the innate immune 
system triggers it or when antigen accumulates to levels able to activate it.  The adaptive 
immune system is acquired over time and is mediated by T and B cells.  Immature T cells 
undergo a selection process in the thymus to remove potentially self-reactive cells.  Less 
than 5% of the thymocytes survive this process to be released as functionally mature, 
circulating T cells (Jackson & Nazar, 2006).  Mature re-circulating T cells that have not 
encountered their specific antigens are referred to as naïve T cells.  Naïve T cells are 
categorized into two groups, one carries the co-receptor CD8 on its surface and the other 
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carries the co-receptor CD4.  CD8
+
 T cells differentiate into CD8
+
 cytotoxic T cells, and 
CD4
+
 T cells differentiate into several CD4
+
 regulatory T cells subtypes.  These 
regulatory T cells include both Th1 and Th2 cells, which are called helper T cells.  The 
Th1 and Th2 cells secrete different cytokines.  Helper T cells activate naïve B cells into 
antibody-producing plasma cells. B cells are capable of producing antibodies, which are 
able to cause the destruction of extracellular microorganisms.  Antibodies protect the 
body’s mucosal surfaces, tissues and blood from infection by neutralizing pathogens or 
causing their elimination before they are destructive to the host.  
 
D.  Neonatal Piglet Adaptive Immune System 
Adaptive immunity begins with processing and presenting of antigens by APCs in 
the mesenteric lymph nodes (MLN) and Peyer’s patches.  The newborn piglet is born 
with few lymphocytes, and during the first two weeks the intestine becomes populated 
with T cells that express CD3
+
 surface marker.  By 2-4 weeks of age, piglets CD4
+
 T cell 
populations grow, and low amounts of CD8
+
 T cells are present.  CD8
+
 T cells become 
more prominent in older piglets.  This CD4
+
 bias leaves the piglet with a Th2 vs. Th1 bias.  
Swine also have an unusually high percentage of double positive CD4
+
CD8
+
 T cells 
compared to humans and mice.  The percentage of double positive T cells increases as the 
piglet ages.  These T cells are thought to represent a mature resting population of 
lymphocytes, which are also referred to as memory cells (Zuckermann & Gaskins, 1996; 
Zuckermann & Husmann, 1996).  Vaccination is an important component of the adaptive 
immune system.  
 
E. Immune Response to Vaccination 
Vaccination is the deliberate induction of adaptive immunity to a pathogen by 
injecting, inhaling or orally administering a vaccine, which is a killed or attenuated 
(nonpathogenic) form of the pathogen (Murphy et al., 2008).  Following vaccination, 
antigen-specific antibody production is induced.  Immunological memory occurs after 
being exposed to an antigen via vaccination, so that the host is able to respond rapidly 
when next exposed to the pathogen it was vaccinated against.  
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 Breastfeeding and vaccination have been shown to be the most significant factors 
for disease prevention and child survival (Dorea, 2009).  Formula fed neonates produce 
less robust antibody responses to vaccination than breast fed infants (Pabst & Spady, 
1990; Sabirov et al., 2009; Pickering et al., 1998; Ogra et al., 1977).  Breastfeeding 
increases response to vaccination relative formula fed infants (Dorea, 2009).  Different 
vaccine responses have been documented in breast fed and formula fed infants (Hanson 
& Silfverdal, 2008; Pabst, 1997).  Breast fed infants had significantly higher levels of 
antibodies following vaccination against poliovirus, diphtheria, and tetanus toxoid than 
did formula fed infants (Hahn-Zoric et al., 1990).  Breast fed infants also had increased 
vaccine response to Haemophilus influenza type b (Hib) vaccine than did formula fed 
infants (Ogra et al., 1977).  These positive effects are seen during breastfeeding and 
persist following weaning.  Infants who were breast fed for at least 90 days displayed 
better serological protection against Hib than infants who were not breast fed as long 
(Silfverdal et al., 2007).  This protection could still be detected a decade later but the 
underlying mechanisms are not fully understood (Silfverdal et al., 1999).  Early 
consumption of human milk may cause fundamental changes in the infant’s immune 
system that cause this protection (Jackson & Nazar, 2006). 
Infants in the United States receive seven vaccinations prior to three months of 
age.  It is important for the neonate to be able to produce adequate amounts of antigen-
specific antibodies and circulating memory cells specific for antigens in the vaccinations.  
Even for breast fed infants, the ability to mount an optimal immune response to 
vaccination could be potentially enhanced by dietary supplementation.  In addition, 
vaccination represents an ideal model in which to examine complex immune responses to 
different dietary treatments, because the immune response to vaccination depends on the 
functional interplay of antigen presenting cells, antigen specific T helper cells, 
intracellular cytokine communication and maturation of B cells into antibody-producing 
plasma cells.  Therefore, studies that examine the effects of dietary supplementation with 
immune stimulating compounds on the overall T helper status of the immune system and 
on the immune response to vaccination are valuable. 
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F.  Development of Gut Associated Lymphoid Tissue (GALT) 
 The gut associated lymphoid tissue (GALT) is comprised of Peyer’s patches, 
MLN, lamina propria, adenoids, appendix, and tonsils.  The Peyer’s patches are 
organized lymphoid tissues lying in the submucosal layer of the intestinal wall 
throughout the small intestine. These dome-like follicle-associated epithelial structures 
located above aggregates of lymphocytes contain uniquely differentiated microfold cells 
(M cells) on the surface that monitor luminal antigens.  The antigen is collected by the M 
cells through endocytosis or phagocytosis and then sampled by APC, macrophages and 
dendritic cells.  These APC then present the antigens to local T lymphocytes or travel 
through the lymphatic system and present the antigens to MLN (Newburg & Walker, 
2007).  
The intestinal mucosa is in constant contact with the microbiota and antigens from 
the diet.  The gut actively restrains these factors with both the innate and adaptive 
immune system.  The innate immune system provides the physical barriers, chemical 
barriers, and reactive elements for local cells and cells recruited to a threatened site 
(Newburg & Walker, 2007).  The gut epithelium creates a tight barrier that separates 
luminal antigens and guts microbiota from invading the host and is able to activate the 
underlying lymphoid elements.  
The TLR are important components of the GALT and to the host’s ability to 
differentiate between self and non-self antigens.  Peyer’s patches are well developed at 
birth, but they are not optimally functioning at this time.  Exogenous stimuli are needed 
to activate the adaptive immune system (Brandtzaeg, 2003).  The infant’s intestinal 
immune system develops rapidly in the early postnatal period as it comes into contact 
with different dietary and microbial antigens in the gut (Brandtzaeg, 2003).  Components 
of both the innate and adaptive immune system enables the infants GALT to discriminate 
between antigens with the potential to cause damage and those without.  Failure to 
regulate tolerance and active immune responses can lead to diseases such as food-related 
allergy, auto-immunity, and inflammatory bowel disorders (Kelly & Coutts, 2000).  
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G.  Piglet as a Model for Neonatal Immunity Development 
 The neonatal piglet is a well documented model for the human infant due to 
similarities in metabolism, intestinal physiology, nutrient requirements, and immune 
development (Moughan et al., 1992; Schneider & Sarett, 1969; Wykes et al., 1993).  The 
gastrointestinal and immune systems of neonatal piglets resemble those of human infants 
better than other animal models, such as rodents (Saif et al., 1997; Meurens et al., 2012).  
Piglets serve as a good animal model for neonatal immunological studies for a number of 
reasons: large litters of offspring are able to be reared independently from their mothers; 
offspring can be reared on bovine milk-based formula; and piglets have similar 
nutritional requirements, digestive systems, gut flora, and respiratory systems to that in 
humans, and have cytokines and chemokine’s homologous to other mammals (Butler et 
al., 2009).   
 The piglet is born with virtually no plasma immunoglobulin G (IgG) in part 
because the epitheliochorial nature of the porcine placenta prevents transfer of maternal 
immunoglobulin’s, and in part because of lack of exposure to antigens.  This makes the 
piglet highly immunodeficient at birth and dependent on the postnatal supply of both 
specific and non-specific immune factors present in maternal colostrum and milk for 
immune protection during development (Gaskins, 1995).  Absorption of intact IgG from 
colostrum is normally complete within the first 24-48 hours after birth when the 
enterocytes of the piglet small intestine cease to transfer intact macromolecules across the 
basolateral membrane of the cell, the process being known as gut closure (Leece, 1973). 
 
II.  Immune System Challenges  
Two newer vaccines used in infants include influenza and RV vaccination 
(Jacobson, 2009).  However, even with vaccinations available, both influenza and RV 
infect millions of children each year and are significant causes of morbidity and mortality 
in neonates.  Our studies utilize an influenza vaccination and RV infection to stimulate 
and challenge the immune system of the neonatal piglet.   
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A.  Influenza and Influenza Vaccination 
1.  Influenza 
Influenza is a contagious illness that causes severe morbidity and death involving 
approximately 5 million people worldwide annually.  Influenza causes respiratory 
syndromes, including otitis media, croup, sepsis, bronchitis, asthma, and pneumonia 
(Neuzil & Edwards, 2002).  About 20% of children and 5% of adults worldwide develop 
influenza A or B every year (Nicholson et al., 2003).  Young children are more likely to 
be infected with influenza than older children or adults (Nicholson et al., 2003), and can 
spread influenza infection in their households and communities.  Children have high rates 
of hospitalization for influenza, which are comparable to the elderly.  However it is not 
common for death to occur in the young.   
Influenza virus is a RNA virus that belongs to the Orthomyxovirdae family and 
consists of negative-sense single-stranded RNA genome (Koyama et al., 2007).  There 
are three types of influenza viruses: A, B, and C, but only types A and B cause 
widespread outbreaks each year.  There are then subtypes for each virus form (Isaacs D, 
2009).  The ssRNA in influenza virus is recognized by the innate immune system through 
TLR7 and retinoic acid inducible gene 1.  Both of these recognition pathways lead to the 
activation of type 1 interferons and provide resistance to infection (Ichinohe et al., 2009).   
 
2.  Influenza Vaccination 
Annual influenza immunization is advised for all infants between 6-23 months-of-
age by the Advisory Committee on Immunization Practices (ACIP) and endorsed by the 
American Academy of Pediatrics and the American Academy of Family Physicians.  The 
goal is to decrease the number of hospitalizations for children, reduce the incidence of 
influenza-associated acute otitis media, and to protect the elderly and infants less than six 
months-of-age who are too young to be immunized.    
Trivalent inactivated influenza vaccine (TIV) contains 3 influenza strains, two 
type A and one type B that represent the influenza viruses most likely to circulate in the 
upcoming winter.  The TIV has been shown to have limited efficacy in young children 
compared to live attenuated influenza vaccine (LAIV) administered into the lung as a 
spray.  Currently LAIV (e.g. Flu Mist, MedImmune, LLC, Gaithersburg, MD) is not 
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being advised for children < 24 months of age in the United States, because of increased 
risk of wheezing post-vaccination. A Multicenter Study conducted in the U.S. compared 
TIV vs. LAIV and found that the efficacy of LAIV was superior to TIV in children’s first 
and second years (Belshe et al., 2000).  Belshe and colleagues also conducted a study that 
did not show an increase of severe asthma or wheezing illness in children aged 6-23 
months who received either LAIV or TIV (Belshe et al., 2007).  However, this study 
found an increase in hospitalizations in children aged 6-11 months 180 days after LAIV 
vaccination, but hospitalizations could not be attributed to a single cause.  Therefore 
LAIV is still not recommended for young children.  It is recommended to give two doses 
of vaccine to children <9 years who have not received a previous dose in order to achieve 
adequate antibody responses (Neuzil & Englund, 2006).  Nationally, 40.7% of children 
aged 6-23 months received ≥1 dose of influenza vaccination in 2007-2008 (Fiore et al., 
2007).   
Concern over the safety of influenza vaccine is seen in the general public, and 
many parents choose not to vaccinate their children (Torun et al., 2010).  There have been 
concerns that inactivated vaccine might cause asthma in adults and children, but this has 
not been proven in clinical studies.  The most common adverse events were fever and 
local reactions (Smith et al., 2006).  TIV contains small amounts of thimerosal (sodium 
ethyl mercury thiosalicylate), which is a preservative.  Thimerosal is a water-soluble 
substance that degrades or metabolizes into ethylmercury (etHg), which is a lipid soluble.  
In animal tissues, etHg binds to protein matrices and is excreted through the gut.  This 
substance has caused concern for some parents but, to date, no side-effects have been 
attributed to thimersol (Dorea, 2007).   
 
B.  Rotavirus and Rotavirus Vaccination 
1.  Rotavirus  
Nearly all children experience at least one RV infection by the age of 5 years 
(Bernstein, 2009).  Rotavirus causes symptoms such as diarrhea, vomiting, and fever. The 
incidence of RV infection is similar for developed and developing countries, but death is 
more frequent in developing countries, with more than 600,000 deaths annually 
worldwide (Desselberger et al., 2009).  Vaccination is the main public health intervention 
10 
 
to combat RV infection and, since 2006, two vaccines have been approved for use in 
many countries, including the United States.   
Rotavirus was given its name due to its wheel-like structure (Lat. Rota = wheel).   
It is a non-enveloped, double-stranded (ds) RNA virus that infects mature epithelial cells 
of the small intestine.  It is composed of 11 segments of dsRNA surrounded by three 
protein coats (Blutt et al., 2004).  The RNA segments encoding RV are made up of six 
structural and six nonstructural proteins (Pesavent et al., 2006).  This triple layered 
particle is made up of an inner layer that contains VP1, VP2, VP3 and enclosing the 
genome, an intermediate layer is made up of VP6, and an outer layer that consists of VP7 
and VP4 (Desselberger et al., 2009).   
Entry of RV into the intestinal epithelial cell is a complex multistep process in 
which several cell molecules are needed (Lopez & Arias, 2006), and viral uptake is 
characterized by a sequence of interactions with primary and secondary receptors (Lopez 
& Arias, 2004).  Once taken into the cell, viral replication occurs in the cytoplasm of 
mature epithelial cells of the small intestine.  After removal of the outer caspid from the 
triple-layered RV particle by cellular enzymes and a low intracellular Ca
2+
 level, a 
double-layered particle emerges.  This double-layered particle becomes transcriptionally 
active and large amounts of new RNA molecules are produced.   
Rotavirus infection produces a humoral immune response.  Intestinal dendritic 
cell (DC) numbers were higher in piglets infected with RV compared to non-infected 
controls at 2 and 4 days post-infection.  Immune response to RV infection is greatest in 
lymphoid tissue adjacent to the site of viral replication in the small intestine (Saif et al., 
1997).  In piglets, the total number of intestinal DC were higher than those in spleen and 
MLN (Gonzalez et al., 2010). 
During a viral or bacterial infection, the initial cytokines to be produced are the 
proinflammatory cytokines, such as IL-1, IL-6, IL-8, and TNF-α, and later the Th1 
cytokines IL-2 and IFN-γ, and the Th2 cytokines IL-4, IL-5, IL-13 and IL-10 (Azevedo et 
al., 2006).  Initially, RV infection elicits inflammatory cytokines from intestinal epithelial 
cells that are vectorially secreted from the basolateral surface (McCormick et al., 1993).  
These include IL-8, monocyte chemotactic protein-1 (MCP-1), and TNF-α.  The 
functional consequences in the intestine of increased local production of these cytokines 
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include chemoattraction and activation of immune cells (Rollo et al., 1999).  Children 
who have RV disease have increased serum levels of TNF-α, IL-6, IL-10, and IFN-γ 
compared to non-infected children (Jiang et al., 2003).  One study found serum 
concentrations of IFN-α, IL-10 and IL-12 were increased in piglets infected with RV on 
day 2 and 4 after infection (Gonzalez et al., 2010).  Another study found that gnotobiotic 
piglets had increased serum IL-6 on days 1 and 3, IFN-γ on days 3 and 5, IL-12 days 1, 3, 
and 10, IL-10 days 1 and 5, and IL-4 on days 3 and 5 post infection with RV compared to 
controls.  These same RV-infected piglets had consistently higher intestinal cytokine 
levels of IFN-γ, IL-10, IL-4, and IL-6 early at post infection days 3 and 5 (Azevedo et al., 
2006).  Another study demonstrated that a piglet sacrificed 12 post rotavirus infection had 
significantly higher IFN-γ than uninfected piglets (Hulst et al., 2008).  This indicates that 
the secretion of both Th1 and Th2 type cytokines is increased in children and piglets with 
natural RV infection.   
Innate immunity has been show to play an important role in controlling RV 
infection.  Rotavirus infection causes the rapid activation of NF-κβ and the induction of 
NF-κβ-directed cytokines, such as IL-8 (Rollo et al., 1999).  These cytokines attract and 
activate immune cells at the site of infection.  Dendritic cells play a crucial role in the 
induction of the innate immune response and are the most efficient APC, inducing 
acquired responses by B and T cells (Lopez-Guerrero et al., 2010).  Strong intestinal and 
systemic B- and T-cell responses are generated against virulent RV (Azevedo et al., 
2006).  The frequency of intestinal DC (both plasmacytoid and conventional) and 
macrophages/ monocytes are higher in RV infected piglets compared to controls on days 
2 and 4 post infection (Gonzalez et al., 2010).  Intestinal macrophages in the lamina 
propria are derived from blood monocytes and play a unique role as effector cells of the 
innate immune system.  Resident lamina propria macrophages are non-inflammatory in 
the normal intestine, but can be used as host defense system, if needed.  RV infection in 
gnotobiotic pigs showed that infection alone activated/recruited significantly more 
monocytes/macrophages in the intestine and spleen 5 days post infection than control 
gnotobiotic control animals and gnotobiotic pigs colonized with lactic acid bacteria 
(Zhang et al., 2008).  Rotavirus proteins have been detected in macrophages in both 
intestinal and extra intestinal lymphoid tissues (Zhang et al., 2008).  Natural killer cells 
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also play an important role in the innate defense mechanism of the host aimed at the 
elimination of virus-infected cells (Fawaz et al., 1999).  One of the hallmarks of RV 
infection is the absence of neutrophil infiltration (Rollo et al., 1999). 
CD14
+
 monocytes/macrophages are also higher in the ileum and spleen of RV-
infected piglets compared to non-infected piglets (Zhang et al., 2008).  CD14 is a specific 
receptor that is expressed on subsets of monocytes and macrophages (Antal-Szalmas et 
al., 1997).  Investigation of the differentiation of porcine myeloid bone marrow 
hematopoietic cell populations suggests that CD14 is a maturation-dependent antigen and 
study of CD14 expression may be useful for assessment of cell maturity (Summerfield et 
al., 2001).   
 
2.  Rotavirus Vaccinations 
 RotaTeq®, developed by Merck (Whitehouse Station, NJ), is based on the 
attenuated bovine RV WC3 strain.  It is comprised of five mono-reassortments in which 
the VP7 gene of the WC3 RV strain was replaced by the VP7 genes of human G1, G2, 
G3 and G4 strains, and the VP4 gene by another human strain, the other 10 genomic 
RNA segments in mono-assortments by the WC3 strain.  RotaTeq® is highly effective in 
preventing RV gastroenteritis caused by G1, G2, G3, G4, and G9 strains (Jiang et al., 
2010).   
Rotarix® (GlaxoSmithKline; Research Triangle Park, NC) is made from an 
attenuated human RV isolate, 89-12, and is of the G1P1A type.  It has also been found to 
be highly effective in preventing RV gastroenteritis (Jiang et al., 2010).  This vaccine 
provides protection against G2, G3, G4, and G9 strains.  Rotavirus vaccination is highly 
recommended by the world health organization in both developed and developing 
countries (Tu et al., 2011). 
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III. Bioactive Ingredients  
A. (1,3/1,6)-β-D-glucan 
1.  Origin and Structure 
Glucans are a diverse class of glucose polymers that can be short or long, 
branched or unbranched,  or  isomers, and soluble or particulate (Goodridge et al., 
2009).  There are many sources of glucans, but fungal cell wall glucans -1,3-glucan with 
varying numbers of 1,6 branches are the most common.  Common sources of -1,3-
glucan ( G) are yeast (Saccharomyces cerevisiae), mushroom, bacteria and seaweed.   
G from all of these sources has been shown to have effects on immune cells.  
However, it is difficult to make conclusions regarding the impact of G due to 
inconsistencies in the biological responses.  One potential source of variation seen in 
these studies may be the form of βG utilized.  βG can be extracted from a number of 
sources, and these forms have been shown to have varying levels of bioactivity.  
Although the molecular structures of the various βG chains with branch points at 
(1,3/1,6) are highly conserved, the three-dimensional structure of the molecule can be 
different among organisms and depends on the chain length, branch type, and branch 
frequency.  The method by which βG are processed or manufactured can also have a 
significant impact on their immune stimulatory activity (Bohn, 1995; Mueller et al., 
2000; Saito et al., 1991; Seljelid et al., 1981; Willment et al., 2001).  There is also data 
that indicates that more water-soluble βG polymers are more active, and the immune-
potentiating activity of βG can also depend on the helical conformation and on the 
presence of hydrophilic groups located on the outside surface of the helix.  Evidence also 
suggests that the activity is dependent on the size, with high molecular weight (100,000-
200,000) fractions being most active, while fractions from the same source with 
molecular weights of 5,000-10,000 showed no activity (Blaschek et al., 1992; Fabre et 
al., 1984; Kojima et al., 1986).  
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2.  Immune Activation 
βG belong to a group of Biological Response Modifiers (BRM), which means 
they do not have direct cytotoxic activities, but they are able to boost the natural defense 
mechanisms of the host.  These microbially-derived glucan polymers are MAMP that are 
recognized by PRR, which allow the innate immune system to quickly recognize the 
presence of glucans, which are originally found in yeast cell walls and therefore seen as a 
pathogen.  There are four PRR that recognize βG: dectin-1, complement receptor 3 
(CR3), lactosylceramide and scavenger receptors (Goodridge et al., 2009).  In humans, 
the CR3 receptor is a receptor mediating the physiological functions of yeast (1,3/1,6)- β 
-D-glucan (Baran et al., 2007; Li et al., 2007).  CR3 is an integrin dimmer and is 
expressed my cells including monocytes, macrophages, DC, neutrophils, and natural 
killer cells.  CR3 has a high affinity for G, but can also bind to other carbohydrates 
(Goodridge et al., 2009).    
Dectin-1 is the most well characterized G receptor.  Dectin-1 is a type II 
membrane receptor that belongs to the C-type lectin family of receptors.  These receptors 
contain an extracellular C-terminal C-type lectin domain, a short stalk region, a single 
transmembrane domain, and a short 40 amino acid amino-terminal intracellular tail.  In 
mice and pigs, dectin-1 is expressed on the surface of many organs and is located on the 
cell surface of dendritic cells, leukocytes, monocytes, macrophages, and neutrophils.  
Three isoforms of dectin-1 have been reported in the pig (Sonck et al., 2009) and it is 
expressed in the pig’s stomach, duodenum, jejunum, ileum, colon, rectum, MLN, spleen 
and lung.  Dectin-1 signals to a variety of macrophage, DC, and neutrophil responses, 
including phagocytosis, oxidative burst, neutrophil degranulation, fungal killing, and the 
production of inflammatory lipid mediators, cytokines, and chemokines that recruit and 
coordinate the activation of other immune cells (Goodridge et al., 2009).   
 Uptake of particulate antigenic matter, including microorganisms and vaccine-
bearing microspheres, by the intestinal mucosa takes place in the domes of the gut-
associated lymphoid tissues and is achieved by membranous (M) cells, which 
continuously transport particles from the lumen to the underlying tissue where some 
particle components initiate immune reactions (Beier & Gebert, 1998).  Using Baker’s 
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yeast (S. cerevisiae) as a tracer, the kinetics of particle uptake in the Peyer’s patches (PP) 
of pigs was investigated (Beier & Gebert, 1998).  Transcytosis of yeast particles by M 
cells occurred within 1 h.  Without significant phagocytosis by intraepithelial 
macrophages, the particles migrated down to and across the basal lamina within 2.5-4 h, 
where they were quickly phagocytosed and transported out of the Peyer’s patch domes. 
 
3.  Physiological Function 
 A 28-day dietary supplementation with yeast βG improved the humoral immunity 
of pigs and modulated cellular immunity of weanling pigs by mitigating the elevation of 
pro-inflammatory cytokines (IL-6 and TNF-α) and increasing the production of anti-
inflammatory cytokines (IL-10) after an immunological challenge with 
lipopolysaccharide (LPS) (Li et al., 2005).  Furthermore, three days of dietary 
supplementation with yeast βG exerted anti-viral effects against swine influenza virus in 
5-day-old piglets, while increasing levels of IFNγ in the bronchiolar lavage fluid (Jung et 
al., 2004).  These findings were supported by an anti-viral effect against porcine 
reproductive and respiratory syndrome virus in weanling pigs (Xiao et al., 2004).  In 
addition, IFNγ production was also increased upon ex vivo stimulation with βG in 
PBMCs isolated from the treated animals.  In both studies (Li et al., 2005; Xiao et al., 
2004), yeast βG administration was associated with an up-regulation of the Th1 cytokine 
IFN-γ.  Indeed, a hallmark of βG therapy is a switch from a Th2 to a Th1 response. 
 Previous literature has shown that βG affects lymphocyte populations. For 
example, CD4
+
 and CD8
+ 
lymphocytes were higher in weaned pigs fed βG from S. 
cerevisiae-supplemented diets as compared with pigs fed control diets (Hahn et al., 
2006).  However, it took eight weeks of dietary treatment for this effect to be detected.  
Another study supplemented adult mice with βG treatments obtained from culture filtrate 
of the fungus Sclerotinia sclerotiorum IFO 9395.  The mice given βG showed greater 
spleen cell proliferation when stimulated with T or B cell mitogens than did those from 
control mice spleen cells (Suzuki et al., 1989).  In other studies, βG from S. cerevisiae 
has been shown to enhance the activities of natural killer cells and peritoneal 
macrophages, as well as stimulate cytotoxic T lymphocytes, B cells, and macrophages in 
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mice (Cross et al., 2001).  However, these effects were only seen when βG was applied to 
cells in vitro or administered intraperitoneally. 
 βG seems to have a greater impact in studies of disease challenged animals.  In 
fact, dietary supplementation with a commercially-available βG (Original XPC; Diamond 
V, Cedar Rapids, IA) improved growth of weaned pigs challenged with Salmonella (Price 
et al., 2010).  Additionally, WGP® given orally increased the survival rate of mice 
infected with anthrax (Kournikakis et al., 2003).  Finally, WGP® has demonstrated 
effectiveness by switching a Th2 response to a protective Th1 cell-mediated response in 
tumor-bearing mice when it was given orally and combined with anti-tumor monoclonal 
antibodies (Baran et al., 2007).    
 
4.  Vaccine Effect 
 βG has demonstrated the ability to increase vaccination response.  βG increased 
the effectiveness of a DNA vaccine against human immunodeficiency virus-1, when used 
as an adjuvant  (Ara et al., 2001).  A number of other studies however, have shown little 
effect of βG supplementation on antibody response to systemic immunization.  For 
instance, yeast βG did not enhance the efficiency of vaccinations for porcine reproductive 
and respiratory syndrome (PRRS) virus (Hiss & Sauerwein, 2003), or different 
Enterotoxinogenic Escherichia coli (ETEC) antigens (Decuypere et al., 1998).  βG from 
S. cerevisiae supplemented to piglets vaccinated with an atrophic rhinitis vaccine actually 
produced fewer antigen-specific antibodies (Hahn et al., 2006), but pigs supplemented 
with βG from S. cerevisiae injected with ovalbumin produced more antibodies (Li et al., 
2005).  Studies examining whether enteral βG supplementation can enhance immune 
responses to vaccination are limited.   
 
B.  Nucleotides 
1.  Origin and Structure 
Nucleotides (NT) are low molecular weight compounds that consist of a 
nitrogenous base (purine and pyrimidine bases), a sugar molecule (pentose), and 1-3 
phosphate groups.  NT are nucleic acid precursors, physiologic mediators, components of 
coenzymes, and sources of cellular energy.  They are important functional components of 
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human milk and their content in human milk is higher than that of bovine milk, from 
which infant formula is made.  However, sow milk is much higher in NT content than 
human milk.  Not only is the total amount different between species, but the ratio of the 
individual NT also differ (Table 1.1) (Leach et al., 1995; Mateo et al., 2004).  For 
example, cytidine (42%) is the predominant NT in human milk, whereas in porcine milk, 
uridine comprises ~90% of the total NT (Table 1.1).  This suggests that species-species 
secretory mechanisms may be present.  Catabolic enzymes, such as kinases for specific 
NT, may have been present during the process of secretion, accumulation, and storage 
within the mammary gland (Thorell et al., 1996).  The NT content of human milk is 72 
mg/L using the total potentially available nucleosides (TPAN) method of analysis (Leach 
et al., 1995).  Currently, infant formula is fortified with between 20 and 70 mg 
nucleotides/L.  Nucleotides in milk may originate from two different sources, either 
dietary sources or NT synthesized de novo within the mammary gland.  Interestingly, NT 
content in human milk increases and porcine milk decreases as lactation progresses.  This 
change may be a response to a changing need for NT by nursing infants or piglets.  
However, it is uncertain whether the NT present in milk are secreted in response to a 
specific need of the neonate or indirectly result from other metabolic events within the 
mammary secretory cell, such as synthesis of lactose, protein, and fat.  For instance, 
during the synthesis of lactose and sialyllactose, which occurs within Golgi vesicles, 
5’UMP and 5’CMP are formed and may therefore be released into the alveolar lumen 
during exocytosis (Arthur et al., 1991).  There is a lack of information on how levels and 
composition of NT in the milk are regulated.   
 
2.  Immune Activation 
 Nucleic acid analogs enhance both humoral and cellular immune responses (Xiao, 
2009).  Metabolites of nucleic acids, namely nucleotides and nucleosides, are recognized 
by host receptors, TLR- 3, 7, 8, 9 and NOD-like receptors (NLR-NOD2) (Ishii & Akira, 
2008).  Both dsRNA and ssRNA are known ligands for TLR.  TLR and NLR have unique 
signaling pathways.  TLR 7, 8, 9 stimulate the MyD88 pathway, TLR 3 stimulates the 
Toll-IL-1 receptor-domain-containing adaptor (TRIF) pathway, and NOD2 stimulates the 
NFκβ pathway.  Each signaling pathway results in the induction of cytokine expression. 
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Using, quantitative real-time PCR, NOD2 mRNA expression was demonstrated in a 
number of tissues from newborn and adult pigs (Tohno et al., 2008).  When piglets were 
first born (prior to ingestion of colostrum), NOD2 expression was mainly localized in the 
MLN and spleen, but at one year-of-age, NOD2 expression was similar in all tissues 
tested, including esophagus, small intestine, ileal Peyer’s patches, colon, MLN and spleen 
(Tohno et al., 2008). 
 
Table 1.1.  Nucleotide Content (mg/L) and Composition in Human and Porcine Milk 
Nucleotide Human
1 
Porcine
2 
 Colostrum Mature Colostrum Mature 
Adenosine 6.9 15.2 13.2 14.2 
Cytidine 23.4 33.7 4.9 7.59 
Guanosine 6.9 14.9 17.8 19.8 
Uridine 8.58 15.8 1833.5 405.2 
Total Nucleotides 45.78 79.6 1869.4 446.8 
1
 Leach, Baxter, Molitor, Ramstack, & Masor, 1995 
2
 Mateo, Peters, & Stein, 2004 
 
3.  Physiological Function 
Dietary NT exert various physiological functions and are particularly important 
for the growth and development of tissues with rapid turnover, such as the intestinal 
mucosa. The main forms of NT in human milk are nucleoproteins and nucleic acids, 
whereas pure NT are supplemented to infant formula.  These are converted by pancreatic 
and intestinal nucleases into nucleosides and nucleobases, the preferred forms for 
absorption (Schlimme et al., 2000).  Transport of nucleosides and bases into the 
enterocyte occurs via facilitated diffusion and specific Na+dependent carrier-mediated 
mechanisms (Bronk, 1998).  Most are rapidly degraded in the enterocyte and excreted in 
urine.  In humans, purine nucleotides/nucleosides and bases are degraded to uric acid and 
pyrimidines are degraded to ß-alanine and ß-aminoisobutyric acid (Carver, 1995). 
There are two NT biosynthetic pathways: de novo and the salvage pathways.  The 
de novo pathway uses small precursors for NT synthesis, whereas the salvage pathway 
uses nucleosides and bases resulting from the breakdown of NT to re-synthesize nucleic 
acids.  Dietary NT contribute to the salvage pathway by providing preformed nucleosides 
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and nitrogenous bases.  Under most conditions, endogenous NT are made available to the 
intestinal mucosa via hepatic supply and salvage pathway.  Nucleotides are possibly of 
special importance in the development and proliferation of tissues with a rapid cell 
turnover such as intestine, bone marrow and lymphocytes.   
Nucleotides are considered to be semi-essential for infants, since the endogenous 
synthesis is insufficient to meet their needs.  Exogenous (NT) can optimize function both 
by supplying the nutrients and by sparing the organism from the cost of synthesizing new 
NT, which is a costly process (Uauy, 1989).  Dietary purine and pyrimidine bases are 
thought to be largely utilized and degraded by the liver and enterocytes before entry into 
the systemic circulation.  Up to 5% of orally-administered labeled NT was used for tissue 
nucleic acid synthesis in adult mice (Sonoda & Tatibana, 1978).   
A beneficial effect of NT on gastrointestinal growth and function has been shown 
in several animal studies (Lopez-Navarro et al., 1996; Ortega et al., 1995).  Pigs fed a 
NT-supplemented (500 mg/L) diet showed significant intestinal growth compared to 
control pigs (Domeneghin et al., 2006; Yu et al., 2002).  In addition, NT supplemented to 
cell culture media increased proliferation in intestinal cell lines, CaCo-2 and IEC-6 
(Holen, 2004).   
Peripheral blood mononuclear cells did not proliferate with the addition of NT 
alone, but did when cultured with both NT and influenza virus antigen (Holen et al., 
2005).  The impact of NT on the immune system is through a number of pathways, 
including lymphocyte activation and proliferation, natural killer cell activity and 
macrophage activation, delayed cutaneous hypersensitivity, rejection of allogenic grafts 
and an increased production of other factors that modulate the immune system (Aggett et 
al., 2003; Carver, 1994; Carver, 1999; Grimble & Westwood, 2001; Jyonouchi, 1994; 
Van Buren et al., 1994). 
 
4.  Vaccine Effect 
 It has been documented that the response to vaccination is greater in breast- than 
formula-fed infants (Dorea, 2009).  Clinical studies have demonstrated that 
supplementation of infant formula with 33-72 mg/L NT improved the vaccination 
response relative to infants fed unsupplemented formula, however, the efficacy of NT 
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differs based on the type of vaccine administered and between studies (Schaller et al., 
2007).  Infants (n=311) fed formula containing 72 mg NT/L had higher Hib and 
diphtheria antibody titres, but not antibodies to polio than infants fed non-supplemented 
formula (Pickering et al., 1998).  Schaller and colleagues (2004) demonstrated that NT 
supplementation at 72 mg/L significantly improved the response of term human infants 
(n=477) to poliovirus-VN1 vaccination, tended to improve the response to Hib and 
diphtheria vaccinations, but did not affect the response to tetanus toxoid vaccination 
(Schaller et al., 2004).  Lastly, a study with 140 infants reported an increase in antibody 
response to tetanus toxoid in infants supplemented with 33.5 mg/L NT, however no 
difference was detected in diphtheria toxoid and hepatitis B antibodies (Hawkes et al., 
2006).  The vaccines were delivered at the same dose and according to the schedule 
recommended by American Academy of Pediatrics.  The magnitude of vaccine response, 
ranging from 1.3-1.8 fold changes higher in NT diet compared to control diet, was similar 
in all studies (Schaller et al., 2007; Hawkes et al., 2006; Pickering et al., 1998; Schaller et 
al., 2004).  Although these studies show inconsistency in which vaccination response is 
increased, each study with supplemented NT showed at least one vaccination response 
that was significantly increased over non-supplemented. 
 However, the mechanism(s) whereby NT increases the vaccination response is 
still unclear.  Modulation of the production of cytokines that impact B cell maturation is 
one hypothesized mechanism of increased Ig production.  Another mechanism could be 
that NT directly stimulate the maturation and differentiation of B cells that are precursors 
to plasma cells.  Past research has shown that Ig production is possibly affected by NT 
supplementation through Th1 and Th2 cytokine production.  For example, feeding NT-
free diets to mice decreased Th1 and Th2 cytokine production (Jyonouchi et al., 1996).  
Additionally, CD5 protein is expressed by Ig producing B cells, and CD5 expression was 
increased in mice with nucleotides in diet, which could explain why Ig production is 
increased (Manzano et al., 2000 ).  B cells are stimulated to proliferate by Th2 cytokines, 
specifically IL-4 and the CD40 ligand, drive the clonal expansion of B cells, which 
precedes antibody production.  Th2 cytokines, IL-5 and IL-6 are also thought to be 
involved with later stages of B cell maturation to Ig-secreting plasma cells (Jyonouchi et 
al., 1996).   
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C.  Human Milk Oligosaccharides 
1.  Origin and Structure 
Human milk oligosaccharides (HMO) are the third most abundant constituent of 
human milk and are found in concentrations of 12 – 15 g/L (Coppa et al., 1993; 
Newburg, 2000).  The composition of oligosaccharides from human milk is unique, and 
the HMO concentration is markedly higher than bovine milk (Newburg et al., 2004a).  
Around 200 different HMO have been identified in human milk (Bode, 2009).   
The HMO vary in size, structure, and abundance (Coppa et al., 1993).  Many 
occur in free form, while others are linked to proteins or lipids (Hosea et al., 2008).  The 
building blocks of milk oligosaccharides are the five monosaccharides D-glucose, D-
galactose, N-acetylglucosamine, L-fucose, and SA.  Lactose forms the reducing ends of 
the HMO and lactose can be fucosylated on the nonreducing end in α1-2 and α1-3 
linkages to form 2'fucosyllactose (2'FL) and 3'fucosyllactose (3'FL), respectively.  
Lactose can also be sialylated on the nonreducing end in α2-3 and/ or α2-6 linkages to 
form 3'sialyllactose (3'SL) and 6'sialyllactose (6'SL), respectively.  More complex HMO 
can be made by different combinations of the five monosaccharides listed above.  HMO 
are synthesized by the glycosyltransferase-catalyzed transfer of monosaccharides from 
sugar nucleotides to elongating carbohydrate structures.  Lactose is used as the basis for 
the synthesis of larger and more complex structures.  These larger structures are 
synthesized by fucosyltransferases, which only certain women have.  HMO vary among 
individuals because they are associated with the same genes that determine Lewis blood 
type and secretor status (Viverge et al., 1990).  Women who are nonsecretors do not 
express measurable 2-linked fucosyloligosaccharides in their milk or other bodily fluids 
(Newburg et al., 2004).   
There are neutral and acidic classes of HMO found in human milk.  Colostrum 
contains double the concentration of oligosaccharides found in mature milk, for example 
breast milk from week 1 of lactation contained 9 g/L, and continued to decrease to a level 
of 4 g/L at 1 year (Chaturvedi et al., 2001).  The different levels of some individual HMO 
in human milk are shown in Table 1.2.  Oligosaccharides are resistant to digestion and, 
thus, remain intact until reaching the large intestine, which allows them to have many 
functions throughout the intestinal tract   
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2. Digestion and Absorption 
 HMO have been shown to resist digestion in the upper gastrointestinal tract of 
infants (Brand-Miller et al., 1998).  In fact, it has been estimated that at least 90% of 
ingested HMO survive transit through the small intestine (Newburg et al., 2005).  
Furthermore, detection of HMO in fecal samples obtained from breast fed infants 
suggests that some of these carbohydrates may even resist fermentation by colonic 
bacteria (Chaturvedi et al., 2001). 
In vitro studies indicate that HMO are not degraded to a significant extent by 
gastrointestinal secretions from either the stomach or the small intestine.  HMO are 
minimally digested (<5%) by human salivary amylase, porcine pancreatic amylase, brush 
border membrane vesicles isolated from porcine small intestine, and the pH similar to the 
one prevailing in the infant’s stomach (Gnoth et al., 2000).  More specifically, there are 
no brush border enzymes capable of cleaving fucosylated oligosaccharides, such as lacto-
N-fucopentaose (LNFP) I and LNFP III in the small intestine, but brush border enzymes 
are able to minimally digest nonfucosylated oligosaccharides such as lacto-N-tetraose 
(LNT) and neo-LNT (Gnoth et al., 2000).  Thus, it is postulated that slight hydrolysis of 
ingested oligosaccharides occurs either in the terminal ileum, where a low level of 
fermentation may occur, or in the low pH environment in the stomach (Molis et al., 
1996).  Previously, an in vitro assay of mild acid hydrolysis (0.05M HCl, 37°C, 120 min) 
showed 8% of inulin was converted to free fructose (Nilsson & Bjorck, 1988), which is 
why it is conceivable that HMO would be slightly hydrolyzed in low pH environments.  
Oligosaccharides could then be absorbed as glucose and galactose by the Sodium-
Glucose Transporter 1 (SGLT1) in the small intestine (Boudry et al., 2010).   
Although most HMO escape digestion in the small intestine, small amounts of 
intact oligosaccharides have been detected in urine, which implies absorption (Rudloff et 
al., 1996; Obermeier et al., 1999).  Assuming that human milk is the only source of 
specific urinary oligosaccharides, renal excretion of these components would account for 
~1% of the daily intake (Kunz et al., 2000).  An experiment investigating the 
transepithelial transport of HMO across Caco-2 monolayers suggested that neutral HMO 
are transported across the intestinal epithelium by receptor-mediated transcytosis as well 
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as via paracellular pathways, whereas translocation of acidic HMO solely represents 
paracellular flux (Gnoth et al., 2001).   
 
Table 1.2.  Content and Composition of HMO in Human Milk 
HMO Average (g/L) 
Concentration 
(g/L) 
Citation 
LNnT 
Galβ1-
4GlcNAcβ1-
3Galβ1-4Glc 
0.3 0.45 Asakuma et al., 2008 
 0.25 Thurl et al., 2010 
 0.17 Chaturvedi et al., 2001 
 0.3 Newburg et al., 2004 
Sialic Acid 
Mixture of 
3'SL and 6'SL 
0.7 0.45-1.15 Wang & Brand-Miller, 2003 
 0.25-0.88 Miller et al., 1994 
 0.3-1.5 Nakano et al., 2001 
3′SL 
Neu5Acα2-
3Galβ1-4Glc 
0.2 0.1-0.3 Kunz et al., 2000 
 0.27 Thurl et al., 2010 
 0.07 Bao et al., 2007 
 0.1-0.3 Martin-Sosa et al., 2003 
6′SL 
Neu5Acα2-
6Galβ1-4Glc 
0.5 0.3-0.5 Kunz et al., 2000 
 1.22 Thurl et al., 2010 
 0.29 Bao et al., 2007 
 0.2-0.3 Martin-Sosa et al., 2003 
2′FL 
Fucα1-
2Galβ1-4Glc 
2.7 2.03 Asakuma et al., 2008 
 2.6 Thurl et al., 2010 
 2.43 Chaturvedi et al., 2001 
 1.88 Newburg et al., 2004 
 2.4-4.9 Musumeci et al., 2006 
3′FL 
Galβ1-4Glc3-
Fuc α 1 
0.5 0.25 Asakuma et al., 2008 
 0.79 Thurl et al., 2010 
 0.86 Chaturvedi et al., 2001 
 0.28 Newburg et al., 2004 
 
 The gut of a newborn is permeable to intact sugars for the first few days of life 
(Weaver et al., 1984).  These may be absorbed in considerable amounts for a period after 
birth, but a reduction in uptake seems to follow the onset of enteral nutrition.  Babies of 
34 to 37 weeks gestation achieve a mature intestinal permeability within four days of 
starting oral feeds (Weaver et al., 1984; van Elburg et al., 2003).  In vivo studies 
investigating intestinal permeability have used lactulose (MW=342) and mannitol 
(MW=182).  These sugars are indigestible in the small intestine and are absorbed through 
paracellular (lactulose) or transcellular (mannitol) pathways.  Urinary excretion of the 
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sugars is measured to determine intestinal permeability.  The paracellular pathway 
accommodates larger molecules while the transcellular pathway accommodates smaller 
molecules (< 180 MW) (Weaver et al., 1984).  The pathways able to accommodate 
smaller molecules have been ascribed to a highly prevalent population of small water-
filled pores probably situated in cell walls, and a much lower frequency of larger 
channels thought to be paracellular which would be able to accommodate larger 
molecules (Beach et al., 1982).  Therefore it is possible that a paracellular pathway could 
be responsible for transport of oligosaccharides in the small intestine, particularly in the 
young infant whose gut is more permeable for macromolecules.    
 
3.  Immunomodulatory Action 
HMO also have an inhibitory effect on certain pathogenic microorganisms, by 
blocking adhesion of the pathogenic microorganisms to the epithelial surfaces (Ruiz-
Palacios et al., 2003).  Formula fed infants have greater amounts of pathogenic microbes 
in their large intestine compared to breast fed infants (Iseki, 1987), and the high amounts 
of HMO in breast milk could explain this difference in intestinal colonization (Bode, 
2009).   
Rotavirus recognizes glycoconjugate receptors located on the villus-tips of 
enterocytes in order to infect the cells.  Both porcine and human strains of RV bind to 
sialyllactose oligosaccharides on cell membranes (Rolsma et al., 1998).  Inhibition of 
virus binding to host cells by using receptor mimics provides an opportunity to stop the 
infectious cycle.  Various sialylated glycoproteins at concentrations of 10-100 μg/ml 
inhibit RV infection, if preincubated with the virus prior to cell infection (Isa et al., 
2006).  Thus, SA-containing glycoproteins or HMO could be used to protect individuals 
against RV infection, particularly in individuals who do not receive RV vaccination.  In 
addition, neutral HMO exert anti-microbial and anti-viral actions.  For example, the 
incidence of diarrhea is lower in infants of women with higher amounts of 2'FL-containin 
-oligosaccharides in their breast milk (Newburg et al., 2004). This suggests that this class 
of HMO can also act as competitive inhibitors of pathogen binding to their 
glycoconjugate receptors.   
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Recent work in our lab has shown that specific HMO can inhibit RV infectivity in 
vitro (Chen et al., 2011).  Infectivity by OSU porcine RV strain OSU (P9[7],G5) obtained 
from Kuhlenschmidt lab was dose-dependently inhibited by HMO isolated from preterm 
human milk as well as pure forms of 3'SL and 6'SL, but not by LNnT, 2'FL, 3'FL or a 
combination of polydextrose and galactooligosaccharides (PDX/GOS).  3'SL and 6'SL 
inhibited OSU strain RV at a dose of 2 mg/mL.  These data are consistent with the fact 
that the OSU strain requires SA for binding to its target intestinal epithelial cells.  
HMO are thought to play a key role in the immunomodulatory and 
immunoprotective actions of human milk (Kunz & Rudloff, 2008).  HMOs can modulate 
selectins which belong to a subclass of carbohydrate-binding proteins involved in cell 
adhesion in the immune system.  Evidence is emerging that HMO function as ligands for 
selectins that influence inflammatory processes by reducing leukocyte binding to 
endothelial cells (Kunz et al., 2000).  Furthermore, HMO have been demonstrated to 
inhibit platelet-neutrophil complexes, which would suggest they have anti-inflammatory 
capability (Bode et al., 2004).  
Although the effect of HMO in mediating the response to vaccination has not 
been studied, dietary supplementation of neutral and acidic oligosaccharides pectin-
derived acidic oligosaccharides, GOS and FOS (GOS/FOS ratio of 9:1 and fixed total 
dietary dose of 2% (w/w)) have been shown in mice to enhance Th1-dependent 
vaccination response to Influvac® (Solvay Pharmaceuticals, Weesp, Netherlands) (Vos et 
al., 2007).  These oligosaccharides may stimulate Treg related Th2 suppression, resulting 
in increased Th1 response to influenza vaccination. however the mechanism by which 
oligosaccharides induce Th1 responsiveness is not known (van't Land et al., 2010).  This 
same research group demonstrated that a mixture of GOS and FOS dose-dependently 
enhanced delayed-type hypersensitivity (DTH) response to Influvac®; however a mixture 
of FOS inulin (both at 2% w/w of total diet) did not enhance DTH responses (Vos et al., 
2006).  It appears that the timing of exposure to the oligosaccharides is critical.  For 
example, supplementation of GOS, FOS, and pectin-derived acidic oligosaccharides after 
being vaccinated with Influvac® did not affect the DTH response in mice, whereas 
exposure to dietary oligosaccharides prior to vaccination improved the response.  This 
indicates that immune-modulating effects were performed in the early phase of vaccine-
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specific DTH response (Vos et al., 2010).  This could be caused by early polarization of 
naïve T-cells into Th1 or Th2 effector cells.  Feeding mice a diet containing a FOS mix 
also enhanced mucosal immunity response to oral Salmonella vaccine (Benyacoub et al., 
2008).  More research is needed to examine HMO impact on vaccination response in 
other animal models and humans.   
 
4.  Cell Growth 
In addition to their immunomodulatory actions, recent evidence suggests that 
HMO can alter the growth-related characteristics of intestinal cells.  This has been 
observed in both transformed (HT-29 and Caco-2) and non-transformed intestinal cells 
(HIEC) (Kuntz et al., 2008a).  In the transformed cell line HT-29, all individual neutral 
and acidic oligosaccharides, except for the two fucosyllactoses (2'FL and 3'FL) inhibited 
cell growth.  Sialyllactoses induced differentiation in HT-29 and HIEC cells as measured 
by increased alkaline phosphatase activity.  Whereas, a 2-fold increase of apoptosis was 
detected in HT-29 and HIEC cells when exposed to a mixture of neutral oligosaccharides 
at a concentration of 15 mg/mL as measured by caspase-3 like activity (Kuntz et al., 
2008).  In a subsequent study, Kuntz and colleagues (2009) demonstrated that HMO 
inhibited cell growth by suppressing cell cycle progression through induction of 
differentiation and/or by influencing apoptosis.  The molecular mechanism was further 
investigated by examining the effect of oligosaccharides on cell cycle events via flow 
cytometry and cell cycle gene expression levels by using quantitative real-time RT-PCR 
(Kuntz et al., 2009).  Both neutral and acidic HMO induced a cell cycle arrest in 
intestinal epithelial cells in the G2/M phase, which would help explain the anti-
proliferative effect.  Further, HMO increased cyclin B mRNA expression levels, which is 
a regulator of G2/M cell cycle transition.  Kuntz showed that this cell cycle arrest occurs 
through oligosaccharides interacting with epidermal growth factor receptor (EGFR) by 
measuring signal transduction pathways through a protein profiling array to detect 
different phosphorylation events.  This interaction with EGFR then activates ERK1 and 
p38 pathways, which cause an increase in cyclin B, which causes the G2/M cell cycle 
arrest.  Overall, these studies demonstrated that HMO impact epithelial cells, although 
each cell line examined responded slightly different.   
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Chapter 2 
 
Research Objectives, Specific Aims, and Hypotheses 
 
 Infections are a major cause of morbidity and mortality in infants and children 
world-wide.  However, the severity of response of neonates to RV infection or their 
ability to generate sufficient antibodies following influenza vaccination can vary due to 
immune immaturity and dietary differences.  Manipulating the composition of infant 
formula, by adding different ingredients, such as -glucans, NT, and HMO could 
stimulate the development of the neonatal immune and gastrointestinal systems.  Dietary 
-glucans are able to boost the natural defense mechanism by stimulating both innate 
(Descroix et al., 2006) and adaptive immune responses (Akramiene et al., 2007).  NT are 
conditionally essential for infants, particularly under stressful conditions, such as during 
disease and rapid growth.  Clinical studies demonstrate that supplemental NT improve 
immune function, modify the intestinal microbiota and reduce diarrhea in formula fed 
infants.  HMO contribute to the immunomodulatory and immunoprotective actions of 
human milk.  
The overall objective of this thesis research was to investigate how early nutrition 
influences immune and gastrointestinal development.  The overall hypothesis guiding this 
research was that specific ingredients would mediate immune and gastrointestinal 
development of formula fed piglets. To test this hypothesis, three specific aims were 
undertaken. 
 
 Specific Aim 1 investigated the effect of yeast -glucan supplemented to infant 
formula.  The working hypothesis was that -glucan supplementation would boost 
antibody production in response to influenza vaccination and switch the overall immune 
system from a Th2- to a Th1-skewed response earlier in development.  In this study, we 
compared intestinal and immune development in piglets fed formula alone or 
supplemented with a range of doses of purified -glucan as reported in Chapter 3.   
 
28 
 
 Specific Aim 2 determined the mechanism(s) by which NT and HMO modulate 
intestinal epithelial cell growth-related characteristics.  The working hypothesis was that 
NT alone would increase proliferation, HMO would decrease proliferation, and when 
added together, NT would counteract the anti-proliferative effects of HMO.  The impact 
of HMO and NT individual and their combined effects on cell proliferation, cell cycle, 
and apoptosis/necrosis are reported in Chapter 4. 
 
 Specific Aim 3 evaluated an acute treatment of HMO on enterocyte proliferation, 
immune cellularity, and cytokine production in the ileum of healthy and acutely RV-
infected neonatal piglets chronically fed NT.  The working hypothesis was that dietary 
NT would stimulate gut proliferation and cause greater immune response to RV infection, 
and the addition of acidic HMO would decrease RV infectivity in the intestine.  Data on 
how NT and HMO impact PBMC T-cell phenotypes as well as intestinal 
histomorphology, T-cell populations, cytokine expression and RV replication are 
summarized in Chapter 5. 
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Chapter 3 
 
Intestinal and Immune Development are Unaffected by Dietary (1,3/1,6)-β-D-glucan 
Supplementation of Neonatal Piglets 
 
Abstract 
 
 Infants are susceptible to infections in early life, and must rely on their innate 
immune system for protection.  β-glucans potentiate immune responses.  Therefore, we 
evaluated the influence of purified yeast (1,3/1,6)-β-D-glucan (Wellmune WGP®) on the 
development of the gastrointestinal tract as well as the intestinal and systemic immune 
systems in neonatal piglets.  Piglets were fed formula containing 0 (control), 1.8, 18 or 90 
mg WGP/kg body weight and were vaccinated against human influenza.  Piglets were 
euthanized at 7 or 21 days of age.  Piglet weight and small intestinal length and weight 
were unaffected by dietary WGP.  In addition, WGP did not affect ileal crypt depth, 
villus height or ascending colon cuff depth.  Immune parameters not affected by WGP 
supplementation included T cell phenotypes, cytokine gene expression, and cell 
proliferation.  However, vaccination and developmental effects were seen.  Overall, the 
doses of 1.8, 18, and 90 mg (kg/ BW) of dietary WGP had no effect on intestinal or 
immune development and did not improve the antibody response to vaccination in 
neonatal piglets.  
 
Introduction  
  
At the time of birth and continuing for the first two to three weeks of life, 
neonates are susceptible to infections.  They must rely on their innate immune systems 
for protection to a significant extent.  Active adaptive immunity must develop rapidly and 
appropriately in the neonate as immune protection acquired from mother to fetus via 
placental transfer, colostrum and breast milk does not confer protection against antigens 
to which the mother has not been exposed. The process of immune maturation is even 
more important for infants who are not breastfed as they only receive passive immunity 
from placental transfer and no further immune protection through their diet. The United 
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States Centers for Disease Control and Prevention currently recommend that infants 
receive six vaccinations prior to three months of age.  For these vaccinations to be 
effective, it is important for the neonate to produce adequate amounts of antigen-specific 
antibodies and circulating memory cells specific for the antigens in the vaccinations 
being received.  Therefore, studies which examine the effects of dietary supplementation 
with immune stimulating compounds on the overall T helper status of the immune system 
and on the immune response to vaccination are valuable.  Furthermore, the identification 
and characterization of compounds that enhance the growth, development and health of 
those infants remains a priority. 
The rate of maturation of the immune system is influenced by exposure to 
commensal bacteria and to dietary antigens (Kelly & Coutts, 2000; Zanetti, 1992; 
Helgeland et al., 1996; Kaplan et al., 2011; Kelly et al., 2007; Bauer, et al., 2006).  It is 
unknown whether ingredients of infant formula also modulate immune maturation; 
however, modifications to infant formula are hypothesized to enhance the process of 
immune maturation in formula fed infants.  Although an emphasis has been placed on 
identifying and replicating the components found in breast milk, there are other 
compounds that can stimulate immune development.  One such class of compounds is 
found in the group of biological response modifiers, β-glucans (βG).  β-glucans are a 
family of homopolysaccharides of glucose commonly found in fungi, yeasts, plants, and 
seaweeds.  They are able to boost the natural defense mechanisms of the adult host by 
stimulating both innate (Goodridge et al., 2009) and adaptive immune responses 
(Akramiene et al., 2007).  βG are recognized by the pattern recognition receptors of the 
innate immune system (Descroix et al., 2006).  At least four receptors have been 
identified for the recognition of βG: complement receptor 3, lactosylceramide, scavenger 
receptors and dectin-1 which is described as the most important βG receptor (Sonck et al., 
2009; Goodridge et al., 2009).  Thus dietary βG, through binding to innate immune 
receptors, has the potential to stimulate the transition of the neonate from Th2- to Th1-
skewed immunity.  This would accelerate the infant’s ability to fight infections and 
respond to challenges. 
  Others have examined the effects of yeast βG on immunity in young animals 
(Stuyven et al., 2009; Stuyven et al., 2010).  Dietary yeast βG supplementation improved 
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the humoral immunity of pigs and modulated cellular immunity of weanling pigs by 
mitigating the elevation of pro-inflammatory cytokines and increasing the production of 
anti-inflammatory cytokines after an immunological challenge with lipopolysaccharide 
(LPS) (Li et al., 2005).  Furthermore, yeast βG exerted anti-viral effects against both 
swine influenza virus in 5-day-old piglets (Jung et al., 2004) and porcine reproductive 
and respiratory virus in weanling pigs (Xiao et al., 2004).  In both studies, yeast βG 
administration was associated with an up-regulation of the Th1 cytokine IFN-γ.  Indeed, a 
hallmark of glucan therapy is a switch from a Th2 to a Th1 response.   
 To our knowledge, no studies have examined chronic, enteral βG supplementation 
in a neonatal population.  Herein we test a clinically relevant βG, (1,3/1,6)-β-D-glucan 
(Wellmune WGP®, WGP), which is generally recognized as safe by the United States 
FDA, in a developmentally appropriate model.  Based on data obtained in experiments in 
older populations and shorter term studies in βG supplemented neonates, we 
hypothesized that chronic dietary WGP would alter the development of the intestinal 
mucosal and systemic immunity in the neonatal piglet.  Specifically, WGP 
supplementation would boost antibody production in response to influenza vaccination 
and switch the overall immune system from a Th2- to a Th1-skewed response earlier in 
development.  We have investigated the effects of dietary administration of WGP on the 
development of the neonate’s intestinal and immune systems.  Our data demonstrate that 
WGP did not affect intestinal or immune development in neonatal piglets. 
 
Materials and Methods 
 
Chemicals 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise 
indicated. 
 
Dietary Yeast β-Glucan 
(1,3/1,6)-β-D-glucan (Wellmune WGP®, WGP) was obtained from Biothera, Inc. 
(Eagan, MN).  This compound was extracted from Saccharomyces cerevisiae using a 
process that produces a whole glucan particle in which the outer surface of mannoprotein 
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and inner cellular contents are removed (Babicek et al., 2007).  WGP existed as a 
particulate suspension in the bovine milk-based formulas used here-in.  WGP was 
supplemented to formula to provide these doses at 1.8mg/kg BW/day, 18mg/kg BW/day 
or 90mg/kg BW/day.  The lowest dose provided an average WGP intake of 5 mg/day and 
is consistent with Biothera's recommendation of 2 mg/kg BW/day.  The middle dose 
provided an average WGP intake of 50 mg/day.  The highest dose provided an average 
WGP intake of 250 mg/d. The two lowest doses do not surpass the level generally 
recognized as safe by the United States FDA (200mg/serving, GRN No. 239, 
www.FDA.gov accessed Oct 27, 2010).  Furthermore, these levels are within the range 
that has been shown to result in no observed adverse effects in toxicological testing (2-
100 mg/kg BW/day) (Babicek et al., 2007).   
 
Dietary Treatment and Animal Protocol 
Piglets (n=68) were obtained at 48 h postpartum to allow for consumption of colostrum.  
The piglets were randomized to one of four dietary treatment groups: 1) a medicated sow 
milk replacer formula (WGP0) (Formula; Milk Specialties Global Animal Nutrition, 
Carpentersville, IL); 2) Formula + 5 WGP mg/L (WGP1.8); 3) Formula + 50 WGP mg /L 
(WGP18); or 4) Formula + 250 WGP mg/L (WGP90).  Piglets were individually housed 
in environmentally controlled rooms (25°C) in cages capable of maintaining six piglets 
separated by Plexiglas partitions.  Radiant heaters were attached to the tops of the cages 
to maintain an ambient temperature of 30°C.  Formula was offered 14 times daily at a 
rate of 360 ml/kg BW/day.  The piglets were monitored daily for normal growth and food 
intake, as well as the presence of fever, diarrhea or lethargy.  All animal procedures were 
approved by the Institutional Animal Care and Use Committee of the University of 
Illinois.  
 
Vaccination 
On d7 postpartum, a subset of piglets from each treatment group (WGP0 n=5, WGP1.8 
n=6, WGP18 n=5, WGP90 n=6) were vaccinated with a 0.25ml i.m. injection of human 
influenza vaccine (Fluzone , Sanofi Pasteur, Swiftwater, PA).  A blood sample was 
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drawn on d7 from the jugular vein prior to administration of the vaccine. Vaccinated 
animals were boosted on d14 with the same dose of Fluzone .  Blood samples were 
collected longitudinally from all piglets on d14 and d21 by jugular vein or following 
euthanasia, respectively. 
 
Sample Collection 
On day 7 (WGP0 n=5, WGP1.8 n=5, WGP18 n=5, WGP90 n=5) or day 21 (WGP0 n=12, 
WGP1.8 n=13, WGP18 n=11, WGP90 n=12) postpartum, piglets were sedated with an 
intramuscular injection of Telazol® (tiletamine HCl and zolazepam HCl, 3.5mg/kg BW 
each, Pfizer Animal Health, Fort Dodge, IA).  After sedation, blood was collected by 
cardiac puncture into plain vials for serum isolation and heparin-laced vials (BD 
Biosciences, Franklin Lakes, NJ) for isolation of mononuclear cells.  Piglets were then 
euthanized by an intravenous injection of sodium pentobarbital (Fatal Plus; Vortech 
Pharmaceuticals, Dearborn, Michigan; 72mg/kg BW).  After death, a laparotomy was 
performed.  The small intestine was quickly excised from the pyloric sphincter to the 
ileocecal valve, and its length was measured.  The small intestine was cut into three 
segments: duodenum (first 10%), jejunum (middle 75%) and ileum (final 15%).  All 
sections were flushed with ice-cold saline and weighed.  The portion of the ascending 
colon (ASC) most proximal to the ileocecal junction was also excised and rinsed with 
ice-cold saline.  Sections (1-2cm) of each intestinal section were fixed in Bouin’s solution 
or snap frozen in liquid nitrogen.  Remaining ileal segments were opened longitudinally, 
and ileal Peyer’s Patches (IPP) were isolated for the preparation of mononuclear cells and 
snap frozen in liquid nitrogen for RNA analysis.  Spleen and mesenteric lymph nodes 
(MLN) were also collected for isolation of mononuclear cells and snap frozen for RNA 
analysis.  Additionally, lung and bronchial associated lymph nodes were collected, and 
data obtained from those tissues is presented in another manuscript, in which there were 
only minor effects of βG on TGF -2 in bronchial lymph nodes. 
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Intestinal Histomorphology and Immunohistochemistry 
Bouin’s-fixed ileum and ASC samples were embedded in paraffin, sliced to 
approximately 5 µm with a microtome, and mounted on glass microscope slides. Slides 
were Hematoxylin and Eosin (H & E) stained (University of Illinois Veterinary 
Diagnostic Laboratory).  Slides were visualized in the University of Illinois Institute of 
Genomic Biology Imaging Facility using the NanoZoomer Digital Pathology System 
(Hamamatsu Corporation, Bridgewater, NJ) and analyzed using AxioVision 4.8 Digital 
Image Processing Software (Carl Zeiss MicroImaging, Inc., Thornwood, NY).  To assess 
ileal villus length and crypt depth 10 measurements for each parameter were taken per 
piglet.  Additionally, 10 ASC cuff depths were measured per piglet.  Ileum samples were 
also stained for T cells (University of Illinois Veterinary Diagnostic Laboratory).  
Because the tissues were paraffin-embedded and bouin-fixed tissues, antigen retrieval 
was done.  A citrate buffer [pH 6.0] was used to break protein crosslinks formed by 
fixation allowing the antibody to recognize the CD3 protein.  After antigen retrieval, 
slides were incubated with a rabbit anti-human CD3 polyclonal antibody (Biocare 
Medical, Concord, CA).  This antibody cross-reacts with pig CD3 and is extensively used 
by the Veterinary Diagnostic Histology Laboratory at the University of Illinois College of 
Veterinary Medicine (whose staff has verified this cross-reactivity by achieving the 
expected staining of pig lymph node sections).  Staining was visualized using a 
HRP/DAB (horse-radish peroxidase/ diaminobenzidine) system (Super Sensitive 
Polymer-HRP Detection System, Biogenex, San Ramon, CA) following the 
manufacturer’s instructions.  Briefly, slides were blocked [casein/PBS] for 20min, 
secondary anti-rabbit-polymer-HRP antibodies were incubated with slides for 30min.  
HRP was visualized by DAB exposure for 5min.  Slides were counter-stained with 
hematoxylin for 1min.  The NanoZoomer Digital Pathology System was used to image 
slides.  Images were analyzed using AxioVision 4.8 Digital Image Processing Software.  
CD3
+
 cells were counted in ten villus areas (area = 100µm
2
) per piglet.  Care was taken 
to include only the lamina propria area and exclude the epithelial layer and IPP in the 
areas analyzed.  CD3
+
 cell numbers are expressed relative to 100µm
2
 villus area.   
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Isolation of Mononuclear Cells from Peripheral Blood and Immune Tissues  
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient 
centrifugation.  Briefly 10 ml of heparinized blood was diluted in 25 ml of RPMI 1640 
(Life Technologies Invitrogen, Grand Island, NY) and layered over Ficoll-Paque PLUS 
lymphocyte separation medium (GE Healthcare, Uppsala, Sweden). The peripheral blood 
mononuclear cells (PBMC) were recovered after centrifugation (400 x g, 30 min) across 
the density gradient.  Isolated PBMC were placed in complete medium RPMI 1640 (Life 
Technologies Invitrogen, Grand Island, NY) containing 10% fetal calf serum (Life 
Technologies Invitrogen, Carlsbad, CA), 2mM L-glutamine (Life Technologies 
Invitrogen, Carlsbad, CA), 100 μg/ml penicillin, 100 μg/ml streptomycin, and 50 μg/mL 
gentamicin (Life Technologies Invitrogen, Carlsbad, CA).  Red blood cells were lysed 
using ammonium chloride lysing buffer.  Mononuclear cells from spleen, MLN, and IPP 
were obtained by cutting tissues into small pieces and dissociating using a Gentle Macs 
Dissociator (Miltenyi Biotec, Auburn, CA).  Cells were then sequentially passed through 
100 m and 40 m cell strainers (BD Biosciences, Bedford, MA) to form single cell 
suspensions.  Cells were counted using a Countess automated cell counter (Life 
Technologies Invitrogen, Carlsbad, CA).  The number of viable cells was assessed by 
trypan blue (Life Technologies Invitrogen, Eugene, OR) exclusion.  Isolated cells were 
kept in complete medium until use. 
 
Phenotypic Identification of Mononuclear Cells 
The phenotypes of T lymphocyte subpopulations from PBMC, MLN, IPP and spleen 
were monitored using fluorescently labeled mAbs.  Lymphocytes were identified by anti-
swine CD45 (Clone K252-1E4, AbD Serotec, Raleigh, NC).  Anti-CD45 was conjugated 
to Alexa 647 with a Zenon Mouse Antibody Labeling Kit (Invitrogen Molecular Probes, 
Eugene, OR).  T lymphocytes were identified by mouse anti-pig CD3:biotin (Clone 
BB23-8E6, Southern Biotech, Birmingham, AL) which was visualized with 
streptavidin:PE-Cy7 (Southern Biotech). To further differentiate T cell populations, cells 
were stained with mouse anti-pig CD4:FITC (Clone 74-12-4, Southern Biotech) and 
mouse anti-pig CD8:PE (Clone 76-2-11, Southern Biotech) antibodies. All staining 
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procedures took place on ice and care was taken to prevent unnecessary exposure to light.  
Briefly, one million cells per tube were blocked with anti-pig CD16 (G-7, AbD Serotec) 
for 5min.  Next, cells were incubated for 20min in a total of 10µl CD3:biotin.  Cells were 
then centrifuged at 2000rpm, 5min, 4°C.  Sups were removed.  Then, cells were 
incubated for 20 min in a total volume of 40µl (10µl of each mAb: CD45, CD4 and CD8, 
as well as 10µl of strep-PE-Cy7).  Cells were washed twice with phosphate buffered 
saline (PBS)/1% bovine serum albumin (BSA)/0.1% sodium azide, and then fixed with 
2% paraformaldehyde.  Staining was assessed using a LSRII flow cytometer (BD™, 
Biosciences, San Jose, CA).  The relative number of T cell subpopulations was 
determined using FlowJo 7.0 software (FlowJo, Ashland, OR).  CD45
+
CD3
+
 events were 
considered T cells.  CD45
+
CD3
+
CD4
+
CD8
-
 events were considered T helper cells.  
CD45
+
CD3
+
CD8
+
CD4
-
 events were considered cytotoxic T cells.  
CD45
+
CD3
+
CD4
+
CD8
+
 events were considered double positive T cells.   
 
Mitogenic Cell Stimulation 
PBMC, spleen, and MLN cells were plated in 96-well plates (2 x 10
5
 cells/well) in a final 
volume of 200µl complete medium at 37°C under 5% CO2.  20µl of Concanavalin A 
(ConA) (25μg/ml) or 20µl of LPS (20μg/ml) was added on d0 (n=3 wells per sample per 
stimulant).  
3
H-thymidine (Perkin Elmer, Boston, MA) was added 72h after the initiation 
of the mitogenic stimulation at a concentration of 1μCi per well, and plates were 
incubated an additional 24h. Plates were stored at -80°C until analysis.  Cells were 
harvested (TomTech, Harvester 96 Mach III M, Hamden, CT) onto 1.5µm glass fiber 
filter paper (Skatron Instruments, Sterling, VA), and put into vials containing 7ml Ultima 
Gold F Scintillation Fluid (Perkin Elmer, Waltham, MA).  Samples were counted on a 
Beckman Coulter, LS 6500 Scintillation System (Brea, CA).  Data are expressed as a 
change in counts per minute (ΔCPM) which was obtained by subtracting counts from 
unstimulated control wells from counts for wells with mitogens.  Samples were analyzed 
in triplicate.  Data analysis was performed on log transformed ΔCPM. 
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Fluzone  Preparation for ex Vivo Analyses 
Prior to use in ex vivo assays, Fluzone  was dialyzed to remove additives that inhibit cell 
proliferation.  The Fluzone  solution was placed into Spectra/Por® 4 dialysis 
membranes (Spectrum Laboratories, Rancho Dominguez, CA) and submerged in PBS for 
24 hours at 4°C.  Protein content of pre-dialyzed and dialyzed Fluzone  was assessed 
using a Bradford assay (Quick Start Bradford, Bio-Rad, Hercules, CA).  Both samples 
contained 130μg protein/ml. 
 
Assessment of Cell-Mediated Response 
The cell-mediated immune (CMI) response of the piglets was monitored by stimulating 
PBMC and spleen cells with the dialyzed Fluzone  solution ex vivo. This strategy had 
previously been used to assess CMI in response to the influenza vaccine in human 
subjects (Keylock et al., 2007).  2 x 10
5
 cells were added to each well of round bottom 
microtiter plates in 150 μL of complete cell culture media.  50μL of dialyzed Fluzone™ 
(0.875, 1.75, 3.5, or 7μg/ml) was added to each well (n=3 wells per sample per 
stimulant).  On d4, 
3
H-thymidine (Perkin Elmer, Boston, MA) was added at a 
concentration of 1μCi per well and plates were incubated overnight. Cells were treated 
and analyzed as for mitogenic stimulation.   
 
Assessment of Fluzone -Specific Antibody Response 
An ELISA was used to detect swine IgG specific for influenza antigens.  Flat-bottomed 
plates (Nunc, Rochester, NY) were coated with dialyzed Fluzone  vaccine at a 1:80 
dilution in coating buffer [0.5M Carb/Bicarb Buffer, pH 9.6] and incubated overnight at 
4°C. Following incubation, 200µl of PBS/10%FBS was added to each well to block non-
specific binding. Following incubation (1h at 4°C), the plate was washed three times with 
PBS/0.05%Tween 20.  50µl of sera diluted in PBS/10% FBS was added to each well and 
plates were incubated for 1h at 37°C. Plates were washed three times with PBS/Tween.  
50µl of goat anti-pig IgG (GeneTex, Irvine, CA), not gamma chain specific, conjugated 
to peroxidase was added to each well at a dilution of 1:400 in PBS/10%FBS.  Following 
a 1h incubation at 37°C, the plate was washed three times with PBS/0.05%Tween.  50µl 
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of TMB Substrate Reagent (BD Biosciences) was added, and plates were incubated at 
room temperature (RT) for 20min.  Then, 50µl 2N sulfuric acid was added. The plate was 
analyzed on a spectrophotometer (SpectraMax M2e, Molecular Devices, Sunnyvale, CA) 
at 450nm.  Samples were run in duplicate.  Positive stock serum was run on each plate in 
dilutions ranging from 1:100-1:1600.  A standard curve was made using these dilutions.  
Fluzone -specific IgG is expressed in arbitrary units calculated from the linear portion 
of the standard curve.  
 
Assessment of Serum Total Immunoglobulin Levels 
Total serum immunoglobulin levels were detected by ELISA using porcine IgG, IgM and 
IgA Quantification Sets (Bethyl Laboratories, Montgomery, TX, USA).  A 96-well, flat-
bottomed plate (Nunc, Rochester, NY) was coated with 100µl coating antibody (µg 
coating antibody as suggested by the manufacturer diluted in 0.05M carbonate-
bicarbonate buffer, pH 9.6) and incubated overnight at 4°C. The antibody solution was 
poured off, and the plate was washed three times with PBS/0.05% Tween20.  The plates 
were blocked with 300µl of 3% BSA/PBS for 1h at RT. The plates were washed as 
before. Serum samples were serially diluted in 0.05% gelatin/PBS, added to the wells in 
duplicate (100µl per well), and plates were incubated for 1h at RT. Samples for standard 
curves were used as directed.  Plates were washed as before, and 100µl HRP-conjugated 
detection antibody (concentration as recommended by the manufacturer) in 0.05% 
gelatin/PBS was added to each well.  Plates were protected from light and incubated for 
1h at RT.  Plates were washed four times with PBS-Tween 20. 100µl TMB reagent 
solution (OptEIA, BD Biosciences, San Diego, CA) was added to each well and allowed 
to develop protected from light at RT for the time recommended by the manufacturer.  
The reaction was stopped with 100µl 2N sulfuric acid per well.  The absorbance was read 
at 450 nm with 570 nm correction using a spectrophotometer (SpectraMax M2
e
, 
Molecular Devices, Sunnyvale, CA).  Total immunoglobulin values were determined 
based on a standard curve that was run on each plate. 
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Tissue mRNA Expression 
Total RNA was extracted from snap-frozen IPP, ASC, MLN and spleen samples with 
TRIzol reagent (Invitrogen, Carlsbad, CA).  RNA was quantified by spectrophotometry 
(Abs 260nm) using a Nanodrop 1000 (Thermo Scientific, Rockford, IL).  RNA 
concentration was adjusted to 0.25µg/ml using RNase free water.  RNA quality was 
assessed by a 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA).  All 
samples had an RNA integrity number (RIN) greater than 6.  Reverse transcription was 
performed on 3µg total RNA in a reaction volume of 20µl (High Capacity cDNA Reverse 
Transcription Kit, Applied Biosystems, Foster City, CA).  Quantitative real-time PCR 
was conducted using SYBR Green (Applied Biosystems Inc.) and data was collected 
using the Taqman ABI 7900 (Applied Biosystems Inc.).  A total of 40 PCR cycles were 
run.  Primers used are listed in Table 3.1 and final primer concentrations were 300nM.  
The relative standard curve method was used for quantitation.  Standard curves consisted 
of dilutions of pooled spleen cDNA.  β-actin was used as the internal standard reporter 
gene.  Normalized values for each target were calculated by dividing the target quantity 
mean by the β-actin quantity mean.  A fold difference was calculated for each 
measurement by dividing the normalized target values by the normalized calibrator 
sample.  Tissue from the day 21, formula fed, non-vaccinated (NV) animals was used as 
the calibrator in each instance.  All samples that were statistically compared to each other 
were run on the same plate.   
 
Statistical Analysis 
Statistical analyses were performed using SAS (Cary, NC).  Body weight, formula intake, 
and assessment of antibody response were tested between groups by repeated-measures 
analysis of variance (ANOVA).  All other data was analyzed by 2-way ANOVA using 
GLM procedure to determine the effects of diet and vaccination or time and their 
interactions.  In the event of a significant main effect a post hoc Least Significant 
Difference test was used.  Statistical significance was defined as p<0.05 and trends 
reported as p<0.10.  Data are presented as mean ± SD. 
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Results 
Because dietary WGP had no effects on the outcomes measured, the results, 
tables, and figures for all measurements except WGP intake, body weight, intestinal 
weight and intestinal length only include control (WGP0) and high dose WGP (WGP90) 
treatments. 
 
Formula Intake, Body Weight, Intestinal Weight, and Intestinal Length 
Daily formula intake averaged 808 ± 167 ml/day/pig for the first week and 1488 ± 129 
ml/day/pig during the last two weeks of the study.  Mean WGP intake over the 21 day 
period was 0 ± 0, 4.6 ± 0.6, 46.1 ± 7.7, and 225.1 ± 26.6 (mg/day) for WGP0, WGP1.8, 
WGP18, and WGP90, respectively.  Mean WGP intake at d21 was 0 ± 0, 1.7 ± 0.2, 16.5 
± 1.6, and 86.1 ± 10.0 (mg/ kg BW) for WGP0, WGP1.8, WGP18, and WGP90, 
respectively (Table 3.2).  Body weight, small intestinal weight, and small intestinal 
length were not different between dietary treatments (Table 3.2).  Additionally, 
vaccination did not influence formula intake or body weights.  Thus, addition of WGP to 
formula did not affect BW or intestinal growth.     
 
Immunohistochemistry and Histomorphology 
To determine if WGP had an effect on intestinal development, ileal CD3
+
 T lymphocytes 
were measured as well as ileal and ASC histomorphology.  There was a tendency 
(p=0.1218) for increasing dietary WGP to decrease numbers of CD3+ cells in the ileal 
villi of 21d old animals (Figure 3.1A).  Additionally, ASC cuff depth, ileal villi length 
and ileal crypt depth at d21 were not affected by dietary WGP supplementation (Figure 
3.1B).  Therefore, intestinal growth and intestinal T cell numbers were unaffected by 
chronic enteral WGP administration. 
 
T Cell Populations 
T cell phenotypes in PBMC, spleen, MLN, and IPP were evaluated to assess if dietary 
WGP or influenza vaccination would facilitate a more rapid switch from a Th2-skewed to 
Th1-skewed immune response.  No diet or vaccination effects were seen in T cell 
populations for CD45
+
CD3
+
CD4
+
CD8
-
 cells, but they were significantly increased on day 
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21 compared to day 7 in the MLN (Table 3.3).  However, CD45
+
CD3
+
CD8
+
CD4
-
 cells 
were significantly decreased on day 21 compared to day 7 in the PBMC, spleen, and 
MLN (Table 3.4).  The CD45
+
CD3
+
CD4
+
 CD8
-
/CD45
+
CD3
+
CD8
+
CD4
-
 ratio was higher 
at d21 in MLN, but, in IPP, it was higher at d7 (Figure 3.2A).  The 
CD45
+
CD3
+
CD4
+
CD8
+
 (double positive) T cell populations were greater on d21 
compared to d7 in MLN, IPP, spleen, and PBMC (Figure 3.2B).  An increase in the 
proportion of double positive cells as the pig matures has previously been documented 
(Zuckermann & Husmann, 1996).  
 
Mitogenic Cell Stimulation and Assessment of Cell-Mediated Response 
Proliferation was evaluated to determine if cells isolated from animals fed WGP® or 
vaccinated with Fluzone™ showed increased proliferation to specific or non-specific 
antigens.  PBMC, spleen, and MLN from all animals significantly (p<0.0001) 
proliferated in the presence of LPS or ConA compared to unstimulated cells.  Data are 
expressed as a change in counts per minute (ΔCPM) which was obtained by subtracting 
counts from unstimulated control wells from counts for wells with mitogens, which is 
why unstimulated data is not shown.  All animals responded to LPS or ConA similarly, 
independent of in vivo treatment of WGP or vaccination (Table 3.5).  Fluzone  
treatment of 0.875, 1.75, 3.5, and 7μg/mL did not stimulate proliferation compared to 
unstimulated cells in the blood and spleen for vaccinated or non-vaccinated piglets 
(p>0.05) (data not shown).   
 
Assessment of Fluzone -Specific Antibody Response 
Vaccine-specific serum IgG levels were measured to determine if dietary WGP would 
improve the humoral response to vaccination.  Serum Fluzone -specific IgG was similar 
in all vaccinated animals at all-time points regardless of dietary treatment (Figure 3.3).  
Vaccinated animals had a significantly higher amount of Fluzone  specific IgG than 
non-vaccinated animals at d14 and d21 (p<0.0001).  Day 21 piglets had a greater vaccine 
response compared to the d14 piglets (p<0.0001).  Fluzone  specific IgG is low on d7, 
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which implies that sows and piglets were negative for influenza antibodies at start of 
study. 
Assessment of Total Serum Immunoglobulin Levels 
To determine if dietary WGP could increase total immunoglobulin concentrations, sera 
from the WGP0 and WGP90 groups were analyzed for serum IgG, IgM and IgA 
concentrations at d7, d14 and d21. Serum IgG concentrations were higher (p<0.05) at d7 
than at d14 and d21 (Figure 3.4A).  However, serum IgG concentrations were unaffected 
by diet and vaccination.  WGP0 piglets had higher (p=0.04) serum IgM concentrations 
than WGP90 piglets (Figure 3.4B).  However, serum IgM concentrations were 
unaffected by vaccination and day.  Serum IgA concentrations were higher (p<0.05) at d7 
than at d14 and d21 (Figure 3.4C).  However, serum IgA concentrations were unaffected 
by vaccination and diet. 
 
Tissue mRNA Abundance 
Based on previous studies where βG influenced a switch from Th2 to Th1-skewed 
immunity (Jung et al., 2004; Z. Xiao et al., 2004), we examined Th1 and Th2 cytokine 
message.  In addition, gene expression of dectin-1, a primary receptor for βG, was 
measured to test if dietary WGP would regulate the receptor’s expression.  Further, 
measurement of gene expression enabled the determination of developmental or 
vaccination effects.  Expression of dectin-1 did not change in IPP, MLN, ASC, or spleen 
in response to chronic dietary WGP administration.  No dietary or vaccination differences 
in the relative abundance of cytokine mRNAs were detected in whole tissue samples of 
MLN, IPP, or ASC from 21d animals (Table 3.6).  In addition, neither WGP 
supplementation nor day affected mRNA abundance in the spleen.  However, vaccination 
significantly increased (p<0.05) IL-2, IL-4, IL-6, and dectin mRNA abundance in whole 
spleen tissue from 21d animals (Table 3.7).  IL-1β, IL-10, IL-12, TNF-α, or TGF-β2 
mRNA abundance in whole spleen tissue was not altered.   
 
Discussion 
At birth the neonatal immune system is strongly Th2-polarized (Delespesse et al., 
1998).  This bias leaves the newborn more susceptible to infections than older 
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individuals.  Formula-fed neonates also produce less robust antibody responses to 
vaccination than breast-fed infants (Pabst & Spady, 1990; Sabirov et al., 2009; Pickering 
et al., 1998; Schaller et al., 2004; Ogra et al., 1977).  It was hypothesized that 
supplementation of formula with a yeast product, WGP, would potentiate immune system 
responses to vaccination and boost the overall immune system in formula fed piglets.  
However, dietary WGP had no effect on intestinal or systemic immune development in 
full-term, colostrum-fed, neonatal piglets.  Importantly, no adverse effects of orally 
administered WGP were observed, and WGP did not negatively impact the expected 
immune system developmental switch from a Th2- to Th1-skewed immune response.  
Studies examining the effects of βG on local intestinal immune response in neonatal pigs 
are scarce.  The experiment presented herein allowed for the local intestinal immune 
response to be examined in tissues, in addition to being systemically monitored in the 
blood (Gallois et al., 2009).   
 Lymphocyte populations (PBMC, MLN, spleen, or IPP) were not altered by WGP 
supplementation nor was proliferation affected (PBMC, MLN, spleen).  Previous 
literature has shown βG effects on lymphocyte populations. CD4+ and CD8+ T cells were 
higher in weaned pigs fed βG from Saccharomyces cerevisiae supplemented diets as 
compared with pigs fed control diets (Hahn et al., 2006).  However, it took eight weeks 
for this effect to be detected.  In contrast, animals in our study were fed WGP for a total 
of three weeks. Piglets were vaccinated and boostered at such a young age and in a close 
interval because we did not want to investigate piglets past weanling age since we are 
interested in neonatal immune development.  In another study looking at older animals, 
spleen cells from mice supplemented with one to five intragastric βG treatments, obtained 
from culture filtrate of the fungus Sclerotinia sclerotiorum IFO 9395, proliferated more 
strongly when stimulated with T or B cell mitogens than did those from control mice 
(Suzuki et al., 1989).  Not only were the animals older in this study, but also βG was 
administered in a more concentrated form over a shorter time period than in the current 
studies.  Others have shown that cells treated with some forms of βGs proliferate more 
than untreated cells (Sonck et al., 2010). In other studies, βG from S. cerevisiae has been 
shown to enhance the activities of natural killer cells and peritoneal macrophages, as well 
as stimulate cytotoxic T lymphocytes, B cells, and macrophages in mice (Cross et al., 
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2001).  However, these effects were only seen when βG was applied to cells in vitro or 
administered i.p.  We did not evaluate the effects of WGP added to cells in culture 
because we are primarily interested in assessing the effects from dietary exposure in vivo 
and not direct effects on immune cells in vitro.  Thus, differences in our results from 
those previously reported could be due to the age of the experimental subjects, the 
mode/length of administration of WGP or the specific βG used.   
 It is possible, that an immune compromised immune system is needed to see the 
effects of WGP.  In addition, WGP may be a less biologically active form of βG than 
those used in studies mentioned above, however it is a clinically relevant βG, since it is 
generally recognized as safe by the United States FDA for infants.  As such, our ability to 
detect significant changes in body weight, intestinal growth and immune status with 
dietary WGP treatment may have been limited by the fact that full-term, colostrum fed 
piglets rather than diseased or immunocompromised animals were used in our studies.  In 
fact, dietary supplementation of weaned pigs with βG Original XPC (Diamond V, Cedar 
Rapids, IA) improved growth in pigs challenged with Salmonella (Price et al., 2010), and 
WGP given orally increased the survival rate of mice infected with anthrax (Kournikakis 
et al., 2003).  Finally, WGP has demonstrated effectiveness by switching a Th2 response 
to a protective Th1 cell-mediated response in tumor-bearing mice when it was given 
orally and combined with anti-tumor monoclonal antibodies (Baran et al., 2007).  Thus, 
the health of our animals may have limited our ability to detect effects of WGP 
supplementation, but the study was designed to assess effects in healthy formula fed 
infants using a FDA-approved βG.   
 We did detect differences in some genes based on the vaccination status of an 
animal.  Tissue mRNA abundance of IL-2, IL-4, IL-6, and dectin was significantly higher 
in whole spleen tissue from 21d vaccinated animals compared to those from non-
vaccinated animals.  Previously these cytokines have not been found to be significantly 
increased in serum concentrations of adults vaccinated against influenza (Bogomolov et 
al., 2008).  However, blood cultures from infants who had been vaccinated against 
tuberculosis, had greater cytokine response when exposed to TB for 15 out of 21 
cytokines tested, including IL-2, IL-4, and IL-6 (Lalor et al., 2010).  Most cytokines 
tested tended to be increased, although not all significantly, in vaccinated animals 
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compared to non-vaccinated animals.  Because we collected samples on day 7, prior to 
vaccination, and on day 21, one week after the last vaccination, our ability to detect some 
cytokine differences was compromised.  
Although cytokine expression was increased due to vaccination in our study, a 
WGP effect on Fluzone vaccination response was not seen. We used an ELISA to test 
this because it often detects antibodies in serum samples that show up negative in HI tests 
(Takemae et al., 2011).  Our lab has shown that an influenza hemagglutination inhibition 
(HI) assay was not able to detect influenza antibodies in our non-vaccinated or vaccinated 
piglets, which indicates the lack of sensitivity of the assay.  This study suggests that 
dietary WGP does not improve immune response to influenza vaccination in a full-term, 
colostrum-fed, and otherwise healthy neonatal piglet population.  This is surprising since 
a number of studies have shown that βG supplementation improves immune responses. A 
number of other studies, however, have shown little effect of βG supplementation on 
antibody response to systemic immunization.  For instance, yeast βG did not enhance the 
efficacy of vaccinations for porcine reproductive and respiratory syndrome (PRRS) virus 
(Hiss & Sauerwein, 2003), or different EnteroToxinogenic Escherichia coli (ETEC) 
antigens (Decuypere et al., 1998).  βG from S. cerevisiae supplemented to piglets 
vaccinated with an atrophic rhinitis vaccine actually produced fewer antigen-specific 
antibodies (Hahn et al., 2006), but pigs supplemented with βG from S. cerevisiae injected 
with ovalbumin produced more antibodies (Li et al., 2005).  An oral dietary supplement 
may have a greater chance of affecting an oral vaccination than an i.m. vaccination.  
However, most vaccinations are administered i.m. with the exception of the rotavirus 
vaccine.  Additionally, we have tried to use oral rotavirus vaccine in our piglet model, but 
we could not detect an effect of vaccination on antibody titer (unpublished observation).  
This is likely because rotavirus commonly infects pig herds and so maternally transferred 
anti-rotavirus antibody levels were high.  Ultimately, we are interested in the effects of 
oral βG on immune development and our functional outcome was an i.m. vaccination 
since the majority of neonatal vaccinations are given i.m.  
To gain a perspective of systemic immune development of piglets, total serum 
IgG, IgM and IgA concentrations were measured.  We found that the serum IgG 
concentrations were higher (p<0.05) at d7 than at d14 and d21.  Our developmental study 
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showed similar results to Bourne et al (Bourne, 1973).  Serum IgM concentrations were 
higher (p<0.05) in WGP0 piglets compared to WGP90 piglets.  IgA serum concentrations 
were higher on d7 than on d14 and d21 (P<0.05).  Our previous developmental study as 
well as Bourne’s research suggests that this is a typical developmental pattern in pigs 
receiving colostrum (Bourne, 1973). 
One potential source of variation seen in these studies may be the form of βG 
utilized.  βG can be extracted from a number of sources, and these forms have been 
shown to have varying activity levels.  Although the molecular structures of the various 
βG chains with branch points at (1,3/1,6) are highly conserved, the three-dimensional 
structure of the molecule can be different among organisms and depends on the chain 
length, branch type, and branch frequency.  The method by which βG are processed or 
manufactured can also have a significant impact on their immune stimulatory activity 
(Bohn, 1995; Mueller et al., 2000; Saito et al., 1991; Seljelid et al., 1981; Willment et al., 
2001).  There is also data that indicates more water-soluble polymers are more active, 
and, related to that, the immunopotentiating activity of βG can depend on the helical 
conformation and on the presence of hydrophilic groups located on the outside surface of 
the helix.  Evidence also suggests that the activity is dependent on the size, with high 
molecular weight (100,000-200,000) fractions being most active, while fractions from the 
same source with molecular weights of 5,000-10,000 showed no activity (Blaschek et al., 
1992; Fabre et al., 1984; Kojima et al., 1986).  Additionally, dietary WGP did not affect 
antibody or cell-mediated immune responses to influenza virus vaccination in mice 
(Pence et al., 2012).  Thus, the physical structure of WGP may have limited its ability to 
affect change when administered orally.  Again, we utilized WGP since it is a clinically 
relevant βG, which is generally recognized as safe by the United States FDA for the 
population we wanted to target.   
In conclusion, the effects of orally administered βG on immunity vary by βG 
source and animal model.  Further studies are needed to examine the effectiveness of 
modulating the neonate’s immune system with different forms of βG. 
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Figures 
 
Figure 3.1.  Immunohistochemistry and Histomorphology for 21d animals (A)  
Number of CD3 cells per 100μm2 of ileum villus did not differ by dietary treatment 
(p=0.12).  (B) Dietary WGP did not affect ASC colon cuff depth (p=0.54), ileal villus 
length (p=0.15), or ileal crypt depth (p=0.55). Values are expressed as mean ± SD. 
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Figure 3.1 continued 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean ± SD 
p=0.5375 
p=0.1452 
p=0.5536 
49 
 
 
 
Figure 3.2. T Helper Cells, Cytotoxic T Cells, and Double Positive T Cells in 7d and 
21d piglets.  (A)  The ratio of CD45
+
CD3
+
CD4
+
CD8
-
/CD45
+
CD3
+
CD8
+
CD4
-
 T cells 
was significantly higher on d21 than on d7 (p=0.009) in MLN and significantly higher on 
d7 than on d21 (p=0.046) in IPP. (B)  The percentage of double positive 
(CD45
+
CD3
+
CD4
+
CD8
+
) T cells was significantly higher on d21 in MLN, IPP, spleen, 
and PBMC (p=0.0113, 0.03, 0.045, 0.004, respectively).  Values are expressed as mean ± 
SD.  *p<0.05. 
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Figure 3.2 continued 
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Figure 3.3.  Fluzone–Specific serum IgG levels.  Piglets were vaccinated on d7 and d14 
with a 0.25ml i.m. injection of human influenza vaccine.  A pre-vaccination blood sample 
was drawn on d7, and blood samples were collected longitudinally from all piglets on 
d14 and d21.  On d14 and d21, vaccinated piglets had greater serum Fluzone-specific IgG 
than non-vaccinated piglets (p<0.0001).  Vaccinated piglets had greater serum Fluzone-
specific IgG levels at d21 than at d14 (p<0.0001).  Values are expressed as mean ± SD.  
Repeated measures ANOVA: overall model p=0.02, diet p=0.17, day p<0.001, and 
diet*day interaction p=0.68. 
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Figure 3.4. Total serum IgG, IgM, and IgA concentrations. (A) Total serum IgG 
concentrations were higher on day 7 than on day 14 and day 21 (p=0.002).  No diet 
(p=0.6) or vaccination (p=0.88) differences were detected.  Data are expressed as mean ± 
SD.  Data with different letters are significantly different.  Model p=0.002, day p<0.0001, 
diet p=0.6, and day*diet interaction p=0.49.  (B) Total serum IgM concentrations were 
higher in WGP0 piglets than in WGP90 piglets (p=0.04).  Data are expressed as mean ± 
SD. Data with different letters are significantly different.  No day (p=0.09) or vaccination 
(p=0.23) differences were detected.  Model p=0.04, day p=0.09, diet p=0.01 and day*diet 
interaction p=0.80.  (C) Total serum IgA concentrations were higher on d7 than on d14 or 
d21 (p<0.0001).  Data are expressed as mean ± SD. Data with different letters are 
significantly different.  No diet (p=0.49) or vaccination (p=0.17) differences were 
detected.  Model p<0.0001, day p<0.0001, diet p=0.49 and day*diet interaction p=0.32. 
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Figure 3.4 continued 
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Figure 3.4 continued  
 
C
0
1
2
3
4
d7 d14 d21
T
o
ta
l 
S
er
u
m
 I
g
A
 (
m
g
/m
l)
WGP0, NV WGP0, V
WGP90, NV WGP90, V
 Mean ± SD 
a 
b 
b 
55 
 
 
Tables 
Table 3.1.  Primers used for quantitative RT-PCR 
 
 
 
 
 
 
 
 
 
1 
Nygard et al., 2007 
2 
Sonck et al., 2009 
3 
Borca et al., 2008 
4 
Collado-Romero et al., 2010 
Gene Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) Gene Bank 
Accession ID 
β-actin1 CACGCCATCCTGCGTCTGGA AGCACCGTGTTGGCGTAGAG DQ845171.1 
Dectin
2
 CTCTCACAACCTCACCAGGAGAT CAGTAATGGGTCGCCAATAAGG FJ386384.1 
IL-2
3
 TCAACTCCTGCCACAATGT CTTGAAGTAGGTGCACCGT EU139160.1 
IL-12 p35
3
 CGTGCCTCGGGCAATTATAA CAGGTGAGGTCGCTAGTTTGG NM_213993.1 
IL-4
4
 TTGCTGCCCCAGAGAAC TGTCAAGTCCGTCAGG AY294020 
IL-10
4
 CAGATGGGCGACTTGTTG ACAGGGCAGAATTGATGAC L20001 
IL-6
3
 CTGGCAGAAAACAACCTGAACC TGATTCTCATCAAGCAGGTCTCC AB194100.1 
IL-1β3 AACGTGCAGTCTATGGAGT GAACACCACTTCTCTCTTCA NM 214055.1 
TNF-α3 AACCTCAGATAAGCCCGTCG ACCACCAGCTGGTTGTCTTT EU682384.1 
TGFβ-23 TGTGTGCTGAGCGCTTTTCT GAGCGTGCTGCAGGTAGACA L08375.1 
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Table 3 2.  Body weight, WGP intake average over time and absolute, and total small intestinal weight and length  
 
 Day 7 Day 21 
Measurement WGP0 WGP1.8 WGP18 WGP90 WGP0 WGP1.8 WGP18 WGP90 
Average Body Weight (kg) 
 
2.3±0.4 2.3±0.7 2.2±0.3 2.3±0.5 4.1±0.7 4.5±0.7 4.5±0.8 4.3±0.5 
Average WGP Intake  over 7 or 21 
day period (mg/ day) 
0±0 2.7±0.7 25.5±3.7 45.0±9.9 0±0 4.6±0.6 46.1±7.7 225.1±26.6 
 
WGP Intake at Day 7 or Day 21 
(mg/ kg body weight) 
 
0±0 
 
1.8±0.0 
 
17.6±0.3 
 
88.2±1.1 
 
0±0 
 
1.7±0.2 
 
16.5±1.6 
 
86.1±10.0 
 
Total Small Intestinal Weight 
(g/ kg body weight) 
 
40±9 
 
46±4 
 
39±7 
 
42±4 
 
43±6 
 
42±4 
 
40±4 
 
41±9 
 
Total Small Intestinal Length 
(cm/ kg body weight) 
 
229±28 
 
212±67 
 
223±23 
 
255±39 
 
160±39 
 
160±21 
 
156±29 
 
164±21 
1 
Data are expressed as mean ± SD. 
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Table 3.3. CD45
+
CD3
+
CD4
+
CD8
-
 T cell populations determined by flow cytometry
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Data are expressed as mean ± SD. Values are CD45
+
CD3
+
CD4
+
CD8
-
 events as a percentage of CD45
+
CD3
+
 events. 
 
2 
Model included diet, day, and interaction, Model p-value (Day p-value).  All diet and interaction p-values >0.05. 
 
3 
Model included diet, vaccination, and interaction, Model p-value (Vaccination p-value).  All diet, vaccination, and interaction p-
values >0.05.   
 
  Percentage CD45
+
CD3
+
CD4
+
CD8
-
 P-value
2
 P-value
3
 
Tissue Day WGP0, NV WGP0, V WGP90, NV WGP90, V   
PBMC  7 35.8±22.9  34.2±26.1    
PBMC  21 48.6±5.8 41.6±20.1 53.0±16.1 45.4±14.5 0.5476 (0.0294) 0.8875 (0.2625) 
 
Spleen  
 
7 
 
32.6±24.3 
  
24.2±22.8 
   
Spleen  21 40.7±11.9 33.4±16.8 43.3±14.3 45.7±11.5 0.3909 (0.0358) 0.5992 (0.8780) 
 
MLN   
 
7 
 
46.2±24.8 
  
35.4±30.1 
   
MLN  21 64.3±10.2 60.8±7.9 65.0±11.3 62.0±9.9 0.0255 (0.0003) 0.5500 (0.7237) 
 
IPP  
 
7 
 
45.5±33.6 
  
24.2±22.4 
   
IPP  21 50.7±13.7 44.4±21.7 60.1±21.1 44.4±23.6 0.3216 (0.0481) 0.9481 (0.8806) 
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Table 3.4. CD45
+
CD3
+
CD8
+
CD4
-
 T cell populations determined by flow cytometry
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Data are expressed as mean ± SD.  Values are CD45
+
CD3
+
CD8
+
CD4
-
 events as a percentage of CD45
+
CD3
+
 events. 
 
2 
Model included diet, day, and interaction, Model p-value (Day p-value).   
 
3 
Model included diet, vaccination, and interaction Model p-value (Vaccination p-value).  All diet, vaccination, and interaction p-
values >0.05.   
 
 
  Percentage CD45+CD3+CD8+CD4- P-value
2
 P-value
3
 
Tissue Day WGP0, NV WGP0, V WGP90, NV WGP90, V   
PBMC  7 23.8±28.6  24.6±24.9    
PBMC  21 10.4±5.8 7.3±3.7 7.1±2.3 8.8±6.4 0.0443 (0.0006) 0.7515 (0.2983) 
 
Spleen  
 
7 
 
21.6±26.8 
  
24.1±23.0 
   
Spleen  21 6.2±3.0 4.9±2.9 5.6±2.7 6.8±3.1 0.0015 (<0.0001) 0.7926 (0.7138) 
 
MLN  
 
7 
 
19.5±24.1 
  
30.4±32.3 
   
MLN  21 8.4±4.3 8.7±6.7 6.2±2.7 9.6±5.5 0.0058 (<0.0001) 0.7894 (0.4780) 
 
IPP  
 
7 
 
12.8±24.5 
  
19.4±25.7 
   
IPP  21 3.6±2.3 5.5±4.3 5.2±6.4 3.8±2.1 0.5446 (0.0323) 0.5301 (0.3617) 
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Table 3.5.  Mitogenic cell stimulation of PBMC, spleen and, MLN mononuclear cells 
at day 21
1, 2 
 LPS 
(Log ΔCPM) 
ConA 
(Log ΔCPM) 
 WGP0 WGP90  Model  
p-value 
WGP0 WGP90  Model  
p-value 
PBMC 3.0 3.3 2.7 2.7 0.9465 4.8 4.9 4.5 4.3 0.8181 
Spleen 3.6 3.8 4.1 4.1 0.1541 4.6 4.6 4.7 4.7 0.8690 
MLN 2.9 3.4 3.3 3.5 0.2212 5.1 4.4 5.1 4.4 0.7964 
1 
Data are expressed as mean ± SD. 
 
2 
Model included diet as a main effect.   
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Table 3.6. Cytokine and dectin mRNA expression in MLN, IPP, and ASC of 21 day 
old piglets
1 
 
 WGP0 WGP90 Model p-value 
2 
MLN    
IL-2 1.1±1.0 0.5±0.3 0.1601 
IL-12 0.9±0.6 0.6±0.3 0.4369 
IL-4 1.1±0.8 0.8±0.6 0.4978 
Dectin 0.9±0.7 0.7±0.5 0.6668 
IPP    
IL-2 1.1±1.0 2.2±3.5 0.3157 
IL-12 1.0±0.9 1.2±1.1 0.7665 
IL-4 1.2±1.0 1.2±0.4 0.1392 
Dectin 1.4±1.3 1.6±0.8 0.4426 
ASC    
IL-2 0.7±0.5 0.7±0.9 0.5407 
IL-12 0.7±0.7 0.9±1.0 0.7454 
IL-4 0.7±0.4 0.7±0.5 0.9978 
Dectin 0.6±0.4 0.3±0.2 0.4514 
1
 Data are expressed as mean ± SD, relative to fold difference of gene expression in 
formula diet samples at day 21.   
 
2
 Model p-value includes main effects diet and vaccination, which were both non-
significant, p > 0.05.  Interaction between diet and vaccination was previously run and 
was found to be non-significant.  
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Table 3.7. Cytokine and dectin mRNA expression in spleen of vaccinated and non-vaccinated 21 day old piglets
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Data are expressed as mean ± SD, relative to fold difference of gene expression in formula diet, day 21, non-vaccinated group.   
 
2
Day 21 non-vaccinated animals were compared to day 21 vaccinated animals.  Factors included in model were diet, vaccination, and 
diet*vaccination interaction.   
 
3 
Different letters within the same row shows significance. 
 Day 21, non-vaccinated Day 21, vaccinated Model p-value 
2,3
  
(Vaccination) 
 WGP0 WGP90 WGP0 WGP90  
IL-2 1.0±1.1
 a
 1.3±1.1
a
 12.4±5.9
 b
 2.5±2.4
 b
 0.0321 (0.0056) 
IL-12 1.0±1.1 13.8±4.7 6.3±3.9 2.8±1.4 0.4981 (0.6394) 
IL-4 1.0±0.5
 a
 0.6±0.4
 a
 3.8±1.5
b
 1.3±0.7
 b
 0.0004 (<0.0001) 
IL-6 1.0±0.5
a
 1.0±0.4
 a
 3.1±1.1
 b
 2.2±1.6
b
 0.0299 (0.001) 
TNF-α 1.0±0.3 3.3±2.7 5.3±1.5 2.1±1.7 0.1388 (0.0451) 
Dectin 1.0±0.6 
a 
0.6±0.4
a 
 4.3±2.8
 b
 1.4±0.6
 b
 0.0226 (0.0046) 
TGFβ-2 1.0±0.3  1.9±2.7 6.4±4.5  1.6±1.0  0.0500 (0.084) 
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Chapter 4 
 
Individual and Combined Effects of Nucleotides and Human Milk Oligosaccharides 
on Intestinal Cell Growth-Related Characteristics 
 
Abstract 
There are many components found in human breast milk that can affect intestinal 
development including nucleotides (NT) and human milk oligosaccharides (HMO).  NT 
are currently added to infant formula and HMO are being investigated as potential 
additives.  Both ingredients impact epithelial cell growth, however their combined effects 
had not previously been examined.  Herein, a fetal epithelial cell line (FHs-74 Int) was 
used to determine the impact of NT and HMO on intestinal cell proliferation, apoptosis, 
necrosis and cell cycle.  Cells were incubated with media containing 2.5% FBS and no 
epidermal growth factor (EGF) (Control); Fucosyl-lactose (FL) mix [85% 2'FL/15% 
3'FL], Sialyl-lactose (SL) mix [40% 6'SL/10% 3'SL/50% SL] or LNnT at 125, 250, 500 
or 1000 μg/mL with and without 250 μg/mL NT (43% CMP, 18.5% UMP, 16.4% AMP, 
and 22.0% GMP) for 24 or 72h.  NT alone significantly increased proliferation, but did 
not affect cell cycle or apoptosis/necrosis.  All HMO treatments at 1000 μg/mL 
significantly decreased proliferation and some were also inhibitory at 250 or 500 μg/mL.  
Inhibition of proliferation increased with longer HMO exposure (72h vs. 24h).  When NT 
and HMO were simultaneously added, NT reduced the anti-proliferative effect of HMO.  
FL mix treatments significantly increased cells S phase and SL mix and LNnT treatments 
significantly increased cells in G2/M and S phases which concomitantly decreased cells 
in G0/G1 phase.  HMO with NT significantly decreased the amount of cells in the G2/M 
phase compared to HMO treatments alone.  Higher HMO doses significantly increased 
the percentage of apoptotic and necrotic cells compared to control. The percentage of 
necrotic and apoptotic cells were higher after 24h vs. 72h exposure to HMO.  In 
conclusion, HMO reduced cell proliferation in vitro and this effect is partially 
ameliorated by the presence of NT.  It appears that HMO initially induced 
apoptosis/necrosis, which is later evidenced by G2/M cell cycle arrest and decreased 
proliferation.  Further studies are needed to determine whether HMO influence intestinal 
cell growth in vivo. 
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Introduction  
Intestinal epithelial cells are exposed to numerous dietary components that can 
regulate growth-related characteristics.  Human milk (HM) contains numerous bioactive 
components that are thought to work in concert to promote optimal neonatal development 
(German et al., 2002), and ingredients have been added to infant formula to more closely 
reflect HM composition.  Nucleotides (NT) are currently added to infant formula and 
human milk oligosaccharides (HMO) are being investigated as potential additives. Both 
ingredients impact epithelial cell growth (Holen, 2004; Kuntz et al., 2008; Kuntz et al., 
2009); however their combined effects had not previously been examined. 
Nucleotides are low molecular weight compounds that consist of a nitrogenous 
base (purine and pyrimidine bases), a sugar molecule (pentose), and 1-3 phosphate 
groups.  They are components of HM and their content in HM is higher than that of 
bovine milk, from which most infant formula is made.  The NT content of HM has been 
found to be around 72 mg/L using the total potentially available nucleosides (TPAN) 
analysis (Leach et al., 1995).  Currently, most infant formula is being fortified with 
approximately 70 mg NT/L.   
Dietary NT exert various physiological functions and may be of particular 
importance for growth and development of tissues with rapid turnover rates, such as the 
intestinal mucosa.  Previous studies have shown that NT induce cell proliferation in both 
transformed (Caco-2) and non-transformed intestinal cells (IEC-6) (Holen, 2004; 
Rodriguez-Serrano et al., 2007), particularly in cells that are in partially serum-deprived 
culture conditions.   
At 12-15 g/L in mature milk, HMO are the third most abundant constituent of HM 
(Coppa et al., 1993; Newburg, 2000).  The composition of HMO is unique among species 
and their concentration markedly higher than oligosaccharides in bovine milk (Newburg 
et al., 2004; Kunz et al., 2000).  Approximately 200 different HMO (Bode, 2009) which 
vary in size, structure, and abundance have been identified in HM (Coppa et al., 1993).  
The building blocks of milk oligosaccharides are the five monosaccharides, D-glucose, 
D-galactose, N-acetylglucosamine, L-fucose and SA.  Lactose forms the reducing ends of 
the HMO and lactose can be fucosylated on the non-reducing end in α1-2 and α1-3 
linkages to form 2'fucosyllactose (2'FL) and 3'fucosyllactose (3'FL), respectively.  
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Lactose can also be sialylated on the non-reducing end in α2-3 and/ or α2-6 linkages to 
form 3'sialyllactose (3'SL) and 6'sialyllactose (6'SL), respectively.  More complex HMO 
can be made by different combinations of the five monosaccharides listed above. 
Recent evidence suggests that HMO can alter the growth-related characteristics of 
both transformed (HT-29 and Caco-2) and non-transformed (HIEC) intestinal cells 
(Kuntz et al., 2008).  In HT-29 cells, all neutral and acidic oligosaccharides, except for 
2'FL and 3'FL, inhibited cell growth.   
Thus, NT increase epithelial cell proliferation (Holen E, 2004), while HMO have 
an anti-proliferative effect (Kuntz et al., 2008; Kuntz et al., 2009).  However, human milk 
and infant formula contain multiple ingredients that can modulate intestinal proliferation.  
Therefore, it is important to determine how NT and HMO would act in combination in 
order to better understand how adding HMO to an infant formula already containing NT 
may affect infant intestinal development.  Based on the previous literature, we 
hypothesized that NT alone would increase proliferation, HMO would decrease 
proliferation, and when added together, NT would counteract the anti-proliferative effects 
of HMO.  The cell-growth characteristics were further examined by determining NT and 
HMO effects on cell cycle, apoptosis, and necrosis by using flow cytometric methods.  
 
Methods and Materials 
 
Cell line 
A primary intestinal cell line of human fetal origin FHs-74 Int cells was obtained from 
the American Type Culture Collection (ATCC catalog no. CCL-241, Manassas, VA).  
Cells were maintained in 75 cm
2
 tissue culture flasks (BD Biosciences, Bedford, MA) in 
46-X medium (ATCC, Manassas, VA) containing ingredients of a modified Dulbecco’s 
modified Eagle’s medium (DMEM), insulin, HEPES, and NaHCO3 supplemented with 
30 ng/mL epidermal growth factor (EGF) (Sigma-Aldrich, St. Louis, MO), 10% fetal 
bovine serum (Gibco Invitrogen, Carlsbad, CA), 100 µg/mL penicillin, 100 µg/mL 
streptomycin, and 50 µg/mL gentamicin (Life Technologies Invitrogen).  This medium, 
containing 30 ng/mL EGF and 10% FBS, will be referred to as full medium.  Cells were 
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grown in a tissue culture incubator (Forma Scientific, Inc., Marietta, OH) at 37 ºC with a 
humidified atmosphere of 5% CO2.  Media was changed every 2-3 days.   
 
NT and HMO Treatments 
NT and HMO treatments were added to 46-X medium containing 2.5% FBS and no EGF, 
which will be referred to as reduced medium, for proliferation, cell cycle, and apoptosis/ 
necrosis assays.  Individual sialylated and fucosylated HMO were purchased from V-
Labs (Covington, LA) and combined into a FL mix (85% 2'FL [product no. L302] and 
15% 3'FL [product no. L303]) and a SL mix: (50% sialic acid (SA) [product no. N101], 
40% 6'SL [product no. SL306] and 10% 3'SL [product no. SL302, Covington, LA]). 
Lacto-N-neotetraose (LNnT) was donated by Abbott Nutrition (Columbus OH). The SL 
mix, FL mix and LNnT were tested at 125, 250, 500 or 1000 μg/mL with or without 250 
μg/mL NT (43% CMP, 18.5% UMP, 16.4% AMP, and 22.0% GMP) (Sigma-Aldrich).  
The FL and SL mix ratios were based on taking concentration of each HMO reported in 
the literature and then calculating a ratio within each HMO mix.  The NT dose of 250 
μg/mL was chosen based on preliminary experiments showing that it was the dose that 
significantly increased proliferation above control (Figure 4.1).  The ratio of NT in the 
mixture was based on the ratio found in HM and supplemented to infant formula (Leach 
et al., 1995).  HMO and NT treatments were tested for lipopolysaccharide (LPS) with 
Limulus Amebocyte Lysate Assay (LAL Assay) (Lonza, Walkersville, MD).  LNnT and 
2'FL contained LPS above the threshold level (>0.1endotoxin/mL), therefore samples 
were eluted through an Endotoxin Removing Gel (Thermo Scientific, Rockford, IL) and 
then re-tested using the LAL Assay.  To determine the specificity of HMO on cell growth 
related-characteristics, we tested tri-galactose (Dextra, Reading, United Kingdom) and 
lactose (Sigma-Aldrich, St. Louis, MO) at 1000 µg/mL on FHs-74 Int cells.  No changes 
in proliferation, cell death and cell cycle were seen in cells treated with tri-galactose and 
lactose.  This demonstrates HMO can cause these effects in epithelial cells but not all 
carbohydrates alone can cause these changes. 
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Proliferation Assay 
Cells (7,500/ well) were plated in 96-well plates (Corning, New York, NY).  After initial 
seeding, cells were grown in full medium (10% FBS, 30ng/mL EGF) for 24h, which was 
replaced with reduced media (2.5% FBS, no EGF) for 24h.  The reduced medium was 
removed and replaced with reduced media containing NT alone, HMO alone, or a 
combination of NT and HMO for either 24 or 72h.  No reagents or medium was added to 
the cultures during the treatment period (Figure 4.2).  At the end of the experiment, 20 μl 
of CellTiter 96® Aqueous One Solution Reagent (MTS and PES) (Promega, Madison, 
WI) was added to each well, according to manufacturer’s general protocol, and incubated 
at 37°C for 3h.  The absorbance at 490nm was read on a spectrophotometer (SpectraMax 
M2e, Molecular Devices, Sunnyvale, CA).  Data are expressed as a percentage of control 
(media alone).   
 
Cell Cycle Assay 
FHs-74 Int cells (80,000/ well) were plated in to 24-well plates (Becton Dickinson, 
Franklin Lakes, NJ).  After initial seeding, cells were grown in full medium (10% FBS, 
30ng/mL EGF) and allowed to adhere for 24h.  Thereafter, medium was replaced with 
reduced media (2.5% FBS, no EGF) for 24h.  Then the medium was replaced with 
reduced media containing NT alone, HMO alone, or a combination of NT and HMO for 
24 and 72h.  The cells were removed from the plate by incubating with trypsin-EDTA 
solution, 0.25% (Sigma-Aldrich) for 5min at 37ºC, pelleted by centrifugation at 500g for 
5min and washed twice with PBS.  Cells were then fixed by suspending the cells in 70% 
ethanol at -20°C for 24h.  Thereafter, the suspension was centrifuged for 5min at 500g, 
and the pellet was washed twice with PBS.  After washing and centrifugation, cells were 
incubated and stained with 0.5 mL (5 μg/mL) propidium iodide (PI) (Sigma-Aldrich) for 
30 min at room temperature.  Cell cycle analysis was performed using a LSRII flow 
cytometer (BD Biosciences, San Jose, CA) and analyzed using FlowJo version 7.0 
software (FlowJo, Ashland, OR).  The first peak represented cells in the G0/G1 phase of 
the cell cycle, the second peak represented cells in the G2/M phase. The intervening cells 
between the peaks are in the S-phase of the cell cycle (Figure 4.3).  
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Apoptosis and Necrosis Assay  
FHs-74 Int cells (80,000/ well) were plated in 24-well plates (Becton Dickinson) and 
treated as described for cell proliferation assay.  The cells were trypsinized (Sigma-
Aldrich), pelleted by centrifugation at 500g for 5min and washed twice with PBS.  The 
cells were then stained for apoptosis and necrosis using the Annexin-V-FLUOS Staining 
Kit (Roche, Indianapolis, IN), as described by the manufacturer.  This kit stained with 
both Annexin-V and PI.  Labeled Annexin-V, with its high affinity for phosphatidylserine 
(PS), is a sensitive probe for PS exposed on the outer layer of apoptotic cells.  Since 
necrotic cells also expose PS as a result of lost membrane integrity, PI is utilized as a 
DNA stain to distinguish necrotic cells from apoptotic Annexin-V-labeled cell clusters.  
Staining was assessed using a LSRII flow cytometer (BD Biosciences).  The relative 
proportion of apoptotic and necrotic populations was determined using FlowJo version 
7.0 software (FlowJo) (Figure 4.4).  
 
Statistical Analysis 
Statistical analyses were performed using SAS (Version 6.09, SAS Institute, Cary, NC).  
All data was analyzed by 2-way ANOVA using GLM procedure to determine the effects 
of HMO treatments, NT treatments and their interactions.  In the event of a significant 
main effect, a post hoc Least Significant Difference test was used.  Statistical significance 
was defined as p<0.05.  Data are presented as mean ± SD. 
 
Results 
Proliferation Assay 
NT alone increased proliferation (p=0.0032) and, at the highest dose (1000 µg/mL), all 
HMO treatments significantly reduced proliferation at 72h.  The degree of inhibition of 
proliferation increased (p=0.0365) with longer HMO exposure, 72h (Table 4.1A) vs. 24h 
(Table 4.1B). Overall, these data demonstrate a dose-dependent and time-dependent 
growth inhibition response to HMO.  The 72h data is also presented in Figure 4.5, to 
illustrate the dose-dependency and interaction with NT.  All FL mix doses significantly 
decreased proliferation compared to media alone.  The addition of NT abolished the anti-
proliferative effect of the FL mix.  A dose response was seen for SL mix treatments.  The 
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500 and 1000 µg/mL SL mix treatments significantly decreased proliferation. The 250 
and 1000 µg/mL SL mix doses with NT significantly decreased proliferation in 
comparison to control, which shows NT did not relieve the inhibition as much as with FL 
mix.  A dose response was seen for LNnT treatments, only 500 and 1000 µg/mL LNnT 
significantly decreased proliferation, but only 1000 µg/mL with NT significantly 
decreased proliferation. The addition of NT decreased the anti-proliferative effects at the 
LNnT higher doses.   
 
Cell Cycle Analysis 
Although NT increased proliferation rate, they did not affect the distribution of cells in 
each phase of the cell cycle compared to control.  HMO had greater effects on cell cycle 
phases at 24h (Table 4.2A) than at 72h (Table 4.2B), so only 24h data will be presented 
as a figure to simplify data presentation (Figure 4.6).  FL mix treatments without NT 
significantly decreased cells in G0/G1 phase and increased cells in S phase.  The 
percentage of cells in G2/M phase was not significantly affected by FL mix.  SL mix at 
500 or 1000 µg/mL without NT had decreased G0/G1 phase cells and increased S phase 
cells.  The percentage of cells in G2/M phase only increased at highest doses of SL mix, 
500 and 1000 µg/mL, without NT.  G0/G1 decreased and S phase increased in LNnT 
treatments without NT.  LNnT treatments with NT still had increased cells in S phase, but 
did not see significant decrease in G0/G1 and increase in G2/M phase.  Overall, HMO 
increased the percentage of cells in the G2/M and S phases and concomitantly decreased 
the cells in the G0/G1 phase. 
 
Apoptosis Assay  
NT alone did not induce apoptosis or necrosis.  A dose-response was seen when 
examining the effect of all HMO treatments without NT on apoptosis and necrosis at 24h.  
Overall, the percentage of apoptotic and necrotic cells was significantly higher at 24h 
(Table 4.3A) than at 72h (Table 4.3B), so only 24h data is shown in figure (Figure 4.7).  
Higher HMO doses with or without NT significantly increased the percentage of 
apoptotic and necrotic cells compared to control.  NT alone did not induce apoptosis or 
necrosis.  The addition of NT decreased the highest dose of FL mix apoptotic and 
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necrotic impact.  NT did not decrease SL mix ability to induce apoptosis and necrosis, 
but the addition of NT decreased the percent of apoptotic and necrotic cells at all LNnT 
doses.  Overall, higher HMO doses with or without NT dramatically increased the 
percentage of apoptotic and necrotic cells compared to control.   
 
Discussion 
 The neonatal intestine undergoes rapid growth and functional development in the 
early postnatal period.  While growth is driven primarily via crypt stem cell proliferation, 
apoptosis plays an important role in homeostasis of intestinal epithelia (Potten, 1997).  
Human milk components support appropriate intestinal development by promoting both 
growth and functional differentiation (Donovan, 2006).  Recent studies have suggested 
that HMO function to down-regulate intestinal proliferation (Kuntz et al., 2008).  
However, human milk contains a variety of components that may moderate this effect.  
Herein, we specifically investigated the interaction between HMO and NT. 
A concentration-dependent inhibition of growth in FHs-74 Int cells by both 
neutral and acidic HMO was observed, which was partially reversed when NT were 
added to the culture media.  To understand the effects of HMO and NT on growth-
associated events of intestinal cells, flow cytometric analyses were carried out to examine 
cell cycle and apoptosis/necrosis.  It appeared that HMO initially induced 
apoptosis/necrosis, which was later evidenced by G2/M cell cycle arrest and decreased 
proliferation. 
 The observed concentration-dependent inhibition of growth by both neutral and 
acidic HMO is consistent with previous reports in which different HMO treatments at 
1000 µg/mL were anti-proliferative in HT-29, Caco-2 and HIEC cell lines (Kuntz et al., 
2008).  Individual treatments with 2'FL and 3'FL decreased proliferation of HT-29 cells 
by 20.0 and 17.2% by, respectively, but neither decreased proliferation in Caco-2 or 
HIEC cell lines.  Herein, the FL mix decreased FHs-74 Int cell proliferation by 30.2%.  
Kuntz and colleagues also reported that the acidic HMO 3'SL and 6'SL significantly 
decreased proliferation, by an average of 30.8% in all cell lines, which is consistent with 
the 24.7% decrease in FHs-74 Int cell proliferation in the current study.  
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Accumulation of cells in the G2/M stage of the cell cycle in response to HMO 
treatments is consistent with what has been reported previously in the literature using 
different epithelial cell lines (Kuntz et al., 2009).  Kuntz and colleagues demonstrated 
that this increase in cell cycle stage was caused by increased cyclin B mRNA expression 
levels, which is a cell cycle regulatory protein that is generally induced at the G2/M 
transition and becomes deactivated as the cell exits mitosis.  The cell cycle arrest appears 
to occur through neutral and acidic oligosaccharides interacting with epidermal growth 
factor receptor (EGFR), which was determined by measuring signal transduction 
pathways through a protein profiling array to detect different phosphorylation events.  
This interaction with the EGFR then activates ERK1 and p38 pathways, which cause an 
increase in cyclin B mRNA, which leads to the G2/M cell cycle arrest.  Our data 
demonstrate that all HMO treatments decreased the percentage of cells in G0/G1 phase, 
which was also shown by Kuntz and colleagues (2009). Our data also showed that higher 
concentrations of FL mix treatments increased the percentage of cells in S phase, and SL 
mix and LNnT treatments increased the percentage of cells in G2/M and S phases.  This 
could indicate that different HMO act on different stages of the cell cycle.  Kuntz and 
colleagues (2009) did not see this S phase accumulation in HIEC and Caco-2 cells in 
response to being treated with HMO.   
In previous studies, caspase-3 was used to assess apoptosis activity at 24h in cells 
treated with HMO.  Apoptosis was induced in HT-29 and HIEC cells, but not Caco-2 
cells, by neutral HMO at 15 mg/mL, which is above the concentration in human milk.  
However, acidic HMO fractions and individual compounds of the oligosaccharides at 
1000 g/mL did not change caspase-3 activity (Kuntz et al., 2008).  Caspase 3 is an early 
marker of apoptosis (Wenzel et al., 2000) and was reported at 24h by Kuntz and 
colleagues.  It is unknown if this research group measured other time points than 24h 
because our data showed a significant increase in both apoptotic and necrotic cells at 24h 
when treated with HMO at concentrations tested in previously reported study and the 
percentage of cells undergoing apoptosis was higher at 24h than 72h.  It could be that 
apoptosis was not occurring in their cells until a later time point.  The FHs-74 Int cells 
may be more sensitive to HMO than the cell lines previously analyzed by Kuntz and 
colleagues (2008).   
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A limitation of this current study is that a cell line already identified to show anti-
proliferative and low apoptotic effects from HMO treatments was not used 
simultaneously with the FHs-74 Int cells.  Additionally, we analyzed cells for apoptosis 
and necrosis after 4h of HMO and NT treatments, and apoptosis and necrosis was not 
different from control cells indicating that there was not an immediate cytotoxic impact 
on the cells.  We also measured apoptosis and necrosis when cells were treated with 
HMO in full medium, rather than reduced medium and similar levels of apoptosis and 
necrosis were observed as in the reduced media, indicating that apoptosis and necrosis 
would have occurred even in a non-nutrition limiting environment.   
Previous studies have shown that HMO induce differentiation of HT-29 and 
HIEC cells, but not in Caco-2 cells, by measuring alkaline phosphatase activity as a 
marker for differentiation (Kuntz et al., 2008).  However, we utilized FHs-74 Int cells, 
which are genotypically more similar to immature enterocytes (Jou et al., 2010).  Since 
the FHs-74 Int cells are similar to stem-like cells, they do not express markers of 
differentiation in vitro, (Chao & Donovan, 1996), which is a limitation to this study. 
FHs-74 Int cells had to be treated in reduced medium to see NT proliferative 
effects.  Preliminary experiments showed that exogenous NT did not stimulate 
differentiation unless the medium had decreased FBS and no EGF.  It has been 
previously reported that Caco-2 and IEC-6 cells did not seem to benefit from exogenous 
NT supply unless nutrition supply was limited (Holen, 2004).  One can extrapolate that a 
rapidly growing neonate could have limited nutrition supply even with adequate breast 
milk or infant formula intake.  This can explain why NT-supplemented formula increased 
intestinal growth and immune function compared to formula alone (Lopez-Navarro et al., 
1996; Uauy, 1989).  Thus, our cell culture model is representative of a rapidly growing 
neonate who would benefit from exogenous NT, since endogenous NT may not be 
sufficient to sustain maximum intestinal growth.   
In summary, we observed a pronounced growth inhibition effect on FHs-74 Int 
cells by both neutral and acidic HMO.  The presence of NT, a routine addition to infant 
formula, inhibited many of the effects of HMO on cell proliferation and cell cycle, but 
not apoptosis and necrosis.  Thus, the inhibitory effects of HMO alone may not be 
physiologically relevant within the matrix of human milk or infant formula.  It is 
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important to consider how the different additives to infant formula are acting together to 
develop improved infant formula. The greatest influence on the environment of the 
intestinal epithelium is diet, so understanding how infant formula ingredients influence 
intestinal gene regulation and growth characteristics is important (Sanderson & Naik, 
2000).  It is remarkable that two ingredients, readily found in human breast milk, tested in 
the present study can act so differently on the growth-related characteristics of intestinal 
cells.  In vivo studies are needed to define the effects of HMO alone and HMO and NT 
together on intestinal growth characteristics. 
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Figures 
 
 
Figure 4.1 NT dose response on proliferation. Cells were treated with different doses 
of NT in reduced media for 72h.  250 µg/mL dose was chosen because it increased 
proliferation above media treated cells without a large standard deviation.  Data is 
presented as mean, percentage of control ± SD. 
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Figure 4.2. Cell Culture Protocol.  After initial seeding, cells were grown in full 
medium (10% FBS, 30ng/mL EGF) and allowed to adhere for 24h.  Thereafter, medium 
was replaced with reduced medium (2.5% FBS, no EGF) for 24 h.  Then the medium was 
replaced and cells were exposed to different treatments of NT alone, HMO alone, or a 
combination of NT and HMO in reduced medium for 24 and 72h.  No reagents or 
medium was added to the cultures during the culture period. 
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Figure 4.3. Representative histogram of flow cytometric analysis of the cellular DNA 
content in FHs-74 Int cells, stained with propidium iodide.  The first peak represents 
cells in the G0/G1 phase of the cell cycle; the second peak represents cells in the G2/M 
phase. The intervening cells between the peaks are in the S-phase of the cell cycle. 
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Figure 4.4. Flow Cytometry gating procedure for apoptosis and necrosis.  (A) All 
cells were selected on the side scatter vs. forward scatter plot. (B) Shows Annexin vs. PI 
staining.  Cells in bottom left quadrant were considered live cells (Annexin-PI-), bottom 
right quadrant were considered apoptotic cells (Annexin+PI-), and upper right quadrant 
cells were considered to be necrotic cells (Annexin+PI+).  Annexin is a Ca
2+
 dependent 
phospholipids-binding protein with high affinity for phosphatidylserine and is a marker 
for apoptosis.  PI stains for DNA, and allows for discrimination of necrotic cells stained 
positive for Annexin.   
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Figure 4.5. Dose dependent inhibition of proliferation by HMO is counteracted by NT at 72 hours.  Data is presented as mean, 
percentage of control.  All FL mix doses significantly decreased proliferation and the addition of NT abolished this effect.  A dose 
response was seen for SL mix treatments, and the addition of NT decreased the anti-proliferative effects.  A dose response was seen 
for LNnT treatments, and the addition of NT decreased the anti-proliferative effects at the higher doses. Each value represents the 
mean from 2 independent experiments (n=3). 
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Figure 4.6.  Cell Cycle results at 24 hours.  Data is presented as percent of cells in each 
cell cycle stage.  FL mix treatments decreased G0/G1 phase and S phase was increased in 
all treatments except lowest and highest FL mix dose.  G2/M was not significantly 
affected by FL mix.  High SL mix treatments without NT had decreased G0/G1 phase 
and increased S phase.  G2/M only increased at higher doses of SL mix without NT.  
G0/G1 decreased and S phase increased with LNnT treatments.  G2/M increased with 
LNnT treatment but NT abolished this effect. Each value represents the mean from 2 
independent experiments (n=2).   
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Figure 4.7. Dose response for apoptosis and necrosis at 24 hours. (A) Data is 
presented as mean percentage of cells undergoing apoptosis.  A dose response was seen 
when examining the effect of all HMO treatments without NT on apoptosis.  The addition 
of NT decreased the highest dose of FL mix apoptotic impact.  NT did not decrease SL 
mix ability to induce apoptosis.  NT decreased the percent of apoptosis at all LNnT 
doses. (B) Data is presented as mean percentage of cells undergoing necrosis.  A dose 
response was seen when examining the effect of all HMO treatments without NT on 
necrosis.  The addition of NT decreased the highest dose of FL mix necrotic impact.  NT 
did not decrease SL mix ability to induce necrosis.  NT decreased the percent of necrosis 
at all LNnT doses. Each value represents the mean from 2 independent experiments 
(n=2). 
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Tables 
 
 
Table 4.1: Dose dependent inhibition of proliferation by HMO is counteracted by 
NT at (A) 24 and (B) 72 hours. 
1,2,3 
 
A 
HMO Treatment HMO (µg/mL) No NT NT (250 µg/mL)
 4
 
Control  100 ±0 131.7 ± 8.7* 
FL mix 125 127.8 ± 16.5 110.5 ± 27.7 
 250 121.7 ± 28.7 109.2 ± 9.9 
 500 129.8 ± 41.5 112.4 ± 12.4 
 1000 111.2 ± 27.2 127.0 ± 28.8 
SL mix 125 94.7±11.1 105.4±13.6 
 250 76.4±5.6* 97.9±16.8 
 500 74.3±12.8* 108.7±11.3 
 1000 76.6±7.8* 103.3±14.2 
LNnT 125 101.3±7.6 86.8±6.3 
 250 99.9±9.2 89.7±38.8 
 500 103.4±9.5 72.9±8.4* 
 1000 87.9±10.6 97.2±17.4 
 
 
B 
HMO Treatment HMO (µg/mL) No NT NT (250 µg/mL)
 4
 
Control  100 ±0 140.6±39.9 * 
FL mix 125 82.9±21.6* 134.9±27.7 
 250 87.4±33.1* 123.2±9.9 
 500 86.6±6.3* 106.7±12.4 
 1000 69.8±20.5* 113.7±28.8 
SL mix 125 116.4±23.5 88.0±17.5 
 250 95.1±6.7 77.1±20.4* 
 500 82.9±14.3* 90.7±20.7 
 1000 75.3±15.2* 81.9±20.6* 
LNnT 125 121.2±17.6 108.8±9.6 
 250 115.8±25.6 90.4±3.8 
 500 86.8±39.0* 110.5±4.9 
 1000 76.6±27.1* 64.9±14.3* 
1 
Each value represents the mean ± SD from 2 independent experiments (n=3). 
2 
Means differ from control (*p<0.05). 
3 
The growth inhibition is presented as % of control. 
4 
NT concentration was 250µg/mL for each treatment. 
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Table 4.2: Percentage of cells in each phase of the cell cycle in response to NT and HMO treatments at (A) 24 and (B) 72 
hours
1,2,3
 
 
A 
  G0/G1  S  G2/M  
HMO Treatment HMO 
(µg/mL) 
No NT NT 
(250 µg/mL) 
No NT NT 
(250 µg/mL) 
No NT NT  
(250 
µg/mL) 
Control  92.8±0.1 92.4±0.8 2.8±0.3 3.5±0.9 3.1±0.3 3.3±0.4 
FL mix 125 87.5±2.4 87.5±2.4 6.3±1.5 10.5±0.1* 5.1±1.1 6.1±1.0 
 250 80.2±1.1* 83.5±0.8 10.9±0.2* 9.6±1.2* 6.7±1.2 5.9±1.2 
 500 83.0±1.7* 82.8±0.6 10.0±1.3* 10.5±1.1* 5.6±1.9 5.3±0.3 
 1000 88.9±5.3 88.9±5.3 5.4±2.8 8.7±5.4* 4.7±2.3 3.8±0.7 
SL mix 125 90.6±4.2 87.8±4.2 4.5±2.8 5.9±0.6 4.2±1.7 4.1±1.4 
 250 90.0±3.4 83.8±4.8* 5.0±1.6 9.4±2.0* 3.5±1.8 5.5±2.7 
 500 82.8±0.4* 88.2±0.3 9.6±1.3* 6.5±0.8* 6.4±1.6* 3.9±0.1 
 1000 78.5±1.6* 89.2±1.2 12.8±1.6* 5.6±0.1 6.6±0.2* 3.7±0.2 
LNnT 125 74.4±4.2* 90.7±0.9 15.3±3.6* 4.1±0.3 8.3±0.9* 3.6±0.9 
 250 83.9±6.6 91.5±0.6 9.8±3.2* 4.2±0.6 5.3±3.5 3.0±1.2 
 500 81.4±1.6* 86.4±0.9 11.2±0.8* 8.5±1.2 6.2±0.6* 4.1±0.3 
 1000 78.2±9.1* 85.2±0.7 14.4±7.9* 10.2±1.3* 5.6±0.6* 3.8±0.6 
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Table 4.2 continued 
 
B 
  G0/G1  S  G2/M  
HMO Treatment HMO 
(µg/mL) 
No NT NT 
(250 µg/mL) 
No NT NT 
(250 µg/mL) 
No NT NT  
(250 
µg/mL) 
Control  96.3±1.0 96.4±0.3 0.7±0.3 0.6±0.3 2.3±0.1 2.5±0.2 
FL mix 125  87.2±2.1  5.6±0.1*  5.5±0.4* 
 250 92.0±1.5 87.9±1.3 1.6±0.3 6.4±2.2* 4.0±0.8* 4.4±0.5* 
 500 91.6±0.3 88.0±3.5 2.2±0.7 4.1±2.3* 4.0±0.7* 4.6±1.2* 
 1000 94.9±0.1 93.9±1.9 0.8±0.4 1.0±0.4 2.9±0.3 3.7±0.9* 
SL mix 125 90.6±4.2 87.8±4.2 4.5±2.8* 5.9±0.6* 4.2±1.7 4.1±1.4 
 250 90.0±3.4* 83.8±4.8 5.0±1.6* 9.4±2.0* 3.5±1.8 5.5±2.7* 
 500 82.8±0.4* 88.2±0.3 9.6±1.3* 6.5±0.8* 6.4±1.6* 3.9±0.1 
 1000 78.5±1.6* 89.2±0.1 12.8±1.6* 5.6±0.1* 6.6±0.2* 3.7±0.2 
LNnT 125 91.6±1.3* 93.2±2.0 2.4±0.9 2.4±1.8 2.8±2.3 2.1±0.1 
 250 91.8±2.6* 89.1±4.5* 3.1±0.2 5.6±5.8 2.7±1.4 2.8±1.4 
 500 87.9±1.3* 89.8±2.3* 4.3±1.5 3.4±0.9 2.7±0.1 3.9±0.7 
 1000 93.2±0.3 89.8±0.1* 0.6±0.1 2.1±0.1 4.0±0.3 4.4±0.3 
1 
Each value represents the mean ± SD from 2 independent experiments (n=2). 
2 
Means differ from control (*p<0.05). 
3 
NT concentration was 250µg/mL for each treatment. 
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Table 4.3: Percentage of cells undergoing apoptosis and necrosis at (A) 24 and (B) 72 hours 
1,2,3 
 
A 
  Apoptosis  Necrosis  
HMO 
Treatment 
HMO  
(µg/mL) 
No NT NT  
(250 µg/mL) 
No NT NT  
(250 µg/mL) 
Control  2.5±0.2 2.1±0.3 5.0±0.1 4.9±0.6 
FL mix 125 7.7±2.3 10.2±0.3 6.1±0.8 8.9±0.5 
 250 4.3±0.3 5.5±0.3 4.3±0.8 5.9±0.8 
 500 11.2±4.9* 13.7±2.4* 13.5±4.3* 10.8±1.2 
 1000 22.2±1.3* 17.9±0.3* 21.9±2.3* 13.4±0.3* 
SL mix 125 3.1±0.2 2.7±0.4 5.5±1.1 5.2±0.1 
 250 4.5±1.5 7.3±3.1 5.5±0.6 12.7±5.5 
 500 11.7±0.9* 6.6±0.9 9.6±0.3 7.9±0.7 
 1000 10.8±0.6* 14.8±2.8* 8.1±0.4 21.9±5.5* 
LNnT 125 3.3±3.2 3.0±0.2 16.9±0.6 5.3±0.5 
 250 14.5±1.0* 3.8±0.1 23.5±1.6* 4.4±0.3 
 500 15.6±5.2* 7.9±1.4 28.2±4.4* 12.8±0.9 
 1000 17.6±2.7* 15.2±0.5* 29.2±6.9* 12.5±1.2 
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Table 4.3 continued 
 
B 
  Apoptosis  Necrosis  
HMO 
Treatment 
HMO  
(µg/mL) 
No NT NT 
(250 µg/mL) 
No NT NT 
(250 µg/mL) 
Control  1.0±0.2 0.9±0.1 3.3±0.5 2.4±0.2 
FL mix 125 2.4±0.1* 4.7±0.1* 1.8±0.5 11.3±0.5* 
 250 1.5±0.1 3.1±0.1* 1.4±0.1 5.8±1.2* 
 500 1.9±0.4 2.4±0.5* 2.0±0.5 11.5±0.2* 
 1000 1.0±0.5 1.9±0.1* 1.0±0.0 8.1±1.2* 
SL mix 125 1.8±0.1 1.3±0.4 2.8±0.5 2.3±0.2 
 250 0.9±0.4 2.3±0.8 2.5±0.3 4.3±1.3 
 500 2.8±0.2* 1.3±0.2 3.0±0.7 3.2±0.2 
 1000 2.7±0.6 1.3±0.3 3.3±0.1 4.0±0.5 
LNnT 125 5.6±0.1* 0.7±0.1 3.6±0.2 2.5±0.1 
 250 4.8±1.5* 0.4±0.0 2.9±0.4 1.9±0.3 
 500 4.3±0.3* 6.3±0.4* 4.6±0.7 7.6±0.6* 
 1000 2.7±1.0* 5.0±0.8* 2.5±0.4 6.6±1.9 
1 
Each value represents the mean ± SD from 2 independent experiments (n=2). 
2 
Means differ from control (*p<0.05). 
3 
NT concentration was 250µg/mL for each treatment. 
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Chapter 5   
 
Human Milk Oligosaccharides Inhibit Acute Rotavirus Infection with No Effect of 
Nucleotides in Neonatal Piglets 
 
Abstract 
Nucleotides (NT) are currently added to infant formula, and human milk oligosaccharides 
(HMO) are being investigated as potential additives.  Herein, the interaction between 
chronic NT feeding and acute HMO treatment within the ileal lumen of both healthy and 
acutely rotavirus (RV)-infected piglets was studied.  Piglets (n=9 group) were fed 
formula containing 64 mg NT/L (FF) or 314 mg NT/L (FF+NT) from d2 to 21 of age.  At 
d21, a midline laparotomy was performed and six 10-cm loops of ileum were isolated in 
situ.  The following treatments were injected into the loops: media, 2 mg/mL neutral 
HMO (LNnT), 2 mg/mL acidic HMO mixture (aHMO: sialic acid (SA), 6' sialyllactose 
(SL), 3'SL), or each treatment + SA dependent OSU strain RV (1 x 10
7
 FFU). After 6h, 
samples were collected.  Body weight, formula intake, jejunum villus length/crypt depth, 
ileal proliferation, ileal macrophages and T cell phenotypes were unaffected by dietary 
NT.  Loops treated with either HMO treatments + RV had lower RV replication, as 
assessed by NSP4 mRNA expression, than RV-treated loops alone. Ileal loops not treated 
with RV showed no NSP4 expression.  There was no difference in the mRNA expression 
of NF-κβ, TNF-α, CCL2 or IL-1  in ileal mucosa as analyzed by loop or dietary 
treatment.  However, NT fed piglets had significantly greater IL-8 ileal mucosa mRNA 
expression than formula piglets and aHMO loop treatment significantly increased IL-8 
mRNA expression compared to control treated loops.  Thus, chronic dietary NT only had 
minor effects on the parameters measured, but HMO decreased NSP4 replication during 
acute RV infection. 
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Introduction  
 Human milk (HM) contains numerous bioactive components that are thought to work 
in concert to protect the infant against infection (German et al., 2002).  Ingredients have 
been added to infant formula to more closely reflect HM composition (Hernell, 2011). 
The immunomodulatory effects of nucleotides (NT) (Holen et al., 2005) or human milk 
oligosaccharides (HMO) (Bode et al., 2004) separately have been investigated, but little 
is known about the immunomodulatory efficacy of NT or HMO when they are used in 
combination as infant formula ingredients.  NT are currently added to infant formula and 
HMO are being investigated as potential additives (Chichlowski et al., 2011).  These 
ingredients have not been evaluated in their ability to reduce rotavirus (RV) infections in 
vivo.   
 Nearly all children experience at least one RV infection by the age of 5 years 
(Bernstein, 2009).  Rotavirus causes symptoms such as diarrhea, vomiting, and fever. The 
incidence of RV infection is similar for developed and developing countries, but death is 
more frequent in developing countries, with more than 600,000 deaths annually 
worldwide (Desselberger et al., 2009).  Vaccination is the main public health intervention 
to combat RV infection and, since 2006, two vaccines have been approved for use in 
many countries, including the United States. Vaccination accessibility to all populations, 
especially in developing countries, is low therefore it is important to continue 
investigating alternative cost effective strategies including nutritional interventions to 
reduce the occurrence of RV infections. 
  Using the total potentially available nucleosides (TPAN) analysis method, the NT 
content of HM was found to be 72 mg/L (Leach et al., 1995), and this is the amount 
supplemented to infant formula. A beneficial effect of NT on gastrointestinal tract growth 
and function has been shown in several animal studies (Lopez-Navarro et al., 1996) 
(Ortega et al., 1995).  Clinical studies have shown that adding NT to infant formula 
improved the vaccination response relative to infants fed control formula (Pickering et 
al., 1998; Schaller et al., 2004).  Infants fed NT-supplemented formula had higher 
numbers and percentages of cytotoxic T cells, natural killer (NK) cells, and T 
lymphocytes positive for intracellular IFN-γ and for IL-4.   
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HMO are complex carbohydrate structures attached to a lactose moiety at the 
reducing end.  HMO are the third most abundant constituent of HM and HMO are found 
in concentrations of 12 – 15 g/L in HM (Coppa et al., 1993; Newburg, 2000).  The 
composition of HMO is unique relative to other species and markedly higher than bovine 
milk (Newburg et al., 2004; Kunz et al., 2000), and around 200 different HMO have been 
identified in HM (Bode, 2009) which vary in size, structure, and abundance (Coppa et al., 
1993).  The building blocks of milk oligosaccharides are the five monosaccharides: D-
glucose, D-galactose, N-acetylglucosamine, L-fucose, and SA.  Lactose forms the 
reducing ends of the HMO and lactose can be fucosylated on the nonreducing end in α1-2 
and α1-3 linkages to form 2'fucosyllactose and 3'fucossyllactose, respectively.  Lactose 
can also be sialylated on the non-reducing end in α2-3 and/ or α2-6 linkages to form 
3'sialyllactose and 6'sialyllactose, respectively.  More complex HMO can be made by 
different combinations of the five monosaccharides listed above. 
HMO have been shown to have an inhibitory effect on certain pathogenic 
microorganisms, by blocking adhesion of the pathogenic microorganisms to the epithelial 
surfaces (Ruiz-Palacios et al., 2003).  The soluble glycans found in HM inhibit pathogens 
from binding to their host cell-surface glycans and are associated with significant 
protection from diarrhea in breast fed infants (Newburg et al., 2005).  RV must be 
recognized by glycoconjugate receptors located on the villus-tips of enterocytes to cause 
infectivity.  Both porcine and human strains of RV bind to sialyllactose oligosaccharides 
on cell membranes (Rolsma et al., 1998).  Interruption of the virus binding to host cells 
by using receptor mimics provides an opportunity to stop the infectious cycle.  Various 
sialylated glycoproteins at concentrations of 10-100μg/mL have the ability to inhibit RV 
infection, if preincubated with the virus prior to cell infection (Isa et al., 2006).  Previous 
work in our lab had shown that specific HMO can inhibit RV infectivity in vitro (Chen et 
al., 2011).  Infectivity by OSU strain RV was dose-dependently inhibited by a complex 
HMO mixture isolated from preterm human milk, 3'SL and 6'SL, but not by LNnT, 2'FL, 
3'FL or a combination of polydextrose and galactooligosaccharides (PDX/GOS).  At a 
dose of 2 mg/mL, 3'SL inhibited OSU strain RV by 20% and 6'SL inhibited RV by 50%. 
The initial epithelial cell is infected by RV and virus and viral proteins are 
released. The viral nonstructural protein NSP4, an enterotoxin, has been found to have 
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toxin-like activity to induce diarrhea (Ramig, 2004).  The NSP4 mRNA activity will be 
measured to determine RV replication in this study. Rotavirus infection causes the rapid 
activation of NF-κβ and the induction of NF-κβ-directed cytokines, such as IL-8 (Rollo et 
al., 1999).  These cytokines are known to attract and activate immune cells (Azevedo et 
al., 2006).  Indeed, the frequency of intestinal dendritic cells (DC) (both plasmacytoid 
and conventional) and macrophages/monocytes are higher in RV-inoculated piglets 
compared to controls on days 2 and 4 post infection (Gonzalez et al., 2010).    
The ultimate goal will be to add HMO to formula, however, currently HMO are 
extremely expensive, and it would be cost prohibitive to add HMO to formula.  Therefore 
we developed an acute piglet RV infection model in which RV is introduced into section 
of intestine along with different HMO as the first step in determining which HMO 
fraction would be most efficacious in vivo.  A piglet necrotizing enterocolitis model 
developed by Di Lorenzo and colleagues (Di Lorenzo et al., 1995), and used previously 
in our lab (Gorski et al., 2002), was modified to serve as an acute RV infection model for 
this study.   
The overall objective of this study was to assess how chronic NT supplementation 
and acute treatment with HMO in the ileal lumen impact both healthy and acutely RV 
infected piglets.  The hypothesis was that NT would increase overall immune response 
(Grimble & Westwood, 2001) and HMO treatment would decrease RV infectivity by 
inhibiting RV infection (Chen et al., 2011; Newburg, 2004; Rolsma, 1998).  To our 
knowledge no previous studies have examined the interaction between NT and HMO and 
HMO effect on RV infection in vivo. 
 
Methods and Materials 
Animals 
The study design is depicted in Figure 5.1.  Piglets (n=18) were obtained from 
University of Illinois Swine Research Center after receiving 48 hours of colostrum from 
the sow.  They were a reared on non-medicated, sow-milk replacer (Milk Specialties 
Global Animal Nutrition, Carpentersville, IL) either naturally containing 64 mg NT/L at a 
ratio of NT; 34.3% cytidine monophosphate (CMP), 25.2% uridine monophosphate 
(UMP), 19.5% adenosine monophosphate (AMP), and 21.0% guanosine monophosphate 
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(GMP) (FF; n=9) or non-medicated sow-milk replacer + additional 250 mg/L NT 
(FF+NT; n=9) until 21-days of age (Table 5.1).  The NT mixture added is based on the 
ratio of NT found in breast milk and supplemented to infant formula; 43% CMP, 18.5% 
UMP, 16.4% AMP, and 22% GMP (Sigma-Aldrich, St. Louis, MO).  Piglets were 
individually housed in cages capable of maintaining six piglets separated by Plexiglas 
partitions in environmentally-controlled rooms (25°C).  Radiant heaters were attached to 
the tops of the cage to maintain an ambient temperature of 30°C.  Formula was offered 20 
times daily at a rate of 360 ml/kg BW/day.  The piglets were monitored for normal 
growth and food intake, as well as the presence of fever, diarrhea or lethargy.  The 
following scale was used daily to score stool consistency; 1=firm/no diarrhea 2=stiff-
flowing 3=easy-flowing/loose 4=watery/diarrhea 5=severe diarrhea.  All animal 
procedures were approved by Institutional Animal Care and Use Committee of the 
University of Illinois. 
 
Acute RV Infection  
Piglets were fasted 8h prior to being sedated by intramuscular injection of ketamine (2.2 
mg/kg; Bioniche Pharma USA LLC., Lake Forest, IL) and xylazine (2.2 mg/kg; Akorn, 
Inc., Decatur, IL) and maintained under isoflurane (98% O2/2% isoflurane) for 6h.  
Twenty-four hours prior to sedation, piglets were injected with 2.5 mg/kg bodyweight 5-
ethyyl-2'-deoxyuridine (EdU; Invitrogen, Eugene, OR), a nucleoside analog of thymidine, 
to permit the evaluation of intestinal cell proliferation.  A midline laporatomy was 
performed and six 10-cm loops of ileum were isolated in situ as described by (Di Lorenzo 
et al., 1995) and previously conducted in our laboratory (Gorski et al., 2002).  Briefly, 
beginning at the ileal-cecal junction, 10-cm sections were measured and loops were 
formed by tying the intestine with suture (Deknatel Silk Surgical Suture, Research 
Triangle Park, NC).  Approximately 1-cm sections were kept between each loop.  The 
following treatments were injected into the loops in the amount of 2mL per loop: media, 
2 mg/mL neutral HMO (LNnT) (donated by Abbott Nutrition, Columbus OH), 2 mg/mL 
acidic HMO mixture (aHMO) [40% 6'SL (V-Labs product no. SL306, Covington, LA) 
/10% 3'SL (V-Labs product no. SL302, Covington, LA) /50% SL (V-Labs product no. 
N101, Covington, LA)], or each treatment + SA dependent porcine RV strain OSU 
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10 cm loops 
of ileum 
10 cm loops of 
ileum 
 
(P9[7],G5) obtained from Kuhlenschmidt lab who obtained it from American Type 
Culture Collection (1 x 10
7
 focus forming units/mL (FFU)) (Figure 5.2).  The OSU strain 
RV was activated prior to injection by treating it with crystallized trypsin at a final 
concentration of 10 µg/mL for 30min at 37°C (Invitrogen Gibco, Grand Island, NY), 
which is required to permit RV penetration of cell membranes following cell attachment.  
The acidic HMO mixture ratio was calculated by completing a literature search on the 
concentration of each HMO found in human breast milk and then calculating a ratio 
within acidic HMO mix.  The order of the treatments among the 6 loops were randomized 
between piglets.  Six hours after treatment injections, piglets were euthanized by an 
intracardiac injection of 60mg/kg BW sodium pentobarbital (Euthanasia-5 solution; 
Vortex Pharmaceuticals, Dearborn, MI)  and blood was collected by cardiac puncture into 
plain vials for serum isolation and heparin-laced vials (BD Biosciences, Franklin Lakes, 
NJ) for isolation of mononuclear cells.  The entire intestine was removed, flushed with 
ice-cold saline, weighed and measured.  Samples (1-2 cm) of jejunum and the ileal loops 
were either snap frozen in liquid nitrogen, fixed in Formalin solution, or opened 
longitudinally and mucosa scraped and then snap frozen in liquid nitrogen.   
 
Isolation and Phenotypic Identification of Mononuclear Cells 
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient 
centrifugation.  Briefly 10 mL of heparinized blood was diluted in 25 ml of RPMI 1640 
(Invitrogen Gibco, Grand Island, NY) and layered over Ficoll-Paque PLUS lymphocyte 
separation medium (GE Healthcare, Uppsala, Sweden).  The PBMC were recovered after 
centrifugation (400 x g, 30 min) across the density gradient.  Isolated PBMC were placed 
in complete culture medium (RPMI 1640 (Invitrogen Gibco, Grand Island, NY) 
containing 10% fetal calf serum (Invitrogen Gibco), 2mM L-glutamine (Invitrogen 
Gibco), 100 μg/mL penicillin, 100 μg/mL streptomycin, and 50 μg/mL gentamicin 
(Invitrogen Gibco).  The number of viable cells was assessed by trypan blue (Invitrogen 
Gibco) exclusion.  The phenotypes of PBMC T lymphocyte subpopulations were 
monitored by flow cytometry using fluorescently labeled mAbs.  T lymphocytes were 
identified by mouse anti-pig CD3:PE-Cy5 (Clone PPT3, Southern Biotech, Birmingham, 
AL).  To further differentiate T cell populations, cells were stained with mouse anti-pig 
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CD4:FITC (Clone 74-12-4, Southern Biotech) and mouse anti-pig CD8:PE (Clone 76-2-
11, Southern Biotech) (Table 5.2).  All staining procedures took place on ice and care 
was taken to prevent unnecessary exposure to light.  Briefly, PBMC (1 x 10
6
/ tube) was 
blocked with anti-pig CD16 (G-7, AbD Serotec) for 5min.  The cells were then incubated 
for 20min in a total volume of 30µl (10µl of each mAb: CD3, CD4 and CD8).  Cells were 
washed twice with phosphate buffered saline (PBS)/1% bovine serum albumin 
(BSA)/0.1% sodium azide, and then fixed with 2% paraformaldehyde.  Staining was 
assessed using a LSRII flow cytometer (BD™, Biosciences, San Jose, CA).  The relative 
number of T cell subpopulations was determined using FlowJo 7.0 software (FlowJo, 
Ashland, OR).  CD3
+
 events were considered T cells.  CD3
+
CD4
+
CD8
-
 events were 
considered T helper cells.  CD3
+
CD8
+
CD4
-
 events were considered cytotoxic T cells. 
CD3
+
CD4
+
CD8
+
 events were considered double positive T cells.  CD3
-
CD4
-
CD8
+
 events 
were considered NK cells. 
 
Intestinal Histomorphology 
Formalin-fixed ileum and jejunum sections were embedded in paraffin, sliced to 
approximately 5 μm with a microtome, and sections were mounted on glass microscope 
slides. Jejunum slides were stained with Hematoxylin and Eosin (H&E)  by the 
University of Illinois Veterinary Diagnostic Laboratory.  Slides were then visualized in 
the Imaging Facility of the University of Illinois Institute of Genomic Biology using the 
NanoZoomer Digital Pathology System (Hamamatsu Corporation, Bridgewater, NJ) and 
analyzed using AxioVision 4.8 Digital Image Processing Software (Carl Zeiss 
MicroImaging, Inc., Thornwood, NY).  Five to 10 measurements of jejunal villus length 
and crypt depth were taken per piglet.  
 
Immunohistochemistry for Proliferation  
Unstained slides containing sections of ileum were fluorescently stained for proliferation 
and total nuclei.  Initially the unstained slides were dewaxed by soaking slides for 5 
minutes in each of the following solutions; fresh Histo-Clear II (3 times) (Thermo 
Scientific, Barrington, IL), 100% ethanol (1 time), 70% ethanol/ 30% PBS (1 time), 50% 
ethanol/ 50% PBS (1 time), 25% ethanol/ 75% PBS (1 time), 100% PBS (3 times).  
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Slides were incubated with Image IT Signal FX (Life Technologies, Invitrogen) for 1h.  
Slides were then stained for proliferation using the Click-iT
TM
 EdU Alexa Fluor 488 
Imaging Kit (Life Technologies, Invitrogen) according to the manufacturer’s instructions.  
Slides were then washed once with PBS and then counter stained with 4',6-diamidino-2-
phenylindole (DAPI) (Life Technologies, Invitrogen) for 10min to detect total nuclei.  
After washing slides 2 times for 5min with PBS, coverslip (Thermo Fisher Scientific, 
Barrington, IL) was mounted on each slide along with 2 drops Prolong® Gold anti-fade 
reagent (Life Technologies, Invitrogen).  Samples were imaged using a Zeiss 
Multiphoton Confocal microscope (LSM 700) (Carl Zeiss MicroImaging, Inc., 
Thornwood, NY) and analyzed using AxioVision 4.8 Digital Image Processing Software 
(Carl Zeiss MicroImaging, Inc.).  Percent area of EdU positive area divided by total 
DAPI positive area was found for 400 x 200µm (80,000 µm
2
) area region in ileal crypt. 
 
Immunohistochemistry for Monocytes and Macrophages 
Unstained slides containing sections of ileum were fluorescently stained for 
monocytes/macrophages and total nuclei.  Initially the unstained slides were dewaxed by 
soaking slides for 5 minutes in each of the following solutions; fresh Histo-Clear II (3 
times) (Thermo Scientific, Barrington, IL), 100% ethanol (1 time), 70% ethanol/ 30% 
PBS (1 time), 50% ethanol/ 50% PBS (1 time), 25% ethanol/ 75% PBS (1 time), 100% 
PBS (3 times).  Because the tissues were paraffin-embedded and formalin-fixed tissues, 
antigen retrieval was done.  A citrate buffer [pH 6.0] was used to break protein crosslinks 
formed by fixation allowing the antibody to recognize the CD163 and CD14 proteins.  
After antigen retrieval, slides were incubated with Image IT Signal FX (Life 
Technologies, Invitrogen) for 1h.  Slides were then stained with primary antibody 
CD163, IgG1 and a second primary antibody CD14, IgG2a (1:50 dilution) (AbD Serotec, 
Raleigh, NC) for 2h. Slides were then washed with PBS 3 times for 5min and then 
incubated with Alexa fluor 555, goat anti-mouse IgG1 and Alexa fluor 647, goat anti-
mouse IgG2a (1:100 dilution) (Life Technologies) for 1h (Table 5.3).  Slides were then 
washed with PBS3 times for 5min and then counter stained with 4',6-diamidino-2-
phenylindole (DAPI) (Life Technologies, Invitrogen) for 10min to detect total nuclei.  
After washing slides 2 times for 5min with PBS, coverslip (Thermo Fisher Scientific, 
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Barrington, IL) was mounted on each slide along with 2 drops Prolong® Gold anti-fade 
reagent (Life Technologies, Invitrogen).  Samples were imaged using a Zeiss 
Multiphoton Confocal microscope (LSM 700) (Carl Zeiss MicroImaging, Inc., 
Thornwood, NY) and analyzed using AxioVision 4.8 Digital Image Processing Software 
(Carl Zeiss MicroImaging, Inc.).  The area stained positive for CD163 or CD14 positive 
was divided by total DAPI positive area for entire whole ileum section captured (850 x 
850µm) and for 400 x 200µm (80,000 µm
2
) area region in ileal crypt.  The double 
positive area for CD163 and CD14 for entire whole ileum section captured (850 x 
850µm) was also found. 
 
Cytokine Expression and Rotavirus Replication  
Total RNA was isolated from ileal mucosal samples (0.1g) using the Qiagen, RNeasy 
Plus Mini Kit (Applied Biosystems, Foster City, CA) following the manufacturer’s 
protocol.  RNA was quantified by spectrophotometry (Abs 260nm) using a Nanodrop 
1000 (Thermo Scientific, Rockford, IL).  RNA concentration was adjusted to 0.25µg/ml 
using RNase free water.  RNA quality was assessed by a 2100 Bioanalyzer (Agilent 
Technologies, Inc., Santa Clara, CA).  All samples had an RNA integrity number (RIN) 
greater than 6.  Reverse transcription was performed on 3µg total RNA in a reaction 
volume of 20µl (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems).  
Reverse transcriptase products were analyzed by quantitative real-time PCR in TaqMan® 
custom primers and probes or gene expression assays of target genes: NSP4, NF-κβ, IL-
8, TNF-α, CCL2 and IL-1  (Table 5.4).  Reference cDNA ribosomal protein L19 
(RPL19) was used as an endogenous control (Applied Biosystems).  All reactions were 
analyzed using the 7900HT Fast Real-Time PCR Detection System instrument and 
software (Applied Biosystems Inc.).  Assays were performed in 10 μL singleplex 
reactions containing TaqMan® Universal PCR Master Mix, customized primers and 
probes, and cDNA according to the manufacturer’s instructions (Applied Biosystems).  
Universal reaction conditions were used as follows: 2 min at 50°C and 10 min at 95°C 
and then 40 cycles of 15 sec at 95°C and 1 min at 60°C.  Each reaction was run in 
triplicate.  The expression levels of cytokines were standardized to RPL19 mRNA and 
expressed as fold differences, which corresponds to a ratio to the mean value for the 
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control loop.  The expression levels of NSP4 were standardized to RPL19 mRNA and 
expressed as normalized target.  
 
Statistics 
Statistical analyses were performed using SAS (Version 6.09, SAS Institute, Cary, NC).  
Body weight, formula intake, and diarrhea scores were tested between groups by 
repeated-measures analysis of variance (ANOVA).  Outliers were identified using Cook’s 
D test and normality was checked using Shapiro-Wilks test.  Histomorphology and flow 
data was analyzed with 2-way ANOVA using GLM procedure to determine if litter or 
diet was significant.  PCR and immunohistochemistry data was analyzed using 2-way 
ANOVA using GLM procedure to determine the effects of litter and loop position.  If 
these factors were not significant, a PROC MIXED, randomized-block analysis, was used 
to determine the effects of diet, HMO and RV loop treatments, and their interactions.  
The interactions were dropped if not significant.  In the event of a significant main effect 
a post hoc Least Significant Difference test was used to compare differences among the 
treatments.  Statistical significance was defined as p<0.05.  
 
Results 
 
Formula Intake, Body Weight and Stool Consistency 
Daily formula intake (Figure 5.3) and body weight (Figure 5.4) were not different 
between dietary treatments.  Average body weight on d21 was 5.5  0.5 kg.  Stool 
consistency was not significantly different between dietary treatments.  Mean stool 
consistency score over the 19-day period was 1.7  0.2 and 2.0  0.2 for FF and FF + NT, 
respectively.  Thus, addition of NT to the formula did not affect formula intake, body 
weight or stool consistency. 
 
T Cell and NK Cell Populations 
PBMC were evaluated to assess if dietary NT would facilitate a change in T- and NK cell 
populations.  No diet effects were seen in T- or NK cell populations (Table 5.5).  T 
Helper cells (CD3
+
CD4
+
CD8
-
) were 55.4%  9.0% and 51.1%  10.6% for FF and FF + 
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NT, respectively.  Cytotoxic T Cells (CD3
+
CD4
-
CD8
+
) were 19.1%  6.7% and 18.6%  
4.2% for FF and FF + NT, respectively.  Higher T helper cell populations compared to 
cytotoxic T cells was expected.  Double positive T cells (CD3
+
CD4
+
CD8
+
) were 4.5%  
2.0% and 3.9%  1.4% for FF and FF + NT, respectively.  An increase in the proportion 
of double positive cells as the pig matures has previously been documented (Zuckermann 
& Husmann, 1996), so this level of double positive T cells would be expected in a 21d 
old piglet.  Natural killer cells (CD3
-
CD4
-
CD8
+
) were 9.4%  5.4% and 8.9%  6.2% for 
FF and FF + NT, respectively.  These percentages of NK cells are similar to what has 
previously been seen in our lab for piglets of a similar age (unpublished).  Thus, T cell 
and NK cell populations were not affected by diet and were found to be within normal 
ranges of young piglets. 
 
Intestinal Histomorphology 
To determine if NT had an effect on intestinal development, jejunum villi height and 
crypt depths were measured.  Jejunum villi height and crypt depth at d21 were not 
affected by dietary NT supplementation (Table 5.6).   
 
Ileum  Proliferation 
To determine if dietary NT or loop HMO treatments had an effect on epithelial cell 
proliferation in the intestine, ileal loop sections were stained for EdU (Figure 5.5).  The 
percentage of area of EdU
+ 
cells divided by the DAPI positive area was not affected by 
diet or loop treatments in the crypt region (Table 5.7).  
 
Ileum Monocytes and Macrophages 
To determine if NT, HMO or acute RV infection caused an increase in immune 
cellularity, monocytes/macrophages were identified by fluorescently labeled anti-CD163 
and CD14 (Figure 5.6).  Diet and loop treatments did not impact the percentage of area 
CD163
+
 or CD14
+ 
divided by DAPI positive areas of crypt regions.  Nor was double 
positive area of CD163
+
CD14
+ 
affected by diet and loop treatments in ileal region (Table 
5.8). 
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Tissue mRNA Expression 
Preliminary analysis of NSP4 and cytokine mRNA abundance in ileum showed stronger 
signal in ileal mucosa than whole ileal tissue.  Therefore, only ileal mucosa was used to 
measure mRNA expression in all loop samples.  Loops treated with the HMO mixture + 
RV had lower RV replication, as assessed by NSP4 mRNA expression, than other RV-
treated loops (p=0.007) (Figure 5.7).  Ileal loops not treated with RV showed no NSP4 
expression.  There was no difference in the mRNA expression of NF-κβ, TNF-α, CCL2 
or IL-1   mRNA expression in ileal mucosa as analyzed by loop, dietary treatment or RV 
infection (Table 5.9).  However, NT fed piglets had greater IL-8 mRNA expression than 
formula fed piglets (p=0.038), aHMO treated loops had significantly greater IL-8 mRNA 
expression than control treated loops (p=0.032), and the interaction between diet and 
treatment was significant (p=0.052) (Figure 5.8). 
 
Discussion 
Rotavirus remains the major cause of gastroenteritis worldwide and developing 
nutritional interventions to prevent or reduce the incidence of this disease could offer cost 
effective alternatives to vaccination.  We successfully showed that treatment with HMO 
reduced RV replication in acutely RV infected piglets in vivo. We also demonstrated 
there was no NSP4 replication in the loops not treated with RV, which confirmed the 
creation of a model wherein the viral infection was confined to challenged loops and 
absent from adjacent loops.  Thus, it was possible to compare host responses to RV 
infected and uninfected tissues within the same animal.    
Previous work in our lab had shown that specific HMO inhibited RV infectivity in 
vitro.  Using a focus forming unit (FFU) assay, infection of epithelial cells by the sialic-
acid dependent OSU RV strain was dose-dependently inhibited by HMO, 3'SL and 6'SL, 
but not by LNnT, 2'FL, 3'FL or a combination of polydextrose and 
galactooligosaccharides (PDX/GOS).  In the in vitro model, a 50% inhibition of RV 
infectivity was achieved with 4 mg/ml of 3'SL and 2 mg/ml 6'SL (Chen et al., 2011).  
However, when either 2 mg/mL of the acidic HMO mixture or LNnT was added to the 
intestinal loop model with OSU strain RV, a significant decrease in NSP4 replication was 
observed.  We can speculate that the LNnT was able to interact with the RV 
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glycoconjugate receptors in some capacity.  The in vitro experiment only allowed 
incubation of the LNnT with the OSU strain RV for 30 minutes; however our model 
allowed the two ingredients to interact for 6h.  This longer interaction may have been 
able to cause a change in the ability for LNnT to decrease RV binding to epithelial cells.  
LNnT treatments could have also altered the epithelial cells in some way that inhibited 
RV from binding to them. 
In addition neutral HMO have been shown in the literature to exert anti-microbial 
and anti-viral actions.  Women with breast milk containing higher amounts of 2-linked 
fucosyl- oligosaccharides have infants with decreased diarrhea (Newburg et al., 2004a).  
This suggests that neutral class of HMO can also act as competitive inhibitors of 
pathogen binding to their glycoconjugate receptors.  Further research is needed in order 
to determine the direct mechanism of this competitive inhibition by LNnT. 
Surprisingly, 250 mg/L additional NT added to the FF diet did not significantly 
change any of the outcomes measured except increase IL-8 cytokine production when 
aHMO loop treatments were also present.  It could be possible the interaction between 
dietary NT and aHMO loop treatment was causing an increase of neutrophils to migrate 
to the tissue and increase IL-8.  Previous studies have demonstrated that nucleotide 
supplemented rats with sulphonic acid induced damage to the colon have increased IL-8 
expression (Adjei, et al. 1996).  However we did not determine any additional impact of 
dietary NT in the neonatal piglet.  We chose this amount of NT to add to the FF diet, 
because we wanted it to be physiologically relevant to what could realistically be added 
to infant formula.  However, sow’s milk has a higher amount of NT in both colostrum 
and mature milk compared to HM (Leach et al., 1995; Mateo et al., 2004), and our 
chosen dose may have been too low to see significant effects in the rapidly growing 
neonatal piglet.  A beneficial effect of NT on gastrointestinal growth and function has 
been shown in several animal studies (Lopez-Navarro et al., 1996; Ortega et al., 1995), 
and pigs fed a NT-supplemented (500 mg/ L) diet showed significant intestinal growth 
compared to control pigs (Domeneghini et al., 2006; Yu et al., 2002).  It could also be 
hypothesized that our control diet, which contained 64 mg/L was not limiting enough to 
piglets to see significant changes when adding 250 additional mg/L NT.  Infant formula 
not supplemented with NT was analyzed and was found to contain 2.7 mg CMP, 4.2 mg 
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UMP, 0.6 mg AMP, and 0.5 mg GMP (Pickering et al., 1998).  Therefore non-
supplemented formula only contained around 8 mg/L. 
We had hypothesized that CD14 and CD163 antibodies used for the 
immunohistochemistry would stain the same cells, monocytes/macrophages.  However, 
anti-CD 163 labeled significantly more cells than anti-CD14 in our ileal samples.  In 
addition, it seemed that CD14
+
 cells were also CD163
+
.  Previous studies have suggested 
that CD14 is a maturation-dependent antigen and that CD14 expression may be useful for 
assessment of cell maturity.  CD14 has been used in previous studies as a functional 
marker of innate immunity in neonatal pigs after RV infection (Zhang et al., 2008).  RV 
infection induced higher frequencies of CD14
+
 monocytes/ macrophages in the ileum and 
lower amounts in the blood compared to non-infected pigs (Zhang et al., 2008).  It would 
have been interesting to isolate monocytes/ macrophages from the ileal tissue and 
perform flow cytometry to determine the cell populations.  However, due to the current 
study design, there was not a sufficient amount of tissue for each loop to isolate necessary 
monocytes/macrophages to perform flow cytometry. 
This model, although an important first step in determining NT and HMO 
individual and combined impact in vivo, has limitations.  Although after performing the 
laparotomy, the intestinal tissue appeared visually healthy and well oxygenated; the 
circulation may have been disturbed.  This could explain why we did not observe an 
increase in monocyte/ macrophage populations or cytokine mRNA abundance in the 
loops treated with RV.  In addition, each animal was injected with RV, which allowed 
each animal to serve as their own control.  However, we did not have any piglets not 
injected with RV to serve as a baseline.   
Another limitation of this study was the limited time for the acute RV infection.  
The piglets were euthanized after 6h of RV infection.  It would have been ideal to have a 
longer RV infection but due to the complications of a longer sedation time, it was not 
possible.  Longer time points are normally used to study RV infection in neonatal piglets, 
such as 1-4d post infection (Lopez-Guerrero et al., 2010).  However, previous studies 
have shown an increase of NF-κβ at 2h (Rollo et al., 1999) and maximum rate viral RNA 
synthesis at 3h (Stacy-Phipps & Patton, 1987).  Additionally our lab has previously 
shown an increase of NF-κβ at 4h post-infection and an increase of NSP4 replication by 
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12h post-infection after orally challenging piglets with RV (not published).  Villus 
atrophy normally does not occur until 24h post-infection (Saif et al., 1997). 
In conclusion, the effects of orally administered NT on immunity and 
gastrointestinal development were not seen in the current study, however, previous 
studies have shown benefits, especially at higher doses.  Both neutral and acidic HMO 
significantly decreased RV replication in this specific model.  Further in vivo studies are 
needed to examine the effectiveness of modulating the neonate’s immune system with 
feeding HMO in combination with NT. 
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Figures 
 
Figure 5.1. Study design of piglet study.  Piglets (n=18) were obtained from University 
of Illinois Swine Research Center after receiving 48 hours of colostrum from the sow.  
They were reared on non-medicated, sow-milk replacer (Milk Specialties Global Animal 
Nutrition, Carpentersville, IL) containing 64 mg NT/L (Formula; FF; n=9) or non-
medicated sow-milk replacer + additional 250 mg/L nucleotides (Formula + NT; FF+NT; 
n=9) until 21-days-old. 
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Figure 5.2. Treatment of loops with HMO and HMO + RV.  Below is an example of loop treatments.  The following treatments 
were injected into the loops in the amount of 2mL per loop: media, 2 mg/mL neutral HMO (LNnT) (donated by Abbott Nutrition, 
Columbus OH), 2 mg/mL acidic HMO mixture (aHMO) [40% 6'SL (V-Labs product no. SL306, Covington, LA) /10% 3'SL (V-Labs 
product no. SL302, Covington, LA) /50% SA (V-Labs product no. N101, Covington, LA)], or each treatment + SA dependent porcine 
RV strain OSU (P9[7],G5) obtained from Kuhlenschmidt lab who obtained it from American Type Culture Collection (1 x 10
7
 FFU). 
Each loop was separated by a suture.  The order of treatments was randomized among piglets.   
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Figure 5.3.  Formula intake was not different between dietary treatments. Data are 
expressed as mean.  Statistical significance was set at p≤0.05. Formula intake was similar 
across diet groups during the 19 day period.   
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Figure 5.4. Body Weight was not different between dietary treatments. Data are 
expressed as mean.  Statistical significance was set at p≤0.05. The increase in body 
weight during the 19 day period did not differ between diet groups.   
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Figure 5.5. Representative image of immunohistochemical detection of proliferating 
cells in ileum. (A) Ileum section stained with DAPI only. (B) Ileum section stained with 
EDU only. (C) Proliferation: ileum section stained with EdU
+
 (yellow) and DAPI
+
 
(green).   
 
A                                                                                   B 
 
 
 
 
 
 
C  
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Figure 5.6. Representative image of immunohistochemical detection of immune cells 
in ileum. (A) Ileum section stained with DAPI only. (B) Ileum section stained with 
CD163 only. (C) Ileum section stained with CD14 only. (D) Representative ileum section 
stained with CD163
+
 (green), CD14
+
 (red), CD163
+
CD14
+
 (yellow) and DAPI
+
 (blue). 
 
A                                                                            B 
 
 
 
 
 
 
 
 
 
C                                                                            D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
 
Figure 5.7. HMO significantly reduced NSP4 in ileal loops mucosa.  Loops treated 
with the HMO + RV had lower RV replication, as assessed by NSP4 mRNA expression, 
than RV-treated only loops.  aHMO + RV treatment showed lower NSP4 mRNA 
expression compared to LNnT + RV treatment.  Ileal loops not treated with RV showed 
extremely low or no NSP4 expression.  Diet was not significant.  Data is presented Mean 
± SEM. 
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Figure 5.8. Ileal mucosal IL-8 mRNA expression.  NT fed piglets had greater IL-8 
mRNA expression than formula piglets (p=0.038) and aHMO treatment had significantly 
greater IL-8 mRNA expression than control loops (p=0.032).  RV did not impact IL-8 
mRNA expression so it was dropped from model.  Data is presented Mean ± SEM. 
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Tables 
Table 5.1. Composition of sow milk replacer diet
1 
Component Per kg Powder Reconstituted (g/L)
2 
  
Lactose (g) 479.0  87.0  
Crude Protein (g) 250.0 45.8  
Crude Fat (g) 130.0  23.8  
Ash (g) 66.0 12.1 
  
Amino Acids   
Arginine (g) 6.7  1.2  
Histidine (g) 4.7  0.9  
Isoleucine (g) 14.5  2.7  
Leucine (g) 25.0 4.6  
Lysine (g) 22.  4.1  
Methionine (g) 5.0  0.9  
Phenylalanine (g) 8.2  1.5  
Threonine (g) 18.1  3.9  
Tryptophan (g) 6.9  1.3  
Valine (g) 14.6  2.7  
Nucleotides (mg)
3 
354.1 64.4 
  
Vitamins    
Vit B1 (mg) 8.5 0.2 
Vit B2 (mg) 27.3 5.0 
Vit B6 (mg) 2.0 0.4 
Vit B12 (µg) 73.7 13.7 
Vit A (KIU) 44.0 8.1 
Vit D (KIU) 12.1 2.2 
Vit E (IU) 33.2 6.1 
Vit C (mg) 121.9 22.3 
Choline (g) 1.8 0.32  
Pantothenic Acid (mg) 61.6 11.3 
Niacin (mg) 47.4 8.7 
Folic Acid (mg) 3.35 0.61 
Biotin (mg) 0.26 0.05 
  
Minerals and Electrolytes   
Calcium (g) 6.2 1.1 
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TABLE 5.1. (Continued) 
Component Per Kg Powder Reconstituted (g/L) 
  
Minerals  
 
 
  
Chloride (g) 8.1 1.48 
Cobalt (mg) 1.23 0.23 
Copper (mg) 12.1  2.2 
Iodine (mg) 10.2  1.87  
 
 
10.2 1.87 
Iron (mg) 106.0 19.4 
Magnesium (g) 12.0 2.2 
Potassium (g) 18.0 3.3 
Selenium (mg) 0.32 0.06 
Sodium (g) 6.3 1.2 
1 
Baby Pig Liqui-Wean, MSC, Dundee, IL. 
 
2 
Reconstituted at 180 g/L 
 
3
 Nucleotide content for Baby Pig Liqui-Wean Diet was analyzed by TPAN method by 
Abbott Laboratory (16 mg/L UMP; 21 mg/L CMP; 14 mg/L GMP; 13 mg/L AMP) 
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Table 5.2.  Antibodies used in phenotypic identification of mononuclear cells 
Cell population Marker Fluorochrome Clone Company 
CD3 T cells Anti-pig CD3 PE‐Cy5 PPT3 Southern Biotech 
CD4 T cells Anti-pig CD4 FITC 74-12-4 Southern Biotech 
CD8 T cells Anti-pig CD8 PE 76-2-11 Southern Biotech 
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Table 5.3.  Immunohistochemistry Antibodies 
Cell Population Marker(Primary Antibody) Secondary Antibody Fluorochrome Company 
Monocyte/Macrophage CD163 IgG1 a-IgG1 Alexa 555 AbD Serotec 
Monocyte/Macrophage CD14 IgG2a a-IgG2a Alexa 647 AbD Serotec 
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Table 5.4.  Primers used in qPCR 
 
Gene TaqMan Gene Expression Assay 
1
 
TNF-  Ss03391318_g1 
IL-1  Ss03393804_m1 
IL-8 Ss03392435_m1 
NF-  
CCL2 
Ss03388577_m1 
Ss03394377_m1 
Reference cDNA (RPL19) Ss03375624_g1 
 Custom Sequence 
NSP4 Forward: CAT TGG ACC CGA TGG TTG AC 
Probe: 6fam AGA AGC CAC AGT CAA TMGB 
Reverse: GCT GAG CCA CAC GCG ATAT 
1 
Applied Biosystems, Foster, CA 
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Table 5.5.  T cell and Natural Killer cell populations in the plasma of 21-day-old piglets fed formula or formula +250 mg/L 
NT
1 
 
 T Helper Cells CD3
+
CD4
+
CD8
-
  Cytotoxic T Cells  
CD3
+
CD4
-
CD8
+
 
Double Positive Cells 
CD3
+
CD4
+
CD8
+
  
Natural Killer Cells 
CD3
-
CD4
-
CD8
+
  
 % of Total CD3
+
 T-cells % of Total CD3
-
 T-cells 
FF 55.4  9.0 19.1  6.7 4.5  2.0 9.4  5.4 
FF + NT 51.1  10.6 18.6  4.2 3.9  1.4 8.9  6.2 
1
 Data is expressed as Mean  SD. 
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Table 5.6.  Jejunum Histomorphology
1
 
 Villus Height 
( m) 
Crypt Depth  
( m) 
FF 764.6  247.9 118.3  17.5 
FF + NT 844.7  298.4 106.9  15.7 
1
 Data is expressed as Mean  SD. 
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Table 5.7. EdU
+
 percentage area in ileal crypt region
1 
 
Measurement Area EdU
+
/DAPI
+
 Percentage (%) 
 FF FF + NT Ctrl 
Loops 
aHMO 
Loops 
LNnT 
Loops 
RV  
Loops 
aHMO + 
RV Loops 
LNnT +  
RV Loops 
Ileal Crypt Region
2 43.4±21.8 37.5±16.7 37.8±24.8 38.1±18.9 34.0±16.2 46.8±21.1 51.0±14.1 38.2±24.4 
1
 Data is expressed as Mean  SD. 
 
2
 Percent area of EdU positive area divided by total DAPI positive area was found for 400 x 200µm (80,000 µm
2
) area in ileal crypt 
region. 
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Table 5.8. CD163
+
 and CD14
+
 area in whole ileal section and crypt regions
1
 
Measurement Area CD163
+
/ DAPI
+
 Percentage (%) 
 FF FF + NT Ctrl 
Loops 
aHMO 
Loops 
LNnT  
Loops 
RV Loops aHMO +  
RV Loops 
LNnT +  
RV Loops 
Whole Ileal Section
2 5.9±5.0 9.9±8.8 5.6±5.9 9.4±7.6 4.8±2.0 6.6±8.5 9.3±4.6 9.3±13.1 
Ileal Crypt Region
3 11.7±7.7 9.6±3.6 10.9±6.7 7.7±4.4 10.2±5.8 12.1±6.0 15.6±7.8 9.4±5.6 
 Area CD14
+
/ DAPI
+
 Percentage (%) 
 FF FF + NT Ctrl 
Loops 
aHMO 
Loops 
LNnT 
Loops 
RV Loops aHMO + 
RV Loops 
LNnT + 
RV Loops 
Whole Ileal Section 0.3±0.4 0.5±0.9 1.0±1.4 0.3±0.2 0.3±0.4 0.4±0.4 0.2±0.3 0.4±0.6 
Ileal Crypt Region 1.0±2.0 1.0±1.8 1.6±3.3 0.4±0.3 0.8±1.3 0.9±1.0 0.6±0.6 1.5±3.0 
 Area CD163
+
 and CD14
+
-Double Positive (µm
2
) 
 FF FF + NT Ctrl 
Loops 
aHMO 
Loops 
LNnT 
Loops 
RV Loops aHMO + 
RV Loops 
LNnT + 
RV Loops 
Whole Ileal Section
4 256.3± 
303.2 
269.7± 
294.3 
323.6± 
393.1 
298.1± 
304.8 
154.0± 
117.6 
201.3± 
214.7 
221.8± 
155.5 
294.9± 
474.1 
1
 Data is expressed as Mean  SD. 
2
 The area stained positive for CD163 or CD14 was divided by total DAPI positive area for entire ileum captured picture/ whole ileal 
section (850 x 850µm). 
3
 Percent area of CD163 or CD14 positive area divided by total DAPI positive area was found for 400 x 200µm (80,000 µm
2
) area in 
ileal crypt region. 
4
 The area stained double positive for CD163 and CD14 for entire ileum captured picture/ whole ileal section (850 x 850µm).
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Table 5.9. Cytokine mRNA Abundance
1
 
 
Cytokine FF Loop 
Treatment 
Fold 
Difference 
FF + NT 
Loop Treatment 
Fold 
Difference 
IL-8 Media 1.0  0 Media 1.0  0 
 LNnT 1.5 0.3 LNnT 1.6 0.6 
 aHMO 1.0 0.3 aHMO 3.2 0.9 
 RV 1.3 0.6 RV 1.5 0.5 
 LNnT + RV 1.4 0.4 LNnT + RV 1.5 0.3 
 aHMO + RV 1.3 0.4 aHMO + RV 2.4 0.8 
TNF-  Media 1.0  0 Media 1.0  0 
 LNnT 1.3 0.4 LNnT 3.0 1.8 
 aHMO 1.1 0.3 aHMO 3.0 2.0 
 RV 2.0 0.4 RV 1.8 1.0 
 LNnT + RV 1.7 0.6 LNnT + RV 2.3 1.0 
 aHMO + RV 1.7 0.3 aHMO + RV 2.1 0.9 
IL-1  Media 1.0  0 Media 1.0  0 
 LNnT 1.3 0.3 LNnT 1.2 0.4 
 aHMO 1.1 0.2 aHMO 1.6 0.4 
 RV 1.2 0.2 RV 1.3 0.4 
 LNnT + RV 1.2 0.3 LNnT + RV 1.2 0.2 
 aHMO + RV 1.1 0.3 aHMO + RV 1.7 0.5 
CCL2 Media 1.0  0 Media 1.0  0 
 LNnT 1.6 0.9 LNnT 1.4 0.3 
 aHMO 1.3 0.4 aHMO 1.9 0.6 
 RV 1.2 0.3 RV 1.2 0.3 
 LNnT + RV 1.1 0.2 LNnT + RV 2.4 0.7 
 aHMO + RV 1.6 0.4 aHMO + RV 2.0 0.6 
NF-  Media 1.0  0 Media 1.0  0 
 LNnT 1.0 0.2 LNnT 1.1 0.2 
 aHMO 1.2 0.2 aHMO 1.4 0.3 
 RV 1.6 0.3 RV 1.2 0.2 
 LNnT + RV 1.1 0.2 LNnT + RV 1.3 0.3 
 aHMO + RV 1.4 0.3 aHMO + RV 1.3 0.2 
1
 Data is expressed as Mean  SEM. 
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Chapter 6 
 
Conclusions and Future Directions 
 
Infections are a major cause of morbidity and mortality in infants and children 
world-wide.  However, the severity of response of neonates to RV infection or their 
ability to generate sufficient antibodies following influenza vaccination can vary due to 
immune immaturity and dietary differences.  Manipulating the composition of infant 
formula, by adding different ingredients, such as β-(1,3)-glucans (βG), nucleotides (NT), 
and human milk oligosaccharides (HMO) could stimulate the development of the 
neonatal immune and gastrointestinal systems. These studies focused on understanding 
the effects of specific ingredients in the diet on the immune and gastrointestinal 
development in neonates.    
Our first study investigated the effect of yeast β-glucan supplemented to formula 
on immune and gastrointestinal development in the neonatal piglet.  Overall, the results 
showed that yeast β-glucan supplemented to formula did very little to alter the 
development of immunity or gastrointestinal development.  Despite the lack of effect of 
yeast β-glucan on immunological development in this study, it would be interesting to 
further investigate yeast βG supplementation in an infection model where the neonate 
was challenged.  This approach may enhance any immunological differences the yeast 
βG supplementation provides to the neonate.  It would also be interesting to trace the 
uptake and processing WGP through the immune system in a similar way to the studies 
conducted with yeast βG by Beier and Gebert (1998), in order to better understand the 
uptake and processing of the WGP particle.  This work would further our understanding 
of the impact of yeast βG supplementation on immunological development of the 
neonate. Further studies are also needed to examine the effectiveness of different forms 
of βG in modulating the neonate’s immune system. 
In the second study, our objective was to determine the mechanism(s) by which 
NT and HMO modulate intestinal epithelial cell growth-related characteristics.  Overall, 
the results showed that HMO reduced cell proliferation in vitro and that this effect was 
partially ameliorated by the presence of NT.  It appears that HMO initially induced 
apoptosis/necrosis, which was later evidenced by G2/M cell cycle arrest for LNnT and 
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the SL mix treatments and S cell cycle arrest for FL mix treatment, and decreased 
proliferation.  It would be interesting to further investigate the different HMO treatments 
on cell cycle regulation, since processes affecting cell fate are highly regulated and cell 
cycle genes such as cyclins, cyclin-dependent kinases and their inhibitors play an 
important role.  These data would help us to better understand how the different HMO are 
initially modifying cell cycle and apoptosis and eventually proliferation.  It is important 
to note that NT, just one of the many bioactive components found in human milk, was 
able to partially inhibit the effects of HMO.  Thus, these in vitro actions of HMO alone 
may not be physiologically relevant within the matrix of human milk or infant formula 
containing NT.  Further studies are needed to determine whether HMO influence 
intestinal cell growth in vivo. 
In the third study, our objective was to evaluate an acute treatment of HMO on 
enterocyte proliferation, immune cellularity, and cytokine production in the ileum of 
healthy and acutely RV-infected neonatal piglets chronically fed NT.  Overall, the results 
showed chronic dietary NT only significantly increased IL-8 production in ileal mucosa 
when aHMO treatment was also present.  NT did not affect the other parameters 
measured.  Our control diet had a low basal level of NT (64 mg/L), so it is not known 
whether we would have detected biological actions of NT if control diet was completely 
NT free.  It would also be interesting to determine if a higher supplementation of NT 
(greater than additional 250 mg/L NT) was needed to see an impact in the neonatal piglet.  
Both HMO treatments decreased NSP4 replication during acute RV infection.  We had 
hypothesized that aHMO would be able to inhibit SA-dependent RV infection, but further 
investigation is needed to better understand the mechanism by which LNnT also inhibited 
NSP4 replication.  The implications of this research can be far reaching, particularly 
when they are applied to improving the immune system in neonates and, thereby, 
decreasing the ability of pathogenic microorganisms to infect the host.  Future studies are 
warranted to examine HMO and NT supplementation during a longer course of RV 
infection.  Longer-term in vivo NT and HMO studies are needed to examine whether 
these components modulate the neonate’s gastrointestinal and immune system 
development.   
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In conclusion, the effects observed by the addition of individual ingredients to 
infant formula, invites further investigation of the potential benefits of supplementing 
infant formula.  Human milk contains many bioactive components that influence immune 
and gastrointestinal development, and more research is needed to help close the 
developmental gap between formula fed and breast fed infants. 
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Appendix A  
 
Nucleotide and Human Milk Oligosaccharide Impact on Non-Antigen and Antigen-
Specific ex Vivo Stimulation in Piglet Peripheral Mononuclear Cells 
 
Abstract 
Infant formulas lack the complex mixture of human milk oligosaccharides (HMO) found 
in human milk that may be pivotal to the development of the neonatal immune system.  
However infant formula is supplemented with nucleotides (NT), which also impacts the 
development of the neonatal immune system.  No comprehensive analyses of the direct 
effects of HMO and NT on immune cells from neonates have been undertaken.  Herein, 
peripheral blood mononuclear cells (PBMC) isolated from 10 day old sow-reared and 
formula fed piglets were stimulated with HMO (Fucosyl-lactose [FL] mix [85% 
2'FL/15% 3'FL], Sialyl-lactose [SL] mix [40% 6'SL/10% 3'SL/50% Sialic acid (SA)] or 
LNnT at 125, 250, 500 or 1000 μg/mL) in the presence or absence of 72 μg/mL NT mix 
(43% CMP, 18.5% UMP, 16.4% AMP, and 22.0% GMP).  T cell phenotype and 
proliferation were measured by flow cytometry and 
3
H-thymidine incorporation.  No 
treatments had significant effects on any parameters examined.  Thus, we hypothesized 
that this lack of response could be due to no antigen-specific stimulation of the PBMC, so 
additional experiments were carried out using the same treatments listed above in the 
presence of Fluzone  at 10, 50 or 100 µg/mL and examining T cell phenotype by flow 
cytometry in piglets previously vaccinated with Fluzone.  No conclusive results were 
found by the follow up experiments.  Therefore, we concluded there were no direct 
effects of HMO and NT on non-antigen or antigen-specific ex vivo stimulation in piglet 
PBMC. 
 
 
 
 
 
 
 
140 
 
Introduction 
 The immunomodulatory effects of nucleotides (NT) (Holen et al., 2005) or human 
milk oligosaccharides (HMO) (Bode et al., 2004) separately have been investigated, but 
little is known about the immunomodulatory efficacy of NT or HMO in combination on 
peripheral blood mononuclear cells (PBMC). 
 Previous studies have determined specific NT derivatives alone did not affect the 
growth of healthy PBMC, but NT derivatives influenced immune cell growth and 
cytokine secretion when cocultured with specific antigen.  Deoxyribonucleic acid (DNA), 
ribonucleic acid (RNA), deoxyadenosine monophosphate, deoxycytidine monophosphate, 
and deoxyuridine monophosphate increased influenza virus antigen induced immune cell 
proliferation (Holen et al., 2005).  In contrast deoxyadenosine monophosphate and 
thymosine monophosphate inhibited the antigen-induced growth response (Holen et al., 
2005).  It was hypothesized that co-culturing virus antigen and NT could influence and 
activate distinct cell fractions in PBMC and involve antigen-presenting cells and T cells 
(Holen et al., 2005).  NT may act as immunomodulators or costimulatory molecules by 
exerting their effect, perhaps mostly, on specific antigen-activated cells among the 
PBMC.   
 Nucleic acid analogs enhance both humoral and cellular immune responses (Xiao, 
2009).  Metabolites of nucleic acids, namely nucleotides and nucleosides, are recognized 
by host receptors, TLRs- 3, 7, 8, 9 and NOD-like receptors (NLRs-NOD2) (Ishii & 
Akira, 2008).  Both dsRNA and ssRNA are known ligands for TLRs.  TLRs and NLRs 
have unique signaling pathways.  TLR 7, 8, 9 stimulate the MyD88 pathway, TLR 3 
stimulates the TRIF pathway, and NOD2 stimulates the NFκβ pathway.  Each signaling 
pathway results in the induction of cytokine expression.    
 HMO are thought to play a key role in the immunomodulatory and 
immunoprotective actions of human milk (Kunz & Rudloff, 2008).  The blood 
concentration of 100-200 mg/L can be calculated based on the HMO concentration in 
human milk, the daily intake, the infant’s blood volume, and the amount excreted with 
the urine over time (Bode, 2006).  Assuming that HMO reach systemic circulation, they 
may alter protein-carbohydrate interactions on a systemic level.  HMO can modulate 
selectins, which belong to a subclass of carbohydrate-binding proteins involved in cell 
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adhesion in the immune system.  Evidence is emerging that HMO function as ligands for 
selectins that influence inflammatory processes by reducing leukocyte binding to 
endothelial cells (Kunz et al., 2000).  HMO may also have the ability to interfere with 
other protein-carbohydrate interactions, such as galectins, which regulate cell growth, 
proliferation, and apoptosis, as well as cell-cell and cell matrix interactions (Perillo et al., 
1998).  HMO could also target dendritic cell-specific intercellular adhesion molecule-
grabbing nonintegrin (DC-SIGN) which is expressed on dendritic cells in the intestine 
and other tissues (Bode, 2006).  Furthermore, HMO have been demonstrated to inhibit 
platelet-neutrophil complexes, which would suggest they have anti-inflammatory 
capability (Bode et al., 2004).   
The overall objective of this study was to assess if NT and HMO can directly 
affect PBMC isolated from piglets.  The working hypothesis was that NT would stimulate 
PBMC through innate immune receptors and HMO could modulate this interaction.  To 
our knowledge no previous studies have examined the interaction between NT and HMO 
on PBMC proliferation and T cell phenotypes.   
 
Materials and Methods 
 
Animals 
Study 1: Late gestation sows were obtained from University of Illinois Swine Research 
Center and transported to the animal facilities in ERML.  Farrowings were monitored and 
formula fed piglets (n=5) were removed from the sow prior to ingestion of colostrum. 
Sow-reared piglets (n=5) remained with the sow throughout the study.  The formula fed 
piglets were orally-administered pregnant sow serum to provide immunoglobluins (5mL 
per kg body weight at birth, 12h, 24h, and 36h).  Formula fed piglets were fed a non-
medicated, sow-milk replacer (Milk Specialties Global Animal Nutrition, Carpentersville, 
IL) and were individually housed in environmentally-controlled rooms (25°C) in cages 
capable of maintaining six piglets separated by Plexiglas partitions.  Radiant heaters were 
attached to the tops of the cage to maintain an ambient temperature of 30°C.  Formula 
was offered 20 times daily at a rate of 360 ml/kg BW/day.  All animal procedures were 
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approved by Institutional Animal Care and Use Committee of the University of Illinois.  
PBMC were isolated from 10 day old piglets (n=5, sow-reared; n=5, formula fed). 
 
Study 2:  Piglets were obtained from University of Illinois Swine Research Center and 
were reared on non-medicated, sow-milk replacer (Milk Specialties Global Animal 
Nutrition, Carpentersville, IL).  The first replicate piglets were colostrum deprived and 
were given Bovine IgG-Escherichia coli Antibody Colostrum Plus (Le Bella Associates, 
Inc., Bellingham, WA) to receive immunoglobulins (170mL: 20mL at birth, 30mL every 
3h) and the second replicate was allowed to receive sow colostrum for 4h after birth to 
receive immunoglobulins from sow then given Bovine IgG-Escherichia coli Antibody 
Colostrum Plus (Le Bella Associates, Inc., Bellingham, WA) for 20h (30mL every 3h).  
Piglets were individually housed in as described above.  On d7 postpartum, piglets (n=6) 
were vaccinated with a 0.25ml intra muscular (i.m.) injection of human influenza vaccine 
(Fluzone , Sanofi Pasteur, Swiftwater, PA).  A blood sample was drawn on d7 from the 
jugular vein prior to administration of the vaccine. Vaccinated animals received a booster 
vaccination on d14 with the same dose of Fluzone™.  All animal procedures were 
approved by Institutional Animal Care and Use Committee of the University of Illinois.  
PBMC were isolated from 21 day old piglets (n=2, vaccinated piglets for replicate 1 and 
n=5, non-vaccinated piglets; n=6, vaccinated piglets for replicate 2). 
 
PBMC Isolation and Treatments 
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient 
centrifugation.  Briefly 10 ml of heparinized blood was diluted in 25 ml of RPMI 1640 
(Life Technologies Invitrogen, Grand Island, NY) and layered over Ficoll-Paque PLUS 
lymphocyte separation medium (GE Healthcare, Uppsala, Sweden). The PBMC were 
recovered after centrifugation (400 x g, 30 min) across the density gradient.  Isolated 
PBMC were placed in complete medium RPMI 1640 (Life Technologies Invitrogen, 
Grand Island, NY) containing 10% fetal calf serum (Life Technologies Invitrogen, 
Carlsbad, CA), 2mM L-glutamine (Life Technologies Invitrogen, Carlsbad, CA), 100 
μg/ml penicillin, 100 μg/ml streptomycin, and 50 μg/mL gentamicin (Life Technologies 
Invitrogen).  Red blood cells were lysed using ammonium chloride lysing buffer.  
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The PBMC were plated for the ex vivo experiments.  The following treatments were 
added to 2 x 10
5 
mononuclear cells from blood/mL in 96 well microtitre plates on day 0.  
The cells for Study 1 were exposed to the following treatments for 24 hours: media alone 
(control), NT mixture (43% CMP, 18.5% UMP, 16.4% AMP, and 22.0% GMP at 72 
μg/mL), SL mixture (40% 6'SL, 10% 3'SL, and 50% SA at 125 μg/mL), NT mixture + SL 
mixture, FL mixture ( 85% 2'FL and 15% 3'FL at 125μg/mL), NT mixture + FL mixture, 
LNnT (100% LNnT at 125 μg/mL), NT mixture + LNnT.  For Study 2, experiments were 
carried out using the same treatments in the presence of Fluzone  at 10, 50, or 100 
µg/mL.   
 
Fluzone™ Preparation for Ex Vivo Analyses 
Prior to use in ex vivo assays, Fluzone™ was dialyzed to remove additives that inhibit 
cell proliferation.  The Fluzone™ solution was placed into Spectra/Por® 4 dialysis 
membranes (Spectrum Laboratories, Rancho Dominguez, CA) and submerged in PBS for 
24 hours at 4°C.  Protein content of dialyzed Fluzone , assessed using a Bradford assay 
(Quick Start Bradford, Bio-Rad, Hercules, CA), was 130μg protein/mL. 
 
Proliferation Assay  
PBMC (2 x 10
5
/cells per well) from Study 1 were plated in 96‐well plates (BD Falcon) in 
a total volume of 200μl. They were cultured in RPMI 1640 medium containing 10% FBS, 
2 mM Glutamine, 1 mM sodium pyruvate, 20 mM HEPES, 50 μg/mL Gentamicin, 1000 
IU/mL Penicillin, and 100 μg/mL Streptomycin. Oligosaccharides (125 μg/mL) and NT 
(72 μg/mL) were added to cells upon plating.  72 hours after the initiation of stimulation, 
plates were incubated for 18 hours with 
3
H-thymidine (Perkin Elmer, Boston, MA) at a 
concentration of 1μCi per well. Plates were stored at -80°C until analysis.  Cells were 
harvested (TomTech, Harvester 96 Mach III M, Hamden, CT) onto 1.5µm glass fiber 
filter paper (Skatron Instruments, Sterling, VA), and put into vials containing 7mL 
Ultima Gold F Scintillation Fluid (Perkin Elmer, Waltham, MA).  Samples were counted 
on a Beckman Coulter, LS 6500 Scintillation System (Brea, CA).  Data are expressed as a 
change in counts per minute (ΔCPM) which was obtained by subtracting counts from 
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unstimulated control wells from counts for wells with NT and HMO.  Samples were 
analyzed in triplicate.  Data analysis was performed on log transformed ΔCPM. 
 
T-cell Phenotype   
The phenotypes of T lymphocyte subpopulations from the cultured PBMC were 
monitored using fluorescently labeled mAbs.  The cells were collected after 24 h and 72 h 
in culture for both Study 1 and Study 2.  T helper subtype was determined using flow 
cytometry. Cells were stained with anti‐pig CD3 (clone PPT3):PE‐Cy5 (Southern 
Biotech, Birmingham, AL), anti‐pig CD4 (clone 74‐12‐4):FITC (Southern Biotech, 
Birmingham, AL) and anti‐pig CD8 (clone 76‐2‐11):PE (Southern Biotech, Birmingham, 
AL). Lymphocytes were selected based on forward and side scatter parameters. A gate 
was made on CD3
+
 cells, and these cells were separated into CD4/CD8 quadrants to 
determine the percentage of T cells in each T helper population.  All staining procedures 
took place on ice and care was taken to prevent unnecessary exposure to light.  Briefly, 
one million cells per tube were blocked with anti-pig CD16 (G-7, AbD Serotec) for 5min.  
Next, cells were incubated for 20min in a total of 30µl (10µl of each mAb: CD3, CD4 
and CD8).  Cells were washed twice with phosphate buffered saline (PBS)/ 1% bovine 
serum albumin (BSA)/ 0.1% sodium azide, and then fixed with 2% paraformaldehyde.  
Staining was assessed using an LSRII flow cytometer (BD™, Biosciences, San Jose, 
CA).  The relative number of T cell subpopulations was determined using FlowJo 7.0 
software (FlowJo, Ashland, OR).  CD3
+
 events were considered T cells.  CD3
+
CD4
+
CD8
-
 
events were considered T helper cells.  CD3
+
CD8
+
CD4
-
 events were considered cytotoxic 
T cells.  CD3
+
CD4
+
CD8
+
 events were considered double positive T cells.   
 
Results and Discussion 
 
Study 1 
Proliferation Assay  
PBMC isolated from FF piglets had significantly greater proliferation than SR piglets 
(p<0.0001) (Figure A1).  Neither NT nor HMO treatments significantly increased cell 
proliferation over control. 
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T-cell Phenotype 
FF piglets showed a greater percentage of T-helper cells (CD3
+
CD4
+
CD8)
-
  than SR 
piglets (p<0.0001) (Figure A2), while SR piglets had significantly greater cytotoxic T 
cells (CD3
+
CD4
-
CD8
+
) than FF piglets (p<0.0001) (Figure A3).  FF piglets had greater 
CD3
+
CD4
+
CD8
+
 T cells than SR piglets (p=0.0260) (Figure A4).  In vitro treatments did 
not significantly impact the proportion of cells compared to the media alone.  In 
conclusion, only diet effects were seen between FF and SR.  No proliferative or T cell 
phenotype effects of NT and HMO treatments were seen in PBMC isolated from 10 day 
old piglets. 
 
Study 2 
T-cell Phenotype   
Replicate 1 (n=2 vaccinated animals) was carried out to determine whether antigen-
specific ex vivo stimulation with Fluzone™ would modify in PBMC populations in cells-
treated with HMO and NT.  Both animals at 24 h showed a tendency to have increased T 
helper cells (CD3
+
CD4
+
CD8
-
) and decreased cytotoxic T-cells  (CD3
+
CD4
-
CD8
+
) as 
Fluzone™ dose increased with HMO treatments without NT compared to cells treated 
with media alone.  Greater proportion of cells were T helper cells (CD3
+
CD4
+
CD8
-
) 
when treated with NT only and NT + HMO.  T helper cells increased with NT treatments, 
which showed a tendency to increase at 50 µg/mL Fluzone™ and then decrease at 100 
µg/mL (Figure A5).  Double positive T cells (CD3
+
CD4
+
CD8
+
) were greater in all HMO 
only treatments as Fluzone™ increased at 24 h.  NT added alone and with HMO showed 
a tendency to increase at 50 µg/mL Fluzone™ and then decrease at 100 µg/mL. 
 
When experiment was repeated in replicate 2, no HMO or NT treatment effects were seen 
in either non-vaccinated (n=5) or vaccinated (n=6) animals.  Overall, vaccinated animals 
had greater T helper cells and less cytotoxic T cells than non-vaccinated animals.  Both 
non-vaccinated and vaccinated animals increased T helper cells and decreased cytotoxic 
T cells as Fluzone™ dose increased.  Vaccinated animals also showed a greater 
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CD3
+
CD4
+
CD8
-
/CD3
+
CD4
-
CD8
+
 ratio response than non-vaccinated animals as the 
Fluzone™ dose increased at 24 hours (Figure A6).   
 
NT and HMO treatments did not significantly affect any of the parameters 
examined in PBMC isolated from piglets in Study 1.  Thus, we hypothesized that this 
lack of response could be due to no antigen-specific stimulation of the PBMC, so 
additional experiments were carried out using the same treatments listed in the presence 
of Fluzone . 
 Interestingly, the 2 vaccinated piglets in Study 2, Replicate 1 showed increased T 
helper cells and decreased cytotoxic T cells in HMO treatments without NT as Fluzone™ 
dose increased.  T helper cells treated with NT only and NT + HMO showed a tendency 
to increase at 50 µg/mL Fluzone™ and then decrease at 100 µg/mL.  Double positive 
cells increased in all HMO treatments without NT as Fluzone™ increased.  NT added 
alone and with HMO showed a tendency to increase at 50 µg/mL Fluzone™ and then 
decrease at 100 µg/mL.  These results were interesting and when we followed up with 
Study 2, Replicate 2, which included both non-vaccinated and vaccinated piglets the 
same results were not seen.  No HMO or NT treatment effects were seen in non-
vaccinated and vaccinated animals.  Overall, vaccinated animals had greater T helper 
cells and less cytotoxic T cells than non-vaccinated animals.  Both non-vaccinated and 
vaccinated animals increased T helper cells and decreased cytotoxic T cells as Fluzone™ 
dose increased.   
 
Limitations and Future Directions 
A limitation of these studies is the PBMC population composition is not known at 
initiation of culture for any of the study replicates.  Retrospectively, a sample of PBMC 
should have been stained for T cell populations immediately after being isolated from 
each piglet.   
Another major limitation of these studies is the variation in the route of 
immunoglobulins to the neonatal piglet which may have led to differences in Fluzone™ 
specific antibodies produced by the piglet.  Study 2, Replicate 1 piglets were given only 
bovine colostrum, and Study 2, Replicate 2 piglets were given colostrum with the sow for 
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4 hours after birth and then followed with bovine colostrum.  The piglets allowed to 
suckle from the sow were exposed to more influenza antibodies than the other piglets, 
since the sow colostrum has been shown to have high levels of Fluzone™ specific 
antibodies.  The animals from Replicate 1 showed an increase in Fluzone™ specific 
antibodies as piglet age progressed, showing a direct response to vaccination.  However, 
the piglets in Replicate 2, receiving sow colostrum for 4 hours showed highest Fluzone™ 
specific antibodies at d7 and decreased by d21. This demonstrates that the piglets 
received background influenza antibodies from sow which confounded vaccination 
response results.  This difference alone may have impacted the immune responses seen ex 
vivo and be able to explain the differences seen between replicate 1 and 2.  This suggests, 
only piglets completely colostrum deprived, with a less robust immune system would be 
able to react against HMO and NT in the presence of antigen.   
Future studies are needed to test the presence of HMO and NT individual and 
combined effects on immune cells.   
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Figures 
 
 
Figure A1, Study 1. NT or HMO treatments did not significantly increase 
proliferation over control cells.  Log CPM from PBMC isolated from 10 day old 
formula fed (FF) piglets had significantly greater proliferation than sow-reared (SR) 
piglets (p<0.0001).  Data is presented as mean ± SD. 
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Figure A2, Study 1.  Percentage of CD3
+
CD4
+
CD8
-
 T cells in Day 10 old  formula 
fed (FF) piglets was greater than sow-reared (SR) piglets (p<0.0001) PBMC after 
being cultured for 72 hours.  NT or HMO treatments did not significantly change T 
helper cell populations. Data is presented as mean ± SD. 
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Figure A3, Study 1.  Percentage CD3
+
CD4
-
CD8
+
 T cells in 10 day old sow-reared 
(SR) piglets was greater than formula fed (FF) piglets (p<0.0001) PBMCs after 
being culture for 72 hours. NT or HMO treatments did not significantly change 
cytotoxic T cell populations. Data is presented as mean ± SD. 
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Figure A4, Study 1. Percentage of CD3
+
CD4
+
CD8
+
 T cells in Day 10 old formula fed 
(FF) piglets was greater than sow-reared (SR) piglets (p=0.0260) PBMC after being 
cultured for 72 hours.  NT or HMO treatments did not significantly change double 
positive T cell population. Data is presented as mean ± SD. 
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Figure A5. Study 2, Replicate 1. A) Vaccinated Piglet 1, CD4
+
/CD8
+
 Ratio.  B) 
Vaccinated Piglet 2, CD4
+
/CD8
+
 Ratio.  CD4
+
/CD8
+
 Ratio increased in vaccinated 
piglets with HMO treatments at higher Fluzone™ doses but not with NT and NT + 
HMO treatments.  Vaccinated piglets at 24 hours showed a tendency to have increased 
CD3
+
CD4
+
CD8
-
 cells and decreased CD3
+
CD4
-
CD8
+
 cells in HMO treatments without 
NT as Fluzone™ increased.  CD3+CD4+CD8- cells treated with NT only and NT + HMO 
showed a tendency to increase at 50 µg/mL Fluzone™ and then decrease at 100 µg/mL.   
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Figure A6. Study 2, Replicate 2. Vaccinated animals (n=6) showed a greater 
CD3
+
CD4
+
CD8
-
/CD3
+
CD4
-
CD8
+
 ratio response than non-vaccinated (n=5) animals 
as the Fluzone™ dose increased at 24 hours.  No HMO or NT treatment effects were 
seen in non-vaccinated and vaccinated animals.  Overall vaccinated animals had greater T 
helper cells and less cytotoxic T cells than non-vaccinated animals.  Both non-vaccinated 
and vaccinated animals increased T helper cells and decreased cytotoxic T cells as 
Fluzone™ dose increased.   
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Appendix B 
 
Supplemental Information for (1,3/1,6)-β-D-glucan Supplementation Study 
 
In this study, two-day-old piglets (n=68) were divided into 4 groups with each 
group receiving formula with a differing amount of WGP® 1/3-1/6 β-D-glucan: 1) a 
medicated sow milk replacer formula (WGP0) (Formula; Milk Specialties Global Animal 
Nutrition, Carpentersville, IL);  2) Formula + 1.8 mg WGP/kg BW/day (WGP1.8); 3) 
Formula + 18 mg WGP/kg BW/day (WGP18); or 4) Formula + 90 mg WGP/kg BW/day 
(WGP90) (Figure B1).  On d7, approximately one third of the piglets in each group were 
euthanized and blood and tissue samples were collected (Figure B2).  Approximately 
half of the remaining piglets in each treatment group (WGP0 n=5, WGP1.8 n=6, WGP18 
n=5, WGP90 n=6) were vaccinated with a i.m. injection (0.25ml) of human influenza 
vaccine (Fluzone , Sanofi Pasteur, Swiftwater, PA).  A blood sample was drawn from 
the jugular vein prior to administration of the vaccine (Figure B3). Vaccinated animals 
received a booster vaccination on d14 with the same dose of Fluzone .  Blood samples 
were collected longitudinally from all piglets on d14 and d21 by jugular vein or following 
euthanasia, respectively.  The piglets were monitored daily for formula intake (Figure 
B4a).  and weight gain (Figure B4b), as well as the presence of fever, diarrhea or 
lethargy, no differences were found across treatments groups for growth or food intake. 
Formula was offered 14 times daily at a rate of 360 ml/kg BW/day.  
Figure B5 exhibits the flow cytometry gating procedure that was used to identify 
CD4
+
, CD8
+
, CD4
+
CD8
+
, and CD4
-
CD8
-
 subpopulations of CD3
+
 cells. First, the 
lymphocyte population was selected on the side scatter vs. forward scatter plot.  Stained 
CD45+ cells were selected after comparing an unstained sample to a stained sample.  The 
region of positive CD45
+
 cells was identified by the area in the unstained sample graph 
that had <0.1% of the unstained cells in it.  That region was then mimicked in the stained 
sample graph. Stained CD3
+
 cells were selected after comparing the stained and 
unstained populations in a similar fashion.  Then CD8
+
, CD4
+
, and CD4
+
CD8
+
 cells were 
identified by comparing stained cells to unstained cells.   
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Ileum samples were stained for T cells (University of Illinois Veterinary 
Diagnostic Laboratory) with a rabbit anti-human CD3 polyclonal antibody (Biocare 
Medical, Concord, CA).  This antibody cross-reacts with pig CD3 and is extensively used 
by the Veterinary Diagnostic Histology Laboratory at the University of Illinois College of 
Veterinary Medicine (whose staff has verified this cross-reactivity by achieving the 
expected staining of pig lymph node sections).  Staining was visualized using a 
HRP/DAB (horse-radish peroxidase/ diaminobenzidine) system (Super Sensitive 
Polymer-HRP Detection System, Biogenex, San Ramon, CA) following the 
manufacturer’s instructions.  Representative CD3-polyclonal antibody stained ileal 
section is shown in Figure B6.   
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Figures 
 
 
Figure B1.  Structure of WGP® 1/3-1/6 β-D-glucan.  The β-glucan particulate is 
extracted from S. cerevisiae using acid and alkaline extraction techniques that results in 
stripping the outer mannoprotein sheath and loss of the inner cellular lipids and proteins, 
leaving the β-glucan shell (adapted from Babicek et al., 2007).   
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Figure B2. Experimental Design. Piglets (n=68) were randomized to one of four dietary treatment groups: a medicated sow milk 
replacer formula (WGP0) (Formula, Milk Specialties Company, Carpentersville, IL); Formula + 5 mg/L WGP® 1/3-1/6 β-D-glucan 
(WGP1.8); Formula + 50 mg/L WGP® 1/3-1/6 β-D-glucan (WGP18); or Formula + 250 mg/L WGP® 1/3-1/6 β-D-glucan (WGP90). 
 
 
 
 
 
 
 
158 
 
 
 
Figure B3.  Vaccination and sampling design. Piglets were euthanized on day 7 or day 
21.  Blood samples were taken on day 7 prior to vaccination, in vaccinated animals and 
day 14 in all animals.  Half of the animals in each diet group were vaccinated on day 7.  
These animals received a booster vaccination with the same dose on day 14. 
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Figure B4. Piglet formula intake and weight.  Data are expressed as mean.  Statistical 
significance was set at p≤0.05.  (A)  Formula intake was similar across all treatment 
groups.  An average formula intake of 808±167 ml/day was consumed for the first 7 days 
and 1488±129 over the course of 21 days. Formula was offered 14 times daily at a rate of 
360 ml/kg BW/day.  (B)  The increase in body weight during the 7 or 21 day period did 
not differ between diet groups.  On day 7, each pig weighed an average of 2.3±0.5 kg.  
On day 21, each pig weighed an average of 4.4±0.8 kg at day 21. 
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Figure B5. Flow cytometry gating procedure.  The lymphocyte population was 
selected on the side scatter vs forward scatter plot.  Stained CD45
+
 cells were selected 
after comparing stained lymphocyte population to unstained lymphocyte population.  
Stained CD3
+ 
cells were selected after comparing the stained and unstained populations.  
Then CD8
+
, CD4
+
, and CD4
+
CD8
+
 cells were identified by comparing stained set to 
unstained set.  
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Figure B6. Immunohistochemistry for 21 day old animal.  Picture is ileal section 
stained with CD3-polyclonal antibody, 10X   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ileal Section 
162 
 
Appendix C  
 
Real Time PCR 
 
Quantitative real-time PCR was conducted using SYBR Green (Applied 
Biosystems Inc.) and data was collected using the Taqman ABI 7900 (Applied 
Biosystems Inc.).  A total of 40 PCR cycles were run.  Primers used are listed in Table 
C1 and final primer concentrations were 300nM.  The standard cDNA, β-actin was used 
diluted 1/150 and sample cDNA was used 1/150 for IL-10, dectin, IL-2, IL-4, IL-6, IL-1β 
and IL-12 genes and diluted to 1/200 for TNF-α and TGF -2 genes.  The relative 
standard curve method was used for quantitation.  Standard curves consisted of dilutions 
of pooled spleen cDNA.  The standard dilutions were established as follows: 100, 20, 4, 
0.8, 0.16, 0.032, 0.0064, and 0.00128.  β-actin was used as the internal standard reporter 
gene.  Normalized values for each target were calculated by dividing the target quantity 
mean by the β-actin quantity mean.  A fold difference was calculated for each 
measurement by dividing the normalized target values by the normalized calibrator 
sample.  All samples that were statistically compared to each other were run on the same 
plate.  The standard curves and dissociation curves are presented in Figures C1, C2, C3, 
C4, C5, C6, C7, C8, C9, and C10.  
Reverse transcriptase products were also analyzed by quantitative real-time PCR 
using TaqMan® custom primers and probes or gene expression assays of target genes: 
NSP4, NF-κβ, IL-8, TNF-α, CCL2 and IL-1 .  Reference cDNA ribosomal protein L19 
(RPL19) was used as an endogenous control (Applied Biosystems).  Primers used are 
listed in Table C2.  All reactions were analyzed using the 7900HT Fast Real-Time PCR 
Detection System instrument and software (Applied Biosystems Inc.).  Assays were 
performed in 10 μL singleplex reactions containing TaqMan® Universal PCR Master 
Mix, customized primers and probes, and cDNA according to the manufacturer’s 
instructions (Applied Biosystems).  The standard cDNA, RPL19 was used diluted 1/100 
and sample cDNA was used non-diluted for NSP4 gene and diluted to 1/10 for NF-κβ, 
IL-8, TNF-α, CCL2 and IL-1  genes. Universal reaction conditions were used as follows: 
2 min at 50°C and 10 min at 95°C and then 40 cycles of 15 sec at 95°C and 1 min at 
60°C.  Each reaction was run in triplicate.  Standard curves consisted of dilutions of 
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pooled spleen cDNA.  The expression levels of cytokines were standardized to RPL19 
mRNA and expressed as fold differences, which corresponds to a ratio to the mean value 
for the control loop.  The expression levels of NSP4 were standardized to RPL19 mRNA 
and expressed as normalized target.  The relative standard curve method was used for 
quantitation.  The standard dilutions were established as follows: 100, 50, 25, 12.5, 6.25, 
3.125, 1.5625, and 0.78.  The standard curves are presented in Figures C11, C12, C13, 
C14, C15, C16, and C17.  The dissociation curves for TaqMan® gene expression assays 
are not shown because they have already been validated and optimized for use in the 
piglet. 
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Figures 
 
Figure C1. Standard curve and dissociation curve plot for β-actin. 
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Figure C2. Standard curve and dissociation curve plot for Dectin. 
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Figure C3. Standard curve and dissociation curve plot for IL-2. 
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Figure C4. Standard curve and dissociation curve plot for IL-12 p35. 
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Figure C5. Standard curve and dissociation curve plot for IL-4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
169 
 
 
 
Figure C6. Standard curve and dissociation curve plot for IL-10. 
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Figure C7. Standard curve and dissociation curve plot for IL-6. 
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Figure C8. Standard curve and dissociation curve plot for IL-1β. 
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Figure C9. Standard curve and dissociation curve plot for TNF-α. 
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Figure C10. Standard curve and dissociation curve plot for TGFβ-2. 
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Figure C11. Standard curve for TNF-α. 
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Figure C12. Standard curve for IL-1β. 
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Figure C13. Standard curve for IL-8. 
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Figure C14. Standard curve for NF-κβ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
178 
 
 
Figure C15. Standard curve for CCL2. 
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Figure C16. Standard curve for RPL19. 
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Figure C17. Standard curve for NSP4. 
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Tables 
 
 
 
Table C1.  Primers used for quantitative RT-PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Nygard et al., 2007 
2 
Sonck et al., 2009 
3 
Borca et al., 2008 
4 
Collado-Romero et al., 2010 
 
 
 
 
Gene Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) Gene Bank 
Accession ID 
β-actin1 CACGCCATCCTGCGTCTGGA AGCACCGTGTTGGCGTAGAG DQ845171.1 
Dectin
2
 CTCTCACAACCTCACCAGGAGAT CAGTAATGGGTCGCCAATAAGG FJ386384.1 
IL-2
3
 TCAACTCCTGCCACAATGT CTTGAAGTAGGTGCACCGT EU139160.1 
IL-12 p35
3
 CGTGCCTCGGGCAATTATAA CAGGTGAGGTCGCTAGTTTGG NM_213993.1 
IL-4
4
 TTGCTGCCCCAGAGAAC TGTCAAGTCCGTCAGG AY294020 
IL-10
4
 CAGATGGGCGACTTGTTG ACAGGGCAGAATTGATGAC L20001 
IL-6
3
 CTGGCAGAAAACAACCTGAACC TGATTCTCATCAAGCAGGTCTCC AB194100.1 
IL-1β3 AACGTGCAGTCTATGGAGT GAACACCACTTCTCTCTTCA NM 214055.1 
TNF-α3 AACCTCAGATAAGCCCGTCG ACCACCAGCTGGTTGTCTTT EU682384.1 
TGFβ-23 TGTGTGCTGAGCGCTTTTCT GAGCGTGCTGCAGGTAGACA L08375.1 
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Table C2.  Primers used in qPCR 
 
Gene TaqMan Gene Expression Assay 
1
 
TNF-  Ss03391318_g1 
IL-1  Ss03393804_m1 
IL-8 Ss03392435_m1 
NF-  
CCL2 
Ss03388577_m1 
Ss03394377_m1 
Reference cDNA (RPL19) Ss03375624_g1 
 Custom Sequence 
NSP4 Forward: CAT TGG ACC CGA TGG TTG AC 
Probe: 6fam AGA AGC CAC AGT CAA TMGB 
Reverse: GCT GAG CCA CAC GCG ATAT 
1 
Applied Biosystems, Foster, CA 
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Appendix D   
 
Rotavirus Immunohistochemistry Staining 
 
 
Study design used in Chapter 5 used an acute rotavirus (RV) infection.  A RV 
immunohistochemistry staining protocol specific for common antigen (VP6) of both 
human and animal group A rotavirus, adapted from non-fluorescent protocol was used to 
determine if RV infection could be detected in ileum villi.  Unfortunately acute rotavirus 
infection (6h) did not allow RV infection to be detected in villi of cell, but was detected 
in ileal lumen. 
Unstained slides containing sections of ileum were fluorescently stained for 
rotavirus and total nuclei.  Initially the unstained slides were dewaxed by soaking slides 
for 5 minutes in each of the following solutions; fresh Histo-Clear II (3 times) (Thermo 
Scientific, Barrington, IL), 100% ethanol (1 time), 70% ethanol/ 30% PBS (1 time), 50% 
ethanol/ 50% PBS (1 time), 25% ethanol/ 75% PBS (1 time), 100% PBS (3 times).  
Because the tissues were paraffin-embedded and formalin-fixed tissues, antigen retrieval 
was done.  A citrate buffer [pH 6.0] was used to break protein crosslinks formed by 
fixation allowing the antibody to recognize the CD163 and CD14 proteins.  After antigen 
retrieval, slides were incubated with Image IT Signal FX (Life Technologies, Invitrogen) 
for 1h.  Slides were then stained with primary antibody Rabbit Antirotavirus Group A 
(1:100 dilution) (AbD Serotec, Raleigh, NC, catalog#APH1360) for 1.5h.  Slides were 
then washed with PBS 3 times for 5min and then incubated with secondary Goat anti-
rabbit IgG:DyLight 549 (1:500 dilution) (Life Technologies, Invitrogen, catalog#A-
11036) for 1h.  Slides were then washed with PBS 3 times for 5min and then counter 
stained with 4',6-diamidino-2-phenylindole (DAPI) (Life Technologies, Invitrogen) for 
10min to detect total nuclei.  After washing slides 2 times for 5min with PBS, coverslip 
(Thermo Fisher Scientific, Barrington, IL) was mounted on each slide along with 2 drops 
Prolong® Gold anti-fade reagent (Life Technologies, Invitrogen).  Samples were imaged 
using a Zeiss Multiphoton Confocal microscope (LSM 700) (Carl Zeiss MicroImaging, 
Inc., Thornwood, NY).  Representative stained positive section is shown in Figure D1.   
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Figure D1. Representative Image of Immunohistochemistry Detection Rotavirus 
(VP6) in Ileum.  (A) Ileum section stained with DAPI only. (B) Ileum section stained 
with VP6 antibody only. (C) Representative ileum section stained with both DAPI
+
 
(yellow) and VP6
+
 (red). 
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